diff --git "a/data/ct_llm/ct_l2_dataset.jsonl" "b/data/ct_llm/ct_l2_dataset.jsonl"
new file mode 100644--- /dev/null
+++ "b/data/ct_llm/ct_l2_dataset.jsonl"
@@ -0,0 +1,500 @@
+{"question_id": "CTL2-0000", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: oglufanide disodium\nCondition: Colorectal Cancer\nPhase: phase_2\nTermination text: \"Drug not available\"", "metadata": {"result_id": 1350, "source_trial_id": "NCT00006037", "intervention_name": "oglufanide disodium", "condition_name": "Colorectal Cancer", "confidence_tier": "bronze", "why_stopped": "Drug not available", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0001", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: palifermin\nCondition: Stevens-Johnson Syndrome\nPhase: phase_1_2\nTermination text: \"Low enrollment numbers precluded completion of the study during a reasonable amount of time.\"", "metadata": {"result_id": 53519, "source_trial_id": "NCT02037347", "intervention_name": "palifermin", "condition_name": "Stevens-Johnson Syndrome", "confidence_tier": "bronze", "why_stopped": "Low enrollment numbers precluded completion of the study during a reasonable amount of time.", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0002", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: bupivacaine\nCondition: Shoulder Pain\nPhase: phase_4\nTermination text: \"Unable to continue enrollment due to lack of resources (research coordinator no longer available).\"", "metadata": {"result_id": 43340, "source_trial_id": "NCT01550302", "intervention_name": "bupivacaine", "condition_name": "Shoulder Pain", "confidence_tier": "bronze", "why_stopped": "Unable to continue enrollment due to lack of resources (research coordinator no longer available).", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0003", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Stage 1 Active Methylenedioxymethamphetamine\nCondition: Cancer\nPhase: phase_2\nTermination text: \"Lack of funds and insufficient patient population for study enrollment.\"", "metadata": {"result_id": 40625, "source_trial_id": "NCT00252174", "intervention_name": "Stage 1 Active Methylenedioxymethamphetamine", "condition_name": "Cancer", "confidence_tier": "bronze", "why_stopped": "Lack of funds and insufficient patient population for study enrollment.", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0004", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Oseltamivir 75 mg\nCondition: Virus Diseases\nPhase: phase_2\nTermination text: \"The study was stopped early due to lack of enrollment.\"", "metadata": {"result_id": 44416, "source_trial_id": "NCT02927431", "intervention_name": "Oseltamivir 75 mg", "condition_name": "Virus Diseases", "confidence_tier": "bronze", "why_stopped": "The study was stopped early due to lack of enrollment.", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0005", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: AxV-128/Tc\nCondition: Chronic Obstructive Pulmonary Disease (COPD)\nPhase: phase_2\nTermination text: \"Difficulty finding Annexin study drug supplier\"", "metadata": {"result_id": 6972, "source_trial_id": "NCT02978144", "intervention_name": "AxV-128/Tc", "condition_name": "Chronic Obstructive Pulmonary Disease (COPD)", "confidence_tier": "bronze", "why_stopped": "Difficulty finding Annexin study drug supplier", "therapeutic_area": "respiratory"}, "split": "fewshot"}
+{"question_id": "CTL2-0006", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Tumor specific peptides: MAGE-3.A1 and / or NA17.A2\nCondition: Metastatic Melanoma\nPhase: phase_1_2\nTermination text: \"due to end of validity of peptide vaccine\"", "metadata": {"result_id": 7726, "source_trial_id": "NCT01723813", "intervention_name": "Tumor specific peptides: MAGE-3.A1 and / or NA17.A2", "condition_name": "Metastatic Melanoma", "confidence_tier": "bronze", "why_stopped": "due to end of validity of peptide vaccine", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0007", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: ALT-801\nCondition: Non-muscle Invasive Bladder Cancer\nPhase: phase_1_2\nTermination text: \"The study was terminated early due to low enrollment.\"", "metadata": {"result_id": 10777, "source_trial_id": "NCT01625260", "intervention_name": "ALT-801", "condition_name": "Non-muscle Invasive Bladder Cancer", "confidence_tier": "bronze", "why_stopped": "The study was terminated early due to low enrollment.", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0008", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Crizotinib 250 MG\nCondition: Endometrial Cancer Recurrent\nPhase: phase_2\nTermination text: \"Patients were recruited during screen phase but fewer patients met criteria.\"", "metadata": {"result_id": 28284, "source_trial_id": "NCT04030429", "intervention_name": "Crizotinib 250 MG", "condition_name": "Endometrial Cancer Recurrent", "confidence_tier": "bronze", "why_stopped": "Patients were recruited during screen phase but fewer patients met criteria.", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0009", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: CT-G20\nCondition: Cardiomyopathy, Hypertrophic Obstructive\nPhase: phase_1\nTermination text: \"The termination criteria of the protocol was met during dose escalation\"", "metadata": {"result_id": 34922, "source_trial_id": "NCT04418297", "intervention_name": "CT-G20", "condition_name": "Cardiomyopathy, Hypertrophic Obstructive", "confidence_tier": "bronze", "why_stopped": "The termination criteria of the protocol was met during dose escalation", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0010", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ispaghula husk\nCondition: Metabolic Syndrome\nPhase: phase_2\nTermination text: \"It was very difficult to fulfill the inclusion criteria, therefore the expected time of inclusion was delayed so much time.\"", "metadata": {"result_id": 34131, "source_trial_id": "NCT00748787", "intervention_name": "Ispaghula husk", "condition_name": "Metabolic Syndrome", "confidence_tier": "bronze", "why_stopped": "It was very difficult to fulfill the inclusion criteria, therefore the expected time of inclusion was delayed so much time.", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL2-0011", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Amivantamab\nCondition: Carcinoma, Hepatocellular\nPhase: phase_2\nTermination text: \"N\\~15 subjects data analysis did not meet statistical consideration of ORR and study primary/secondary objectives were not met. Enrollment was terminated for futility\"", "metadata": {"result_id": 45656, "source_trial_id": "NCT05653427", "intervention_name": "Amivantamab", "condition_name": "Carcinoma, Hepatocellular", "confidence_tier": "bronze", "why_stopped": "N\\~15 subjects data analysis did not meet statistical consideration of ORR and study primary/secondary objectives were not met. Enrollment was terminated for futility", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0012", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: JNJ-64140284 0.1 mg\nCondition: Healthy\nPhase: phase_1\nTermination text: \"Trial stopped: A SAE has occured. As a measure of precaution, the trial has been stopped.\"", "metadata": {"result_id": 18803, "source_trial_id": "NCT03180762", "intervention_name": "JNJ-64140284 0.1 mg", "condition_name": "Healthy", "confidence_tier": "bronze", "why_stopped": "Trial stopped: A SAE has occured. As a measure of precaution, the trial has been stopped.", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0013", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Alendronate\nCondition: Osteoporosis\nPhase: phase_3\nTermination text: \"Slow accrual than anticipated.\"", "metadata": {"result_id": 25545, "source_trial_id": "NCT00236002", "intervention_name": "Alendronate", "condition_name": "Osteoporosis", "confidence_tier": "bronze", "why_stopped": "Slow accrual than anticipated.", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0014", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: DSPE-DOTA-Gd Liposomal Injection\nCondition: Alzheimer Disease\nPhase: phase_1\nTermination text: \"A temperature excursion occurred at the drug supplier's storage facility, which led to the loss of a significant portion of the IMP stock. Consequently, there is not enough IMP available to support continued recruitment\"", "metadata": {"result_id": 33323, "source_trial_id": "NCT05453539", "intervention_name": "DSPE-DOTA-Gd Liposomal Injection", "condition_name": "Alzheimer Disease", "confidence_tier": "bronze", "why_stopped": "A temperature excursion occurred at the drug supplier's storage facility, which led to the loss of a significant portion of the IMP stock. Consequently, there is not enough IMP available to support continued recruitment", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL2-0015", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: ISF35\nCondition: Chronic Lymphocytic Leukemia\nPhase: phase_2\nTermination text: \"drug supply was no longer available\"", "metadata": {"result_id": 18174, "source_trial_id": "NCT00942409", "intervention_name": "ISF35", "condition_name": "Chronic Lymphocytic Leukemia", "confidence_tier": "bronze", "why_stopped": "drug supply was no longer available", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0016", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "hard", "context_text": "Drug: ORIC-101\nCondition: Prostatic Neoplasms\nPhase: phase_1\nTermination text: \"IND Withdrawn\"", "metadata": {"result_id": 783, "source_trial_id": "NCT04033328", "intervention_name": "ORIC-101", "condition_name": "Prostatic Neoplasms", "confidence_tier": "bronze", "why_stopped": "IND Withdrawn", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0017", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Gilotrif\nCondition: Penile Squamous Cell Carcinoma (PSCC)\nPhase: phase_2\nTermination text: \"poor overall accrual\"", "metadata": {"result_id": 38186, "source_trial_id": "NCT02541903", "intervention_name": "Gilotrif", "condition_name": "Penile Squamous Cell Carcinoma (PSCC)", "confidence_tier": "bronze", "why_stopped": "poor overall accrual", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0018", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: pentoxifylline\nCondition: Wounds and Injuries\nPhase: phase_2\nTermination text: \"May 2007: No annual renewal\"", "metadata": {"result_id": 4143, "source_trial_id": "NCT00188552", "intervention_name": "pentoxifylline", "condition_name": "Wounds and Injuries", "confidence_tier": "bronze", "why_stopped": "May 2007: No annual renewal", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0019", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: pregabalin (Lyrica)\nCondition: Epilepsy\nPhase: phase_3\nTermination text: \"This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug. No efficacy or safety concerns factored into this decision.\"", "metadata": {"result_id": 29168, "source_trial_id": "NCT00372528", "intervention_name": "pregabalin (Lyrica)", "condition_name": "Epilepsy", "confidence_tier": "bronze", "why_stopped": "This study was terminated on April 8, 2011 as Pfizer Canada could no longer supply study drug. No efficacy or safety concerns factored into this decision.", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL2-0020", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Allergovit grass or birch\nCondition: Allergic Rhinitis\nTermination text: \"R and D approval not forthcoming\"", "metadata": {"result_id": 41507, "source_trial_id": "NCT01523158", "intervention_name": "Allergovit grass or birch", "condition_name": "Allergic Rhinitis", "confidence_tier": "bronze", "why_stopped": "R and D approval not forthcoming", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0021", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: SP-420\nCondition: Iron Overload\nPhase: phase_1\nTermination text: \"Study is on hold by FDA in the US.\"", "metadata": {"result_id": 44173, "source_trial_id": "NCT04741542", "intervention_name": "SP-420", "condition_name": "Iron Overload", "confidence_tier": "bronze", "why_stopped": "Study is on hold by FDA in the US.", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0022", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: PF-04965842\nCondition: Plaque Psoriasis\nPhase: phase_2\nTermination text: \"Study terminated 26 June 2015 due to changes in the drug development portfolio. This study was not terminated for reasons of safety and/or efficacy\"", "metadata": {"result_id": 3919, "source_trial_id": "NCT02201524", "intervention_name": "PF-04965842", "condition_name": "Plaque Psoriasis", "confidence_tier": "bronze", "why_stopped": "Study terminated 26 June 2015 due to changes in the drug development portfolio. This study was not terminated for reasons of safety and/or efficacy", "therapeutic_area": "autoimmune"}, "split": "fewshot"}
+{"question_id": "CTL2-0023", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Autologous Umbilical Cord Blood\nCondition: Congenital Diaphragmatic Hernia\nPhase: phase_1\nTermination text: \"Competing randomized trial of an experimental therapy limited initial enrollment. The trial was completed, published, and the experimental therapy became broadly desired. Given this, the investigators felt it best to terminate this competing study.\"", "metadata": {"result_id": 12969, "source_trial_id": "NCT03526588", "intervention_name": "Autologous Umbilical Cord Blood", "condition_name": "Congenital Diaphragmatic Hernia", "confidence_tier": "bronze", "why_stopped": "Competing randomized trial of an experimental therapy limited initial enrollment. The trial was completed, published, and the experimental therapy became broadly desired. Given this, the investigators felt it best to terminate this competing study.", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0024", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Polydeoxyribonucleotides\nCondition: Scleroderma Disease\nPhase: phase_4\nTermination text: \"the clinical center has too much difficulty recruiting as a rare condition\"", "metadata": {"result_id": 8223, "source_trial_id": "NCT03388255", "intervention_name": "Polydeoxyribonucleotides", "condition_name": "Scleroderma Disease", "confidence_tier": "bronze", "why_stopped": "the clinical center has too much difficulty recruiting as a rare condition", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0025", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Bosutinib 400 MG Monotherapy\nCondition: Chronic Phase-Chronic Myeloid Leukemia\nPhase: phase_1_2\nTermination text: \"The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.\"", "metadata": {"result_id": 15007, "source_trial_id": "NCT04793399", "intervention_name": "Bosutinib 400 MG Monotherapy", "condition_name": "Chronic Phase-Chronic Myeloid Leukemia", "confidence_tier": "bronze", "why_stopped": "The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0026", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Topical Sirolimus\nCondition: Vascular Anomaly\nPhase: phase_1\nTermination text: \"IRB suspended and subsequent early termination\"", "metadata": {"result_id": 57479, "source_trial_id": "NCT04172922", "intervention_name": "Topical Sirolimus", "condition_name": "Vascular Anomaly", "confidence_tier": "bronze", "why_stopped": "IRB suspended and subsequent early termination", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0027", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: LY3405105\nCondition: Solid Tumor\nPhase: phase_1\nTermination text: \"The study was terminated for lack of sufficient efficacy.\"", "metadata": {"result_id": 12177, "source_trial_id": "NCT03770494", "intervention_name": "LY3405105", "condition_name": "Solid Tumor", "confidence_tier": "bronze", "why_stopped": "The study was terminated for lack of sufficient efficacy.", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0028", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Ferric maltol 30 mg (Feraccru®)\nCondition: Anemia, Iron Deficiency\nPhase: phase_4\nTermination text: \"low recruitment rate; difficulties to achieve planned number of participants within reasonable time frame\"", "metadata": {"result_id": 3147, "source_trial_id": "NCT03774615", "intervention_name": "Ferric maltol 30 mg (Feraccru®)", "condition_name": "Anemia, Iron Deficiency", "confidence_tier": "bronze", "why_stopped": "low recruitment rate; difficulties to achieve planned number of participants within reasonable time frame", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0029", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Talazoparib Oral Capsule\nCondition: Ovarian Cancer\nPhase: phase_1\nTermination text: \"termination of research grant agreement\"", "metadata": {"result_id": 39739, "source_trial_id": "NCT04598321", "intervention_name": "Talazoparib Oral Capsule", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "why_stopped": "termination of research grant agreement", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0030", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Gemcitabine Injection\nCondition: Metastatic Pancreatic Ductal Adenocarcinoma\nPhase: phase_1_2\nTermination text: \"Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the second-line setting has changed the feasibility of further recruitment and potential long-term development opportunities of SLC-0111 with gemcitabine alone.\"", "metadata": {"result_id": 56574, "source_trial_id": "NCT03450018", "intervention_name": "Gemcitabine Injection", "condition_name": "Metastatic Pancreatic Ductal Adenocarcinoma", "confidence_tier": "bronze", "why_stopped": "Changing treatment landscape: The availability of nab-paclitaxel with gemcitabine in the second-line setting has changed the feasibility of further recruitment and potential long-term development opportunities of SLC-0111 with gemcitabine alone.", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0031", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Renzapride\nCondition: Constipation-Predominant Irritable Bowel Syndrome\nPhase: phase_3\nTermination text: \"Terminated due to insufficient efficacy over placebo in Study ATL1251/038/CL.\"", "metadata": {"result_id": 42612, "source_trial_id": "NCT00607971", "intervention_name": "Renzapride", "condition_name": "Constipation-Predominant Irritable Bowel Syndrome", "confidence_tier": "bronze", "why_stopped": "Terminated due to insufficient efficacy over placebo in Study ATL1251/038/CL.", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0032", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Aminolevulinic Acid\nCondition: Non-melanomatous Skin Cancer\nPhase: early_phase_1\nTermination text: \"Of the 8 histologically proven tumors, detection of PpIX proved to be ambiguous.\"", "metadata": {"result_id": 22214, "source_trial_id": "NCT00663910", "intervention_name": "Aminolevulinic Acid", "condition_name": "Non-melanomatous Skin Cancer", "confidence_tier": "bronze", "why_stopped": "Of the 8 histologically proven tumors, detection of PpIX proved to be ambiguous.", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0033", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: becatecarin\nCondition: Ovarian Cancer\nPhase: phase_2\nTermination text: \"Unable to accrue patients to the study.\"", "metadata": {"result_id": 35678, "source_trial_id": "NCT00006262", "intervention_name": "becatecarin", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "why_stopped": "Unable to accrue patients to the study.", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0034", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Islet Transplantation and Bone Marrow\nCondition: Type 1 Diabetes Mellitus\nPhase: phase_2\nTermination text: \"We did not achieve a tolerogenic profile. Subjects withdrew from protocol and enrolled in other islet transplant trials.\"", "metadata": {"result_id": 22217, "source_trial_id": "NCT00315614", "intervention_name": "Islet Transplantation and Bone Marrow", "condition_name": "Type 1 Diabetes Mellitus", "confidence_tier": "bronze", "why_stopped": "We did not achieve a tolerogenic profile. Subjects withdrew from protocol and enrolled in other islet transplant trials.", "therapeutic_area": "metabolic"}, "split": "fewshot"}
+{"question_id": "CTL2-0035", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Levofloxacin 500mg\nCondition: Community Acquired Pneumonia\nPhase: phase_2\nTermination text: \"Financial considerations\"", "metadata": {"result_id": 9895, "source_trial_id": "NCT01081964", "intervention_name": "Levofloxacin 500mg", "condition_name": "Community Acquired Pneumonia", "confidence_tier": "bronze", "why_stopped": "Financial considerations", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0036", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Obinutuzumab\nCondition: B-Cell\nPhase: phase_1\nTermination text: \"The study was closed after \\> 1 year of inactivity.\"", "metadata": {"result_id": 38739, "source_trial_id": "NCT03759184", "intervention_name": "Obinutuzumab", "condition_name": "B-Cell", "confidence_tier": "bronze", "why_stopped": "The study was closed after \\> 1 year of inactivity.", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0037", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Arixtra alone\nCondition: Thromboembolism\nPhase: phase_3\nTermination text: \"Study accrual stopped due to poor accrual.\"", "metadata": {"result_id": 39702, "source_trial_id": "NCT00423683", "intervention_name": "Arixtra alone", "condition_name": "Thromboembolism", "confidence_tier": "bronze", "why_stopped": "Study accrual stopped due to poor accrual.", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0038", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: MNI-330 as a brain SPECT tracer of Beta-Amyloid\nCondition: Alzheimer Disease\nPhase: phase_1\nTermination text: \"Data did not evidence \\[123I\\]MNI-330 as a useful tool in the detection of AD.\"", "metadata": {"result_id": 8789, "source_trial_id": "NCT00657813", "intervention_name": "MNI-330 as a brain SPECT tracer of Beta-Amyloid", "condition_name": "Alzheimer Disease", "confidence_tier": "bronze", "why_stopped": "Data did not evidence \\[123I\\]MNI-330 as a useful tool in the detection of AD.", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL2-0039", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Estradiol/norethindrone acetate\nCondition: Menopause\nPhase: phase_4\nTermination text: \"Enrollment goals not being met\"", "metadata": {"result_id": 58388, "source_trial_id": "NCT02693002", "intervention_name": "Estradiol/norethindrone acetate", "condition_name": "Menopause", "confidence_tier": "bronze", "why_stopped": "Enrollment goals not being met", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0040", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Pyrazinamide\nCondition: Tuberculosis\nPhase: phase_2\nTermination text: \"The study was stopped early due to feasibility concerns.\"", "metadata": {"result_id": 44457, "source_trial_id": "NCT01601626", "intervention_name": "Pyrazinamide", "condition_name": "Tuberculosis", "confidence_tier": "bronze", "why_stopped": "The study was stopped early due to feasibility concerns.", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL2-0041", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: TVB-2640\nCondition: Colon Cancer\nPhase: phase_1\nTermination text: \"Study was terminated by the PRMC for low accrual\"", "metadata": {"result_id": 9573, "source_trial_id": "NCT02980029", "intervention_name": "TVB-2640", "condition_name": "Colon Cancer", "confidence_tier": "bronze", "why_stopped": "Study was terminated by the PRMC for low accrual", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0042", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Methadone\nCondition: Hepatitis C, Chronic\nPhase: phase_4\nTermination text: \"The trial was terminated because of deviations from the protocol.\"", "metadata": {"result_id": 50946, "source_trial_id": "NCT00279565", "intervention_name": "Methadone", "condition_name": "Hepatitis C, Chronic", "confidence_tier": "bronze", "why_stopped": "The trial was terminated because of deviations from the protocol.", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL2-0043", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: [123I] MNI-308\nCondition: Alzheimer Disease\nPhase: phase_1\nTermination text: \"Preliminary data showed \\[123I\\] MNI-308 not a useful tool in detection of AD.\"", "metadata": {"result_id": 60341, "source_trial_id": "NCT00544453", "intervention_name": "[123I] MNI-308", "condition_name": "Alzheimer Disease", "confidence_tier": "bronze", "why_stopped": "Preliminary data showed \\[123I\\] MNI-308 not a useful tool in detection of AD.", "therapeutic_area": "neurology"}, "split": "fewshot"}
+{"question_id": "CTL2-0044", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Glecaprevir and Pibrentasvir\nCondition: Hepatitis C\nPhase: phase_4\nTermination text: \"Unable to meet enrollment goal prior to drug expiration\"", "metadata": {"result_id": 32187, "source_trial_id": "NCT04515797", "intervention_name": "Glecaprevir and Pibrentasvir", "condition_name": "Hepatitis C", "confidence_tier": "bronze", "why_stopped": "Unable to meet enrollment goal prior to drug expiration", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL2-0045", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Lapatinib + 1,23 mg Eribulin\nCondition: Metastatic Breast Cancer\nPhase: phase_2\nTermination text: \"very slow patient recruitment and concerns about the actuality of the study design\"", "metadata": {"result_id": 23110, "source_trial_id": "NCT01534455", "intervention_name": "Lapatinib + 1,23 mg Eribulin", "condition_name": "Metastatic Breast Cancer", "confidence_tier": "bronze", "why_stopped": "very slow patient recruitment and concerns about the actuality of the study design", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0046", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Lenalidomide; Chlorambucil\nCondition: Chronic Lymphocytic Leukemia\nPhase: phase_1_2\nTermination text: \"Slow patient enrollment and new molecules for chronic lymphoid leukemia, have importantly reduced the interest of conducting the phase II of this study.\"", "metadata": {"result_id": 45021, "source_trial_id": "NCT01403246", "intervention_name": "Lenalidomide; Chlorambucil", "condition_name": "Chronic Lymphocytic Leukemia", "confidence_tier": "bronze", "why_stopped": "Slow patient enrollment and new molecules for chronic lymphoid leukemia, have importantly reduced the interest of conducting the phase II of this study.", "therapeutic_area": "oncology"}, "split": "fewshot"}
+{"question_id": "CTL2-0047", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Aliskiren\nCondition: Hypertension\nPhase: phase_4\nTermination text: \"Study was stopped early due to difficulty finding patients who met I/E criteria.\"", "metadata": {"result_id": 52830, "source_trial_id": "NCT01235910", "intervention_name": "Aliskiren", "condition_name": "Hypertension", "confidence_tier": "bronze", "why_stopped": "Study was stopped early due to difficulty finding patients who met I/E criteria.", "therapeutic_area": "cardiology"}, "split": "fewshot"}
+{"question_id": "CTL2-0048", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: AAHI-SC2 Vaccine\nCondition: COVID-19\nPhase: phase_1_2\nTermination text: \"Discontinued prior to enroll in Phase 2\"", "metadata": {"result_id": 49613, "source_trial_id": "NCT05370040", "intervention_name": "AAHI-SC2 Vaccine", "condition_name": "COVID-19", "confidence_tier": "bronze", "why_stopped": "Discontinued prior to enroll in Phase 2", "therapeutic_area": "infectious"}, "split": "fewshot"}
+{"question_id": "CTL2-0049", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: STT-5058\nCondition: Hypertriglyceridemia\nPhase: phase_1\nTermination text: \"recruitment failure\"", "metadata": {"result_id": 49776, "source_trial_id": "NCT04419688", "intervention_name": "STT-5058", "condition_name": "Hypertriglyceridemia", "confidence_tier": "bronze", "why_stopped": "recruitment failure", "therapeutic_area": "other"}, "split": "fewshot"}
+{"question_id": "CTL2-0050", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ketoconazole\nCondition: Granulosa Cell Tumour of the Ovary\nPhase: phase_2\nTermination text: \"Insufficient recruitment rate\"", "metadata": {"result_id": 45390, "source_trial_id": "NCT01584297", "intervention_name": "Ketoconazole", "condition_name": "Granulosa Cell Tumour of the Ovary", "confidence_tier": "bronze", "why_stopped": "Insufficient recruitment rate", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0051", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Carboplatin\nCondition: Infiltrating Bladder Urothelial Carcinoma With Giant Cells\nPhase: phase_2\nTermination text: \"Difficulty with enrollment\"", "metadata": {"result_id": 12703, "source_trial_id": "NCT03912818", "intervention_name": "Carboplatin", "condition_name": "Infiltrating Bladder Urothelial Carcinoma With Giant Cells", "confidence_tier": "bronze", "why_stopped": "Difficulty with enrollment", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0052", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Daptomycin\nCondition: Methicillin-Resistant Staphylococcus Aureus\nPhase: phase_4\nTermination text: \"The study is closed to accrual. Enrollment of new patients stopped at the request of CUBIST Pharmaceuticals due to slow rate of enrollment.\"", "metadata": {"result_id": 28362, "source_trial_id": "NCT01196169", "intervention_name": "Daptomycin", "condition_name": "Methicillin-Resistant Staphylococcus Aureus", "confidence_tier": "bronze", "why_stopped": "The study is closed to accrual. Enrollment of new patients stopped at the request of CUBIST Pharmaceuticals due to slow rate of enrollment.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0053", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Dendritic cells vaccine\nCondition: Glioblastoma\nPhase: phase_1\nTermination text: \"Temozolomide does not favour immune response; secondary GBM to be excluded\"", "metadata": {"result_id": 19042, "source_trial_id": "NCT04002804", "intervention_name": "Dendritic cells vaccine", "condition_name": "Glioblastoma", "confidence_tier": "bronze", "why_stopped": "Temozolomide does not favour immune response; secondary GBM to be excluded", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0054", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: OMS721\nCondition: IgA Nephropathy\nPhase: phase_3\nTermination text: \"IA did not meet the prespecified primary endpoint.\"", "metadata": {"result_id": 36973, "source_trial_id": "NCT03608033", "intervention_name": "OMS721", "condition_name": "IgA Nephropathy", "confidence_tier": "bronze", "why_stopped": "IA did not meet the prespecified primary endpoint.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0055", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Luteinizing hormone-releasing hormone (LHRH)\nCondition: Prostate Cancer\nPhase: phase_2_3\nTermination text: \"enrollment goals not met\"", "metadata": {"result_id": 20313, "source_trial_id": "NCT01603420", "intervention_name": "Luteinizing hormone-releasing hormone (LHRH)", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "why_stopped": "enrollment goals not met", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0056", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: RisperiDONE 0.5 MG\nCondition: Anxiety State\nPhase: phase_3\nTermination text: \"not enough patient\"", "metadata": {"result_id": 28307, "source_trial_id": "NCT03227562", "intervention_name": "RisperiDONE 0.5 MG", "condition_name": "Anxiety State", "confidence_tier": "bronze", "why_stopped": "not enough patient", "therapeutic_area": "psychiatry"}, "split": "val"}
+{"question_id": "CTL2-0057", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Prednisolone\nCondition: Exogenous Allergic Alveolitis\nPhase: phase_2\nTermination text: \"After several years of recruitment only 4 patients were included. Study timelines for study completition too long. Decided to terminate trial.\"", "metadata": {"result_id": 39607, "source_trial_id": "NCT02631603", "intervention_name": "Prednisolone", "condition_name": "Exogenous Allergic Alveolitis", "confidence_tier": "bronze", "why_stopped": "After several years of recruitment only 4 patients were included. Study timelines for study completition too long. Decided to terminate trial.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0058", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: GDC-0853\nCondition: Urticaria\nPhase: phase_2\nTermination text: \"Recruitment was stopped after an interim analysis of the parent GS39684 study.\"", "metadata": {"result_id": 12257, "source_trial_id": "NCT03693625", "intervention_name": "GDC-0853", "condition_name": "Urticaria", "confidence_tier": "bronze", "why_stopped": "Recruitment was stopped after an interim analysis of the parent GS39684 study.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0059", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Bacillus Calmette-Guérin (BCG)\nCondition: Urinary Bladder Neoplasms\nPhase: phase_3\nTermination text: \"Insufficient enrollment, inability to meet protocol objectives, and slow accrual.\"", "metadata": {"result_id": 17687, "source_trial_id": "NCT04149574", "intervention_name": "Bacillus Calmette-Guérin (BCG)", "condition_name": "Urinary Bladder Neoplasms", "confidence_tier": "bronze", "why_stopped": "Insufficient enrollment, inability to meet protocol objectives, and slow accrual.", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0060", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Standard Ibuprofen\nCondition: Patent Ductus Arteriosus\nPhase: phase_4\nTermination text: \"FDA drug recall on July 30, 2010\"", "metadata": {"result_id": 8864, "source_trial_id": "NCT00961753", "intervention_name": "Standard Ibuprofen", "condition_name": "Patent Ductus Arteriosus", "confidence_tier": "bronze", "why_stopped": "FDA drug recall on July 30, 2010", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0061", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Infusion of autologous mononuclear bone marrow cells\nCondition: Idiopathic Dilated Cardiomyopathy\nPhase: phase_2\nTermination text: \"Low recruitment rate, bibliographic evidence of lack of efficacy\"", "metadata": {"result_id": 23831, "source_trial_id": "NCT02033278", "intervention_name": "Infusion of autologous mononuclear bone marrow cells", "condition_name": "Idiopathic Dilated Cardiomyopathy", "confidence_tier": "bronze", "why_stopped": "Low recruitment rate, bibliographic evidence of lack of efficacy", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0062", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: BOTOX-A\nCondition: Low Anterior Resection Syndrome (LARS>20)\nPhase: phase_2\nTermination text: \"Organizational difficulties\"", "metadata": {"result_id": 61294, "source_trial_id": "NCT04991688", "intervention_name": "BOTOX-A", "condition_name": "Low Anterior Resection Syndrome (LARS>20)", "confidence_tier": "bronze", "why_stopped": "Organizational difficulties", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0063", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: MS-553\nCondition: Diffuse Large B-cell Lymphoma (DLBCL)\nPhase: phase_1_2\nTermination text: \"The study is terminated due to major protocol revisions.\"", "metadata": {"result_id": 54920, "source_trial_id": "NCT05720052", "intervention_name": "MS-553", "condition_name": "Diffuse Large B-cell Lymphoma (DLBCL)", "confidence_tier": "bronze", "why_stopped": "The study is terminated due to major protocol revisions.", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0064", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Nicotinamide riboside\nCondition: Breast Cancer Metastatic\nPhase: phase_2\nTermination text: \"Enrollment challenges\"", "metadata": {"result_id": 27677, "source_trial_id": "NCT03642990", "intervention_name": "Nicotinamide riboside", "condition_name": "Breast Cancer Metastatic", "confidence_tier": "bronze", "why_stopped": "Enrollment challenges", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0065", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Nesiritide\nCondition: Heart Failure\nPhase: phase_3\nTermination text: \"Recruitment very difficult. Study drug expired so we have stopped the study.\"", "metadata": {"result_id": 17183, "source_trial_id": "NCT00562692", "intervention_name": "Nesiritide", "condition_name": "Heart Failure", "confidence_tier": "bronze", "why_stopped": "Recruitment very difficult. Study drug expired so we have stopped the study.", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL2-0066", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: Aripiprazole\nCondition: Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features\nPhase: phase_3\nTermination text: \"The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational Plan was met and provided 2 years of safety data.\"", "metadata": {"result_id": 19030, "source_trial_id": "NCT01122927", "intervention_name": "Aripiprazole", "condition_name": "Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features", "confidence_tier": "bronze", "why_stopped": "The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational Plan was met and provided 2 years of safety data.", "therapeutic_area": "psychiatry"}, "split": "val"}
+{"question_id": "CTL2-0067", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Processed Amniotic Fluid\nCondition: Wounds and Injuries\nPhase: phase_1_2\nTermination text: \"Enrollment was halted prematurely after enrolling one participant due to difficulty finding eligible participants.\"", "metadata": {"result_id": 14688, "source_trial_id": "NCT04438174", "intervention_name": "Processed Amniotic Fluid", "condition_name": "Wounds and Injuries", "confidence_tier": "bronze", "why_stopped": "Enrollment was halted prematurely after enrolling one participant due to difficulty finding eligible participants.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0068", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Mifepristone\nCondition: Psychotic Depression\nPhase: phase_3\nTermination text: \"DRC recommended stopping study as it had missed its primary endpoint\"", "metadata": {"result_id": 54534, "source_trial_id": "NCT00637494", "intervention_name": "Mifepristone", "condition_name": "Psychotic Depression", "confidence_tier": "bronze", "why_stopped": "DRC recommended stopping study as it had missed its primary endpoint", "therapeutic_area": "psychiatry"}, "split": "val"}
+{"question_id": "CTL2-0069", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Meropenem\nCondition: Bloodstream Infections\nPhase: phase_4\nTermination text: \"Secondary to third interim analysis by the study DSMB.\"", "metadata": {"result_id": 1476, "source_trial_id": "NCT02176122", "intervention_name": "Meropenem", "condition_name": "Bloodstream Infections", "confidence_tier": "bronze", "why_stopped": "Secondary to third interim analysis by the study DSMB.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0070", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes\nCondition: Metastatic Malignant Neoplasm in the Brain\nPhase: early_phase_1\nTermination text: \"Due to lack of accrual the study was formally terminated on 01-JUL-2020. Primary Completion and Study Completion Dates have been revised based accordingly based on respective definitions\"", "metadata": {"result_id": 37554, "source_trial_id": "NCT02774291", "intervention_name": "Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes", "condition_name": "Metastatic Malignant Neoplasm in the Brain", "confidence_tier": "bronze", "why_stopped": "Due to lack of accrual the study was formally terminated on 01-JUL-2020. Primary Completion and Study Completion Dates have been revised based accordingly based on respective definitions", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0071", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: MRTX849\nCondition: Advanced Cancer\nPhase: phase_1\nTermination text: \"The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.\"", "metadata": {"result_id": 48913, "source_trial_id": "NCT04975256", "intervention_name": "MRTX849", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "why_stopped": "The decision was made to terminate this study to further enrollment, as of 08 March 2022. The decision was made primarily due to a change in development strategy.", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0072", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Doxycycline\nCondition: Pharynx\nPhase: phase_2\nTermination text: \"Insufficient staff to conduct the trial\"", "metadata": {"result_id": 37797, "source_trial_id": "NCT03076281", "intervention_name": "Doxycycline", "condition_name": "Pharynx", "confidence_tier": "bronze", "why_stopped": "Insufficient staff to conduct the trial", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0073", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: TBL12\nCondition: Myeloma\nPhase: phase_2\nTermination text: \"due to lack of funding\"", "metadata": {"result_id": 4019, "source_trial_id": "NCT01302366", "intervention_name": "TBL12", "condition_name": "Myeloma", "confidence_tier": "bronze", "why_stopped": "due to lack of funding", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0074", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: VSL#3\nCondition: Menopausal Osteoporosis\nPhase: phase_2\nTermination text: \"Investigator terminated trial pursuant to research contract rights.\"", "metadata": {"result_id": 1833, "source_trial_id": "NCT03165747", "intervention_name": "VSL#3", "condition_name": "Menopausal Osteoporosis", "confidence_tier": "bronze", "why_stopped": "Investigator terminated trial pursuant to research contract rights.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0075", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: AG013\nCondition: Oral Mucositis\nPhase: phase_2\nTermination text: \"No efficacy could be demonstrated, sponsor decided to prematurely end the study.\"", "metadata": {"result_id": 26875, "source_trial_id": "NCT03234465", "intervention_name": "AG013", "condition_name": "Oral Mucositis", "confidence_tier": "bronze", "why_stopped": "No efficacy could be demonstrated, sponsor decided to prematurely end the study.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0076", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: 90Y-Ibritumomab Tiuxetan\nCondition: Diffuse Large B-Cell Lymphoma\nPhase: phase_2\nTermination text: \"After enrolling 25 patients an interim analysis was done.The study was discontinued in the absence of the minimum number of 6 patients free of events\"", "metadata": {"result_id": 40996, "source_trial_id": "NCT00902525", "intervention_name": "90Y-Ibritumomab Tiuxetan", "condition_name": "Diffuse Large B-Cell Lymphoma", "confidence_tier": "bronze", "why_stopped": "After enrolling 25 patients an interim analysis was done.The study was discontinued in the absence of the minimum number of 6 patients free of events", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0077", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Statins\nCondition: Heart Failure\nTermination text: \"The study was prematurely terminated due to low enrollment.\"", "metadata": {"result_id": 20369, "source_trial_id": "NCT00968383", "intervention_name": "Statins", "condition_name": "Heart Failure", "confidence_tier": "bronze", "why_stopped": "The study was prematurely terminated due to low enrollment.", "therapeutic_area": "cardiology"}, "split": "val"}
+{"question_id": "CTL2-0078", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: SPH4336\nCondition: Liposarcoma, Dedifferentiated\nPhase: phase_2\nTermination text: \"Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less than anticipated.\"", "metadata": {"result_id": 7379, "source_trial_id": "NCT05580588", "intervention_name": "SPH4336", "condition_name": "Liposarcoma, Dedifferentiated", "confidence_tier": "bronze", "why_stopped": "Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less than anticipated.", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0079", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Lapatinib, Vinorelbine\nCondition: Neoplasms, Breast\nPhase: phase_2\nTermination text: \"Evolving standard of care practices in this disease setting was limiting enrolment and leading to a delay in delivering this study information to the public.\"", "metadata": {"result_id": 104, "source_trial_id": "NCT00709618", "intervention_name": "Lapatinib, Vinorelbine", "condition_name": "Neoplasms, Breast", "confidence_tier": "bronze", "why_stopped": "Evolving standard of care practices in this disease setting was limiting enrolment and leading to a delay in delivering this study information to the public.", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0080", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Progesterone\nCondition: Polycystic Ovary Syndrome\nTermination text: \"Haven't enrolled participants since 2010\"", "metadata": {"result_id": 50842, "source_trial_id": "NCT01428193", "intervention_name": "Progesterone", "condition_name": "Polycystic Ovary Syndrome", "confidence_tier": "bronze", "why_stopped": "Haven't enrolled participants since 2010", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0081", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Optivate\nCondition: Von Willebrand Disease\nPhase: phase_3\nTermination text: \"Due to slow recruitment and a delay in reaching the recruitment target.\"", "metadata": {"result_id": 42590, "source_trial_id": "NCT00404300", "intervention_name": "Optivate", "condition_name": "Von Willebrand Disease", "confidence_tier": "bronze", "why_stopped": "Due to slow recruitment and a delay in reaching the recruitment target.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0082", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Astragalus Polysaccharides 500 mg\nCondition: Cancer-related Fatigue\nPhase: phase_2\nTermination text: \"Change study drug dosage form\"", "metadata": {"result_id": 44998, "source_trial_id": "NCT01720563", "intervention_name": "Astragalus Polysaccharides 500 mg", "condition_name": "Cancer-related Fatigue", "confidence_tier": "bronze", "why_stopped": "Change study drug dosage form", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0083", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: irradiation + carboplatin\nCondition: Lung Cancer\nPhase: phase_3\nTermination text: \"The study was stopped due to insufficient recruitment.\"", "metadata": {"result_id": 42576, "source_trial_id": "NCT03637335", "intervention_name": "irradiation + carboplatin", "condition_name": "Lung Cancer", "confidence_tier": "bronze", "why_stopped": "The study was stopped due to insufficient recruitment.", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0084", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: BGB-3245\nCondition: Solid Tumor\nPhase: phase_1\nTermination text: \"The study was terminated by the sponsor for reasons unrelated to safety.\"", "metadata": {"result_id": 27468, "source_trial_id": "NCT04249843", "intervention_name": "BGB-3245", "condition_name": "Solid Tumor", "confidence_tier": "bronze", "why_stopped": "The study was terminated by the sponsor for reasons unrelated to safety.", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0085", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Infliximab\nCondition: Spondylitis, Ankylosing\nPhase: phase_4\nTermination text: \"Poor Enrollment\"", "metadata": {"result_id": 8242, "source_trial_id": "NCT00686894", "intervention_name": "Infliximab", "condition_name": "Spondylitis, Ankylosing", "confidence_tier": "bronze", "why_stopped": "Poor Enrollment", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0086", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Daunorubicin\nCondition: AML, Childhood\nPhase: phase_2\nTermination text: \"Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial; thus, it was terminated.\"", "metadata": {"result_id": 13417, "source_trial_id": "NCT04326439", "intervention_name": "Daunorubicin", "condition_name": "AML, Childhood", "confidence_tier": "bronze", "why_stopped": "Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial; thus, it was terminated.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0087", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Metronidazole\nCondition: Clostridium Difficile Diarrhea\nPhase: phase_4\nTermination text: \"Patients noncompliant with instructions and follow ups could not be completed.\"", "metadata": {"result_id": 60431, "source_trial_id": "NCT02200328", "intervention_name": "Metronidazole", "condition_name": "Clostridium Difficile Diarrhea", "confidence_tier": "bronze", "why_stopped": "Patients noncompliant with instructions and follow ups could not be completed.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0088", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Emerfetamab\nCondition: Acute Myeloid Leukemia\nPhase: early_phase_1\nTermination text: \"Priortization of other Programs\"", "metadata": {"result_id": 6217, "source_trial_id": "NCT03224819", "intervention_name": "Emerfetamab", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "bronze", "why_stopped": "Priortization of other Programs", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0089", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: filgrastim\nCondition: Lymphoma\nPhase: phase_2\nTermination text: \"IRB Study Closure\"", "metadata": {"result_id": 1495, "source_trial_id": "NCT00303719", "intervention_name": "filgrastim", "condition_name": "Lymphoma", "confidence_tier": "bronze", "why_stopped": "IRB Study Closure", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0090", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Duloxetine\nCondition: Chronic Phantom Limb Pain\nTermination text: \"No patients were enrolled in this study. The study onset was delayed due to problems with drug acquisition.\"", "metadata": {"result_id": 46040, "source_trial_id": "NCT00425230", "intervention_name": "Duloxetine", "condition_name": "Chronic Phantom Limb Pain", "confidence_tier": "bronze", "why_stopped": "No patients were enrolled in this study. The study onset was delayed due to problems with drug acquisition.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0091", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: TAK-071\nCondition: Healthy Volunteers\nPhase: phase_1\nTermination text: \"Terminated prematurely as data from cohort no longer needed due to indication change.\"", "metadata": {"result_id": 18714, "source_trial_id": "NCT02769065", "intervention_name": "TAK-071", "condition_name": "Healthy Volunteers", "confidence_tier": "bronze", "why_stopped": "Terminated prematurely as data from cohort no longer needed due to indication change.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0092", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Alpha Methyl Para Tyrosine (AMPT)\nCondition: Cocaine Dependence\nTermination text: \"Study drug became unaffordable for the purposes of the research.\"", "metadata": {"result_id": 27635, "source_trial_id": "NCT02152670", "intervention_name": "Alpha Methyl Para Tyrosine (AMPT)", "condition_name": "Cocaine Dependence", "confidence_tier": "bronze", "why_stopped": "Study drug became unaffordable for the purposes of the research.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0093", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Sevelamer Carbonate (Renvela)\nCondition: Cardiovascular Disease\nTermination text: \"The study stopped due to lack of funding.\"", "metadata": {"result_id": 13497, "source_trial_id": "NCT01238588", "intervention_name": "Sevelamer Carbonate (Renvela)", "condition_name": "Cardiovascular Disease", "confidence_tier": "bronze", "why_stopped": "The study stopped due to lack of funding.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0094", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: TAS0728\nCondition: Advanced Solid Tumors With HER2 Abnormalities\nPhase: phase_1\nTermination text: \"The study was stopped due to unacceptable toxicity during the dose-escalation portion (Phase 1) of the study and did not progress to Phase 2\"", "metadata": {"result_id": 26824, "source_trial_id": "NCT03410927", "intervention_name": "TAS0728", "condition_name": "Advanced Solid Tumors With HER2 Abnormalities", "confidence_tier": "bronze", "why_stopped": "The study was stopped due to unacceptable toxicity during the dose-escalation portion (Phase 1) of the study and did not progress to Phase 2", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0095", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: JS004\nCondition: Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer\nPhase: phase_1\nTermination text: \"The trial was stopped early on the initiative of the sponsor on the basis of a change in the research and development strategy without safety concerns\"", "metadata": {"result_id": 509, "source_trial_id": "NCT05427396", "intervention_name": "JS004", "condition_name": "Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer", "confidence_tier": "bronze", "why_stopped": "The trial was stopped early on the initiative of the sponsor on the basis of a change in the research and development strategy without safety concerns", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0096", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: ezatiostat hydrochloride (Telintra®)\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_2\nTermination text: \"Study TLK199.2102 was terminated for lack of enrollment.\"", "metadata": {"result_id": 7617, "source_trial_id": "NCT00701870", "intervention_name": "ezatiostat hydrochloride (Telintra®)", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "why_stopped": "Study TLK199.2102 was terminated for lack of enrollment.", "therapeutic_area": "oncology"}, "split": "val"}
+{"question_id": "CTL2-0097", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Nifedipine\nCondition: Labor, Premature\nPhase: phase_3\nTermination text: \"The trial was terminated because of difficulties in recruitement.\"", "metadata": {"result_id": 56551, "source_trial_id": "NCT00137501", "intervention_name": "Nifedipine", "condition_name": "Labor, Premature", "confidence_tier": "bronze", "why_stopped": "The trial was terminated because of difficulties in recruitement.", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0098", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: E2082\nCondition: Healthy Participants\nPhase: phase_1\nTermination text: \"Safety Review\"", "metadata": {"result_id": 15073, "source_trial_id": "NCT03402178", "intervention_name": "E2082", "condition_name": "Healthy Participants", "confidence_tier": "bronze", "why_stopped": "Safety Review", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0099", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Delayed-Release (DR) Prednisone\nCondition: Polymyalgia Rheumatica\nPhase: phase_2\nTermination text: \"lack of study recruitment\"", "metadata": {"result_id": 64125, "source_trial_id": "NCT02702778", "intervention_name": "Delayed-Release (DR) Prednisone", "condition_name": "Polymyalgia Rheumatica", "confidence_tier": "bronze", "why_stopped": "lack of study recruitment", "therapeutic_area": "other"}, "split": "val"}
+{"question_id": "CTL2-0100", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: conventional medical treatment (TAU)\nCondition: Obsessive-Compulsive Disorder\nTermination text: \"Main trial terminated after pilot trial: full randomization proved infeasible for nonlocal participants; baseline symptom-based allocation added confounding variable; comparison with CBGT alone was deemed sufficient to assess SC-ICBT effectiveness\"", "metadata": {"result_id": 53500, "source_trial_id": "NCT05528224", "intervention_name": "conventional medical treatment (TAU)", "condition_name": "Obsessive-Compulsive Disorder", "confidence_tier": "bronze", "why_stopped": "Main trial terminated after pilot trial: full randomization proved infeasible for nonlocal participants; baseline symptom-based allocation added confounding variable; comparison with CBGT alone was deemed sufficient to assess SC-ICBT effectiveness", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0101", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: Sitravatinib\nCondition: Non-small Cell Lung Cancer (NSCLC)\nPhase: phase_3\nTermination text: \"Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to voluntarily terminate the study.\"", "metadata": {"result_id": 55216, "source_trial_id": "NCT04921358", "intervention_name": "Sitravatinib", "condition_name": "Non-small Cell Lung Cancer (NSCLC)", "confidence_tier": "bronze", "why_stopped": "Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to voluntarily terminate the study.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0102", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: adalimumab\nCondition: Rheumatoid Arthritis\nPhase: phase_4\nTermination text: \"The study was closed due to the slow enrollment rate.\"", "metadata": {"result_id": 62606, "source_trial_id": "NCT01283971", "intervention_name": "adalimumab", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "bronze", "why_stopped": "The study was closed due to the slow enrollment rate.", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0103", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Axicabtagene Ciloleucel\nCondition: B-cell Lymphoma Recurrent\nPhase: phase_2\nTermination text: \"Funder of the study terminated contract\"", "metadata": {"result_id": 5058, "source_trial_id": "NCT06912529", "intervention_name": "Axicabtagene Ciloleucel", "condition_name": "B-cell Lymphoma Recurrent", "confidence_tier": "bronze", "why_stopped": "Funder of the study terminated contract", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0104", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: standard medical treatment\nCondition: Acute-On-Chronic Liver Failure\nPhase: phase_3\nTermination text: \"Due to corporate business reasons only (non-safety related decision)\"", "metadata": {"result_id": 14189, "source_trial_id": "NCT03702920", "intervention_name": "standard medical treatment", "condition_name": "Acute-On-Chronic Liver Failure", "confidence_tier": "bronze", "why_stopped": "Due to corporate business reasons only (non-safety related decision)", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0105", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Albendazole and praziquantel\nCondition: Neurocysticercosis\nPhase: phase_3\nTermination text: \"Albendazole and albendazole placebo are not available in our local suppliers or in the international market. Consequently, it is no possible to re-initiate the enrollment to complete the original sample size.\"", "metadata": {"result_id": 62584, "source_trial_id": "NCT02947581", "intervention_name": "Albendazole and praziquantel", "condition_name": "Neurocysticercosis", "confidence_tier": "bronze", "why_stopped": "Albendazole and albendazole placebo are not available in our local suppliers or in the international market. Consequently, it is no possible to re-initiate the enrollment to complete the original sample size.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0106", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: vinorelbine\nCondition: Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers\nPhase: phase_2\nTermination text: \"The Sponsor discontinued the development of Simlukafusp alfa due to portfolio prioritization, not due to any safety, efficacy, or quality issues.\"", "metadata": {"result_id": 2094, "source_trial_id": "NCT03386721", "intervention_name": "vinorelbine", "condition_name": "Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers", "confidence_tier": "bronze", "why_stopped": "The Sponsor discontinued the development of Simlukafusp alfa due to portfolio prioritization, not due to any safety, efficacy, or quality issues.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0107", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Comparator: raltegravir\nCondition: HIV Infection\nPhase: phase_3\nTermination text: \"Primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir\"", "metadata": {"result_id": 55782, "source_trial_id": "NCT00443729", "intervention_name": "Comparator: raltegravir", "condition_name": "HIV Infection", "confidence_tier": "bronze", "why_stopped": "Primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0108", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: ASP8273\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1_2\nTermination text: \"Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.\"", "metadata": {"result_id": 42027, "source_trial_id": "NCT02192697", "intervention_name": "ASP8273", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "why_stopped": "Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0109", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: NA Cl\nCondition: Bone Demineralization Lesions in the Injured Marrow\nPhase: phase_3\nTermination text: \"Recruiting Difficulty\"", "metadata": {"result_id": 49244, "source_trial_id": "NCT01802658", "intervention_name": "NA Cl", "condition_name": "Bone Demineralization Lesions in the Injured Marrow", "confidence_tier": "bronze", "why_stopped": "Recruiting Difficulty", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0110", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Glargine\nCondition: Hyperglycemia Steroid-induced\nPhase: phase_4\nTermination text: \"Unable to recruit sufficient number of patients\"", "metadata": {"result_id": 51224, "source_trial_id": "NCT03511521", "intervention_name": "Glargine", "condition_name": "Hyperglycemia Steroid-induced", "confidence_tier": "bronze", "why_stopped": "Unable to recruit sufficient number of patients", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0111", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: N-Acetylcysteine\nCondition: Ischemic Reperfusion Injury\nPhase: phase_2\nTermination text: \"The first phase was completed\"", "metadata": {"result_id": 21430, "source_trial_id": "NCT01726465", "intervention_name": "N-Acetylcysteine", "condition_name": "Ischemic Reperfusion Injury", "confidence_tier": "bronze", "why_stopped": "The first phase was completed", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0112", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: AuriNovo\nCondition: Microtia\nPhase: phase_1_2\nTermination text: \"Company decision, not safety related.\"", "metadata": {"result_id": 23821, "source_trial_id": "NCT04399239", "intervention_name": "AuriNovo", "condition_name": "Microtia", "confidence_tier": "bronze", "why_stopped": "Company decision, not safety related.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0113", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ezurpimtrostat\nCondition: Hepatocellular Carcinoma\nPhase: phase_2\nTermination text: \"Study terminated due to recruitement issues\"", "metadata": {"result_id": 17690, "source_trial_id": "NCT05448677", "intervention_name": "Ezurpimtrostat", "condition_name": "Hepatocellular Carcinoma", "confidence_tier": "bronze", "why_stopped": "Study terminated due to recruitement issues", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0114", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Ketamine\nCondition: Major Depressive Disorder\nPhase: phase_2\nTermination text: \"Increasing off-label practice of IV ketamine administration for treatment-resistant depression.\"", "metadata": {"result_id": 16257, "source_trial_id": "NCT02882711", "intervention_name": "Ketamine", "condition_name": "Major Depressive Disorder", "confidence_tier": "bronze", "why_stopped": "Increasing off-label practice of IV ketamine administration for treatment-resistant depression.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0115", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: Follitropin delta\nCondition: Infertility\nPhase: phase_1\nTermination text: \"This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.\"", "metadata": {"result_id": 56527, "source_trial_id": "NCT06511791", "intervention_name": "Follitropin delta", "condition_name": "Infertility", "confidence_tier": "bronze", "why_stopped": "This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0116", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Lanabecestat\nCondition: Alzheimer's Disease\nPhase: phase_3\nTermination text: \"As the feeder study (AZES) was stopped for futility after an independent assessment, this trial was also stopped.\"", "metadata": {"result_id": 37208, "source_trial_id": "NCT02972658", "intervention_name": "Lanabecestat", "condition_name": "Alzheimer's Disease", "confidence_tier": "bronze", "why_stopped": "As the feeder study (AZES) was stopped for futility after an independent assessment, this trial was also stopped.", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0117", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: MRX-6\nCondition: Atopic Dermatitis\nPhase: phase_2\nTermination text: \"Interim analysis showed lack of efficacy\"", "metadata": {"result_id": 54972, "source_trial_id": "NCT02031445", "intervention_name": "MRX-6", "condition_name": "Atopic Dermatitis", "confidence_tier": "bronze", "why_stopped": "Interim analysis showed lack of efficacy", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0118", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Botox\nCondition: Lower Urinary Tract Discomfort\nPhase: phase_3\nTermination text: \"The study was terminated due to low enrollment\"", "metadata": {"result_id": 11140, "source_trial_id": "NCT02078895", "intervention_name": "Botox", "condition_name": "Lower Urinary Tract Discomfort", "confidence_tier": "bronze", "why_stopped": "The study was terminated due to low enrollment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0119", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: 4-Aminosalicylic acid\nCondition: Crohn's Disease\nPhase: phase_2\nTermination text: \"Efforts at recruitment have halted as recruitment was poor.\"", "metadata": {"result_id": 23402, "source_trial_id": "NCT00417690", "intervention_name": "4-Aminosalicylic acid", "condition_name": "Crohn's Disease", "confidence_tier": "bronze", "why_stopped": "Efforts at recruitment have halted as recruitment was poor.", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0120", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Caffeine (100 mg)\nCondition: Diverticulitis\nTermination text: \"lack of effect at interims analysis\"", "metadata": {"result_id": 50118, "source_trial_id": "NCT02510911", "intervention_name": "Caffeine (100 mg)", "condition_name": "Diverticulitis", "confidence_tier": "bronze", "why_stopped": "lack of effect at interims analysis", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0121", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Homologous booster\nCondition: Multiple Sclerosis\nPhase: early_phase_1\nTermination text: \"Most potential participants had already received their booster vaccinations outside of the study\"", "metadata": {"result_id": 46642, "source_trial_id": "NCT05081271", "intervention_name": "Homologous booster", "condition_name": "Multiple Sclerosis", "confidence_tier": "bronze", "why_stopped": "Most potential participants had already received their booster vaccinations outside of the study", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0122", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: ABI-007\nCondition: Hemodialysis Graft Dysfunction\nPhase: phase_2\nTermination text: \"Terminated due to pipeline prioritization\"", "metadata": {"result_id": 6731, "source_trial_id": "NCT00249002", "intervention_name": "ABI-007", "condition_name": "Hemodialysis Graft Dysfunction", "confidence_tier": "bronze", "why_stopped": "Terminated due to pipeline prioritization", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0123", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Platelet rich plasma (PRP)\nCondition: Patellar Tendinopathy\nPhase: phase_2\nTermination text: \"79% participant retention after 1 year\"", "metadata": {"result_id": 41867, "source_trial_id": "NCT02116946", "intervention_name": "Platelet rich plasma (PRP)", "condition_name": "Patellar Tendinopathy", "confidence_tier": "bronze", "why_stopped": "79% participant retention after 1 year", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0124", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Etrolizumab\nCondition: Crohn's Disease\nPhase: phase_1\nTermination text: \"The study was terminated due to program discontinuation, based on mixed efficacy results in the adult ulcerative colitis and Crohn's disease studies. There were no safety concerns.\"", "metadata": {"result_id": 49790, "source_trial_id": "NCT03478956", "intervention_name": "Etrolizumab", "condition_name": "Crohn's Disease", "confidence_tier": "bronze", "why_stopped": "The study was terminated due to program discontinuation, based on mixed efficacy results in the adult ulcerative colitis and Crohn's disease studies. There were no safety concerns.", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0125", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: V591\nCondition: Coronavirus Disease (COVID-19)\nPhase: phase_1_2\nTermination text: \"The study was terminated based on an interim assessment of immunogenicity\"", "metadata": {"result_id": 22176, "source_trial_id": "NCT04498247", "intervention_name": "V591", "condition_name": "Coronavirus Disease (COVID-19)", "confidence_tier": "bronze", "why_stopped": "The study was terminated based on an interim assessment of immunogenicity", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0126", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: 0.5 mg of ranibizumab\nCondition: Coronary Artery Disease\nPhase: phase_4\nTermination text: \"The study was terminated under the political pressure of the Federal Security Service of the Russian Federation (FSB) and the Russian Society of Cardiology\"", "metadata": {"result_id": 7134, "source_trial_id": "NCT01319188", "intervention_name": "0.5 mg of ranibizumab", "condition_name": "Coronary Artery Disease", "confidence_tier": "bronze", "why_stopped": "The study was terminated under the political pressure of the Federal Security Service of the Russian Federation (FSB) and the Russian Society of Cardiology", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0127", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: DI-Leu16-IL2\nCondition: B-cell Non-Hodgkin Lymphoma\nPhase: phase_1_2\nTermination text: \"Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.\"", "metadata": {"result_id": 2284, "source_trial_id": "NCT01874288", "intervention_name": "DI-Leu16-IL2", "condition_name": "B-cell Non-Hodgkin Lymphoma", "confidence_tier": "bronze", "why_stopped": "Clinical benefit was noted in the earlier portion of the trial; hence, participants were not enrolled in 2 expansion cohorts and the study was terminated early.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0128", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Nifedipine Extended-Release Tablets\nCondition: Hypertension in Pregnancy\nPhase: phase_4\nTermination text: \"Unable to continue recruiting\"", "metadata": {"result_id": 60971, "source_trial_id": "NCT04349124", "intervention_name": "Nifedipine Extended-Release Tablets", "condition_name": "Hypertension in Pregnancy", "confidence_tier": "bronze", "why_stopped": "Unable to continue recruiting", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0129", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Blood samples\nCondition: COVID-19 Infection\nTermination text: \"objective of the study demonstrated by other research teams\"", "metadata": {"result_id": 16420, "source_trial_id": "NCT04361344", "intervention_name": "Blood samples", "condition_name": "COVID-19 Infection", "confidence_tier": "bronze", "why_stopped": "objective of the study demonstrated by other research teams", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0130", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Paroxetine\nCondition: Hepatitis C Infection\nPhase: phase_2\nTermination text: \"Telaprevir will not be used in NL, no more inclusions are expected.\"", "metadata": {"result_id": 8785, "source_trial_id": "NCT01841502", "intervention_name": "Paroxetine", "condition_name": "Hepatitis C Infection", "confidence_tier": "bronze", "why_stopped": "Telaprevir will not be used in NL, no more inclusions are expected.", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0131", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: D-Cycloserine\nCondition: Chronic Prostatitis With Chronic Pelvic Pain Syndrome\nPhase: phase_4\nTermination text: \"The study was closed due to recruitment limitations\"", "metadata": {"result_id": 45140, "source_trial_id": "NCT02385266", "intervention_name": "D-Cycloserine", "condition_name": "Chronic Prostatitis With Chronic Pelvic Pain Syndrome", "confidence_tier": "bronze", "why_stopped": "The study was closed due to recruitment limitations", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0132", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Taxotere\nCondition: Breast Cancer\nPhase: phase_2\nTermination text: \"accrual too difficult to meet\"", "metadata": {"result_id": 45949, "source_trial_id": "NCT00206453", "intervention_name": "Taxotere", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "accrual too difficult to meet", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0133", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Nanrilkefusp Alfa\nCondition: Small-cell Lung Cancer\nPhase: phase_1\nTermination text: \"Due to lack of efficacy shown at the time of the interim analysis.\"", "metadata": {"result_id": 50461, "source_trial_id": "NCT04234113", "intervention_name": "Nanrilkefusp Alfa", "condition_name": "Small-cell Lung Cancer", "confidence_tier": "bronze", "why_stopped": "Due to lack of efficacy shown at the time of the interim analysis.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0134", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Asunercept\nCondition: COVID-19\nPhase: phase_3\nTermination text: \"Lack of patients\"", "metadata": {"result_id": 62914, "source_trial_id": "NCT05639192", "intervention_name": "Asunercept", "condition_name": "COVID-19", "confidence_tier": "bronze", "why_stopped": "Lack of patients", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0135", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Oral Clindamycin\nCondition: Abscess Soft Tissue\nTermination text: \"The study was closed due to poor enrollment and lack of interest.\"", "metadata": {"result_id": 51874, "source_trial_id": "NCT01498744", "intervention_name": "Oral Clindamycin", "condition_name": "Abscess Soft Tissue", "confidence_tier": "bronze", "why_stopped": "The study was closed due to poor enrollment and lack of interest.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0136", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: aldesleukin\nCondition: Metastatic Melanoma\nPhase: phase_2\nTermination text: \"Premature closure. Protocol did not meet its primary objective.\"", "metadata": {"result_id": 50836, "source_trial_id": "NCT01369875", "intervention_name": "aldesleukin", "condition_name": "Metastatic Melanoma", "confidence_tier": "bronze", "why_stopped": "Premature closure. Protocol did not meet its primary objective.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0137", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Crixotinib 200 mg and Sunitinib Cohort 1\nCondition: Breast Cancer\nPhase: phase_1\nTermination text: \"Poor accrual so the study was halted on May 16, 2017.\"", "metadata": {"result_id": 62705, "source_trial_id": "NCT02074878", "intervention_name": "Crixotinib 200 mg and Sunitinib Cohort 1", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "Poor accrual so the study was halted on May 16, 2017.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0138", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Iopamidol 300 (Contrast)\nCondition: Acute Kidney Injury\nPhase: phase_4\nTermination text: \"Insufficient number of subjects could be enrolled.\"", "metadata": {"result_id": 42592, "source_trial_id": "NCT02467075", "intervention_name": "Iopamidol 300 (Contrast)", "condition_name": "Acute Kidney Injury", "confidence_tier": "bronze", "why_stopped": "Insufficient number of subjects could be enrolled.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0139", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: CC-90002\nCondition: Myelodysplastic Syndromes\nPhase: phase_1\nTermination text: \"Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion\"", "metadata": {"result_id": 41952, "source_trial_id": "NCT02641002", "intervention_name": "CC-90002", "condition_name": "Myelodysplastic Syndromes", "confidence_tier": "bronze", "why_stopped": "Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a sufficiently encouraging profile for further dose escalation/expansion", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0140", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Triptorelin Acetate\nCondition: Infertility\nPhase: phase_3\nTermination text: \"Lower than anticipated recruitment\"", "metadata": {"result_id": 57412, "source_trial_id": "NCT01007851", "intervention_name": "Triptorelin Acetate", "condition_name": "Infertility", "confidence_tier": "bronze", "why_stopped": "Lower than anticipated recruitment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0141", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Topical Calcipotriene Ointment\nCondition: Breast Cancer\nPhase: phase_1\nTermination text: \"Interim analysis did not show the required cytokine induction by topical calcipotriene to justify continuation of the trial\"", "metadata": {"result_id": 18238, "source_trial_id": "NCT03596073", "intervention_name": "Topical Calcipotriene Ointment", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "Interim analysis did not show the required cytokine induction by topical calcipotriene to justify continuation of the trial", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0142", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Standard of Care\nCondition: Postoperative Pain Management\nPhase: phase_4\nTermination text: \"Due to protocol feasibility given the rapid evolution of medical practice for spinal procedure. Data from approximately 65 FUSION study subjects will be analyzed with the intent to create either a future study or registry for this patient population.\"", "metadata": {"result_id": 29139, "source_trial_id": "NCT03927911", "intervention_name": "Standard of Care", "condition_name": "Postoperative Pain Management", "confidence_tier": "bronze", "why_stopped": "Due to protocol feasibility given the rapid evolution of medical practice for spinal procedure. Data from approximately 65 FUSION study subjects will be analyzed with the intent to create either a future study or registry for this patient population.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0143", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Anakinra 100Mg/0.67Ml Inj Syringe\nCondition: COVID-19\nPhase: phase_2\nTermination text: \"Lack of patients in the trial population from which to recruit and lack of funding\"", "metadata": {"result_id": 33260, "source_trial_id": "NCT04462757", "intervention_name": "Anakinra 100Mg/0.67Ml Inj Syringe", "condition_name": "COVID-19", "confidence_tier": "bronze", "why_stopped": "Lack of patients in the trial population from which to recruit and lack of funding", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0144", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: hLB-001\nCondition: Methylmalonic Acidemia\nPhase: phase_1_2\nTermination text: \"Due to low likelihood of clinical benefit in treated participants.\"", "metadata": {"result_id": 49507, "source_trial_id": "NCT04581785", "intervention_name": "hLB-001", "condition_name": "Methylmalonic Acidemia", "confidence_tier": "bronze", "why_stopped": "Due to low likelihood of clinical benefit in treated participants.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0145", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Epinephrine\nCondition: Pain, Referred\nPhase: phase_2\nTermination text: \"study was published during initial recruitment that showed no difference\"", "metadata": {"result_id": 51530, "source_trial_id": "NCT03383588", "intervention_name": "Epinephrine", "condition_name": "Pain, Referred", "confidence_tier": "bronze", "why_stopped": "study was published during initial recruitment that showed no difference", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0146", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: EXPAREL\nCondition: Pain\nPhase: early_phase_1\nTermination text: \"Adequate enrollment was not reached for this study.\"", "metadata": {"result_id": 33169, "source_trial_id": "NCT02369523", "intervention_name": "EXPAREL", "condition_name": "Pain", "confidence_tier": "bronze", "why_stopped": "Adequate enrollment was not reached for this study.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0147", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: LY2127399\nCondition: Rheumatoid Arthritis\nPhase: phase_2\nTermination text: \"Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773).\"", "metadata": {"result_id": 11783, "source_trial_id": "NCT01576549", "intervention_name": "LY2127399", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "bronze", "why_stopped": "Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773).", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0148", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Evobrutinib\nCondition: Relapsing Multiple Sclerosis\nPhase: phase_3\nTermination text: \"Primary analysis of the RMS phase 3 study (MS200527\\_0082) resulted in the early termination of the study.\"", "metadata": {"result_id": 47905, "source_trial_id": "NCT04338061", "intervention_name": "Evobrutinib", "condition_name": "Relapsing Multiple Sclerosis", "confidence_tier": "bronze", "why_stopped": "Primary analysis of the RMS phase 3 study (MS200527\\_0082) resulted in the early termination of the study.", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0149", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Enzalutamide\nCondition: Ann Arbor Stage II Mantle Cell Lymphoma\nPhase: phase_2\nTermination text: \"Accrual goal not met\"", "metadata": {"result_id": 6571, "source_trial_id": "NCT02489123", "intervention_name": "Enzalutamide", "condition_name": "Ann Arbor Stage II Mantle Cell Lymphoma", "confidence_tier": "bronze", "why_stopped": "Accrual goal not met", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0150", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Mitomycin-C\nCondition: Anal Cancer\nPhase: phase_1\nTermination text: \"Slow, insufficient accrual and failure to meet endpoints.\"", "metadata": {"result_id": 10946, "source_trial_id": "NCT01324141", "intervention_name": "Mitomycin-C", "condition_name": "Anal Cancer", "confidence_tier": "bronze", "why_stopped": "Slow, insufficient accrual and failure to meet endpoints.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0151", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Zoledronate\nCondition: Breast Cancer\nPhase: phase_2\nTermination text: \"The study stopped prematurely due to the low accrual rate\"", "metadata": {"result_id": 38780, "source_trial_id": "NCT02347163", "intervention_name": "Zoledronate", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "The study stopped prematurely due to the low accrual rate", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0152", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Platelet Transfusion - LONG Platelet Transfusion\nCondition: Thrombocytopenia\nPhase: phase_2\nTermination text: \"Due to recruitment difficulty\"", "metadata": {"result_id": 41176, "source_trial_id": "NCT03712618", "intervention_name": "Platelet Transfusion - LONG Platelet Transfusion", "condition_name": "Thrombocytopenia", "confidence_tier": "bronze", "why_stopped": "Due to recruitment difficulty", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0153", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting\nCondition: Lateral Epicondylitis\nPhase: phase_4\nTermination text: \"Because the sample volume was completed during three years.\"", "metadata": {"result_id": 33739, "source_trial_id": "NCT00554476", "intervention_name": "Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting", "condition_name": "Lateral Epicondylitis", "confidence_tier": "bronze", "why_stopped": "Because the sample volume was completed during three years.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0154", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: imatinib mesylate\nCondition: Scleroderma\nPhase: phase_2\nTermination text: \"Frequent adverse events occurred early in treatment with poor tolerability.\"", "metadata": {"result_id": 62236, "source_trial_id": "NCT01545427", "intervention_name": "imatinib mesylate", "condition_name": "Scleroderma", "confidence_tier": "bronze", "why_stopped": "Frequent adverse events occurred early in treatment with poor tolerability.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0155", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Retigabine 900mg/day\nCondition: Epilepsy\nPhase: phase_3\nTermination text: \"Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam\"", "metadata": {"result_id": 23714, "source_trial_id": "NCT01648101", "intervention_name": "Retigabine 900mg/day", "condition_name": "Epilepsy", "confidence_tier": "bronze", "why_stopped": "Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0156", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Gralise\nCondition: Ulcerative Colitis\nPhase: phase_4\nTermination text: \"Study ended due to difficulties in recruitment and low enrollment.\"", "metadata": {"result_id": 43428, "source_trial_id": "NCT01678911", "intervention_name": "Gralise", "condition_name": "Ulcerative Colitis", "confidence_tier": "bronze", "why_stopped": "Study ended due to difficulties in recruitment and low enrollment.", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0157", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Truvada qd\nCondition: HIV\nTermination text: \"Minimal efficacy of maraviroc alone was found in preliminary data analysis of another study.\"", "metadata": {"result_id": 22086, "source_trial_id": "NCT02333045", "intervention_name": "Truvada qd", "condition_name": "HIV", "confidence_tier": "bronze", "why_stopped": "Minimal efficacy of maraviroc alone was found in preliminary data analysis of another study.", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0158", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Liposomal Bupivacaine\nCondition: Raynaud Disease\nPhase: phase_2_3\nTermination text: \"PI leaving institution\"", "metadata": {"result_id": 27997, "source_trial_id": "NCT02374320", "intervention_name": "Liposomal Bupivacaine", "condition_name": "Raynaud Disease", "confidence_tier": "bronze", "why_stopped": "PI leaving institution", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0159", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Fulvestrant and Erlotinib\nCondition: Non Small Cell Lung Carcinoma\nPhase: phase_2\nTermination text: \"Study was terminated due to slow subject accrual\"", "metadata": {"result_id": 10005, "source_trial_id": "NCT00592007", "intervention_name": "Fulvestrant and Erlotinib", "condition_name": "Non Small Cell Lung Carcinoma", "confidence_tier": "bronze", "why_stopped": "Study was terminated due to slow subject accrual", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0160", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ibandronate (Bondronat)\nCondition: Lung Cancer\nPhase: phase_4\nTermination text: \"It is too difficult to recruit suitable patients.\"", "metadata": {"result_id": 28326, "source_trial_id": "NCT00492843", "intervention_name": "Ibandronate (Bondronat)", "condition_name": "Lung Cancer", "confidence_tier": "bronze", "why_stopped": "It is too difficult to recruit suitable patients.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0161", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: KN046\nCondition: Thymic Carcinoma\nPhase: phase_2\nTermination text: \"The termination of this study does not involve safety issues. The overall safety of KN046 is good, and no new safety signals have been found. The decision to terminate this study was made due to the adjustment of the sponsor's development strategy.\"", "metadata": {"result_id": 39821, "source_trial_id": "NCT04469725", "intervention_name": "KN046", "condition_name": "Thymic Carcinoma", "confidence_tier": "bronze", "why_stopped": "The termination of this study does not involve safety issues. The overall safety of KN046 is good, and no new safety signals have been found. The decision to terminate this study was made due to the adjustment of the sponsor's development strategy.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0162", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: DBI-001\nCondition: Atopic Dermatitis\nPhase: phase_2\nTermination text: \"Sponsor suspension and not due to safety or site-related matters.\"", "metadata": {"result_id": 53165, "source_trial_id": "NCT05253755", "intervention_name": "DBI-001", "condition_name": "Atopic Dermatitis", "confidence_tier": "bronze", "why_stopped": "Sponsor suspension and not due to safety or site-related matters.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0163", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Imatinib\nCondition: Patients Who Have Received Allo-HSCT\nPhase: phase_2\nTermination text: \"The trial is terminated due to the extremely low recruitment rate.\"", "metadata": {"result_id": 63017, "source_trial_id": "NCT03343600", "intervention_name": "Imatinib", "condition_name": "Patients Who Have Received Allo-HSCT", "confidence_tier": "bronze", "why_stopped": "The trial is terminated due to the extremely low recruitment rate.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0164", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Mirdametinib\nCondition: Advanced Solid Tumor\nPhase: phase_1_2\nTermination text: \"Lack of tolerability of Brimarafenib when given in combination of Mirdametinib\"", "metadata": {"result_id": 54847, "source_trial_id": "NCT05580770", "intervention_name": "Mirdametinib", "condition_name": "Advanced Solid Tumor", "confidence_tier": "bronze", "why_stopped": "Lack of tolerability of Brimarafenib when given in combination of Mirdametinib", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0165", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Phenylephrine\nCondition: Spinal Anesthesia\nPhase: phase_4\nTermination text: \"Change in clinical practice since the start of the trial in 2011 (phenylephrine superior)\"", "metadata": {"result_id": 44497, "source_trial_id": "NCT01243970", "intervention_name": "Phenylephrine", "condition_name": "Spinal Anesthesia", "confidence_tier": "bronze", "why_stopped": "Change in clinical practice since the start of the trial in 2011 (phenylephrine superior)", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0166", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Sodium Nitrite\nCondition: Cystic Fibrosis\nPhase: phase_1_2\nTermination text: \"Protocol closed due to difficulty recruiting subjects and then expiration of investigational product and lack of a manufacturer.\"", "metadata": {"result_id": 5359, "source_trial_id": "NCT02694393", "intervention_name": "Sodium Nitrite", "condition_name": "Cystic Fibrosis", "confidence_tier": "bronze", "why_stopped": "Protocol closed due to difficulty recruiting subjects and then expiration of investigational product and lack of a manufacturer.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0167", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Butenafine Hydrochloride 1%\nCondition: Interdigital Tinea Pedis\nPhase: phase_1\nTermination text: \"Insufficient number of baseline eligible patient\"", "metadata": {"result_id": 9211, "source_trial_id": "NCT01119742", "intervention_name": "Butenafine Hydrochloride 1%", "condition_name": "Interdigital Tinea Pedis", "confidence_tier": "bronze", "why_stopped": "Insufficient number of baseline eligible patient", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0168", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: XL999\nCondition: Acute Myeloid Leukemia\nPhase: phase_2\nTermination text: \"Study was terminated due to cardiac toxicities\"", "metadata": {"result_id": 7094, "source_trial_id": "NCT00322673", "intervention_name": "XL999", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "bronze", "why_stopped": "Study was terminated due to cardiac toxicities", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0169", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Midazolam\nCondition: Major Depressive Disorder\nPhase: phase_1\nTermination text: \"Inadequate recruitment\"", "metadata": {"result_id": 17172, "source_trial_id": "NCT02661061", "intervention_name": "Midazolam", "condition_name": "Major Depressive Disorder", "confidence_tier": "bronze", "why_stopped": "Inadequate recruitment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0170", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Pioglitazone\nCondition: Fatty Liver\nTermination text: \"Low recruitment in intervention study. Baseline data published.\"", "metadata": {"result_id": 2979, "source_trial_id": "NCT01289639", "intervention_name": "Pioglitazone", "condition_name": "Fatty Liver", "confidence_tier": "bronze", "why_stopped": "Low recruitment in intervention study. Baseline data published.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0171", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Diphenylcyclopropenone (DPCP) Ointment\nCondition: Alopecia Areata\nPhase: phase_3\nTermination text: \"The study was paused/enrollment on hold after 4 screen failed subjects. No further subjects were enrolled, therefore, no data was available to collect/analyze.\"", "metadata": {"result_id": 28911, "source_trial_id": "NCT03651752", "intervention_name": "Diphenylcyclopropenone (DPCP) Ointment", "condition_name": "Alopecia Areata", "confidence_tier": "bronze", "why_stopped": "The study was paused/enrollment on hold after 4 screen failed subjects. No further subjects were enrolled, therefore, no data was available to collect/analyze.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0172", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Lapatinib and Capecitabine and Vinorelbine\nCondition: Metastatic Breast Cancer\nPhase: phase_1\nTermination text: \"new methods of treatment, no more patients appilicable for study\"", "metadata": {"result_id": 27532, "source_trial_id": "NCT01238029", "intervention_name": "Lapatinib and Capecitabine and Vinorelbine", "condition_name": "Metastatic Breast Cancer", "confidence_tier": "bronze", "why_stopped": "new methods of treatment, no more patients appilicable for study", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0173", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Olanzapine\nCondition: Neoplasms\nPhase: phase_3\nTermination text: \"Study suspended due to low enrollment\"", "metadata": {"result_id": 48463, "source_trial_id": "NCT00124930", "intervention_name": "Olanzapine", "condition_name": "Neoplasms", "confidence_tier": "bronze", "why_stopped": "Study suspended due to low enrollment", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0174", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Simvastatin\nCondition: Choroideremia\nPhase: phase_1_2\nTermination text: \"The study has been terminated due to limited participant enrollment.\"", "metadata": {"result_id": 24985, "source_trial_id": "NCT01654562", "intervention_name": "Simvastatin", "condition_name": "Choroideremia", "confidence_tier": "bronze", "why_stopped": "The study has been terminated due to limited participant enrollment.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0175", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Duration of DAPT\nCondition: Coronary Artery Disease\nPhase: phase_4\nTermination text: \"Ending early registration due to low registration status and lack of research\"", "metadata": {"result_id": 9064, "source_trial_id": "NCT05066789", "intervention_name": "Duration of DAPT", "condition_name": "Coronary Artery Disease", "confidence_tier": "bronze", "why_stopped": "Ending early registration due to low registration status and lack of research", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0176", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: SIMVASTATIN 40 mg\nCondition: Cerebral Vasospasm\nTermination text: \"Study PI left the institution and study was stopped at that time.\"", "metadata": {"result_id": 10021, "source_trial_id": "NCT00487461", "intervention_name": "SIMVASTATIN 40 mg", "condition_name": "Cerebral Vasospasm", "confidence_tier": "bronze", "why_stopped": "Study PI left the institution and study was stopped at that time.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0177", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Donepezil Hydrochloride\nCondition: Alzheimer's Disease\nPhase: phase_4\nTermination text: \"Lack of patients to enroll.\"", "metadata": {"result_id": 60626, "source_trial_id": "NCT00165750", "intervention_name": "Donepezil Hydrochloride", "condition_name": "Alzheimer's Disease", "confidence_tier": "bronze", "why_stopped": "Lack of patients to enroll.", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0178", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Quinapril 40 mg\nCondition: Hypertension\nPhase: phase_4\nTermination text: \"Very difficult to recruit patients/slow recruitment(2 patients in nearly 2 years).\"", "metadata": {"result_id": 62799, "source_trial_id": "NCT00313547", "intervention_name": "Quinapril 40 mg", "condition_name": "Hypertension", "confidence_tier": "bronze", "why_stopped": "Very difficult to recruit patients/slow recruitment(2 patients in nearly 2 years).", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0179", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Radioactive labelling of pulmonary nodules\nCondition: Bronchial Neoplasms\nPhase: phase_2\nTermination text: \"Ende of part 1. Only few patients in part 2 enrolled\"", "metadata": {"result_id": 39575, "source_trial_id": "NCT02050724", "intervention_name": "Radioactive labelling of pulmonary nodules", "condition_name": "Bronchial Neoplasms", "confidence_tier": "bronze", "why_stopped": "Ende of part 1. Only few patients in part 2 enrolled", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0180", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: allogeneic fecal microbiota\nCondition: Multiple Sclerosis\nPhase: phase_1\nTermination text: \"the bio-samples are corrupted for technical reasons\"", "metadata": {"result_id": 37159, "source_trial_id": "NCT04203017", "intervention_name": "allogeneic fecal microbiota", "condition_name": "Multiple Sclerosis", "confidence_tier": "bronze", "why_stopped": "the bio-samples are corrupted for technical reasons", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0181", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Moxonidine\nCondition: Vascular Surgery\nPhase: phase_3\nTermination text: \"Study was stopped after pre-definied interim analysis because of no effects\"", "metadata": {"result_id": 52578, "source_trial_id": "NCT00244504", "intervention_name": "Moxonidine", "condition_name": "Vascular Surgery", "confidence_tier": "bronze", "why_stopped": "Study was stopped after pre-definied interim analysis because of no effects", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0182", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Metolazone\nCondition: Chronic Kidney Disease\nPhase: phase_2\nTermination text: \"Lack of resources\"", "metadata": {"result_id": 3930, "source_trial_id": "NCT04542304", "intervention_name": "Metolazone", "condition_name": "Chronic Kidney Disease", "confidence_tier": "bronze", "why_stopped": "Lack of resources", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0183", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: Etrumadenant\nCondition: Prostate Cancer\nPhase: phase_2\nTermination text: \"The study was terminated for strategic reasons, not due to any safety concerns.\"", "metadata": {"result_id": 53306, "source_trial_id": "NCT05177770", "intervention_name": "Etrumadenant", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "why_stopped": "The study was terminated for strategic reasons, not due to any safety concerns.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0184", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Increased dose of Kaletra\nCondition: HIV Infections\nPhase: phase_4\nTermination text: \"One subject's HIV RNA rebounded at week 12. A repeat PhenoSense GT combination resistance assay at week 12 revealed evolution in protease inhibitor resistance.\"", "metadata": {"result_id": 7635, "source_trial_id": "NCT00414284", "intervention_name": "Increased dose of Kaletra", "condition_name": "HIV Infections", "confidence_tier": "bronze", "why_stopped": "One subject's HIV RNA rebounded at week 12. A repeat PhenoSense GT combination resistance assay at week 12 revealed evolution in protease inhibitor resistance.", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0185", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Tobramycin nebulized nasally\nCondition: Cystic Fibrosis\nPhase: phase_3\nTermination text: \"No suffisant recruitment\"", "metadata": {"result_id": 55152, "source_trial_id": "NCT02888730", "intervention_name": "Tobramycin nebulized nasally", "condition_name": "Cystic Fibrosis", "confidence_tier": "bronze", "why_stopped": "No suffisant recruitment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0186", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Group1: IV t-PA and normothermia\nCondition: Stroke, Acute\nPhase: phase_2_3\nTermination text: \"The ICTuS 2 portion of the trial has been halted and data will be analyzed.\"", "metadata": {"result_id": 26734, "source_trial_id": "NCT01123161", "intervention_name": "Group1: IV t-PA and normothermia", "condition_name": "Stroke, Acute", "confidence_tier": "bronze", "why_stopped": "The ICTuS 2 portion of the trial has been halted and data will be analyzed.", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0187", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: rt-PA\nCondition: Argatroban, Rt-PA\nPhase: phase_4\nTermination text: \"it is very difficult to recruit qualified patients\"", "metadata": {"result_id": 18209, "source_trial_id": "NCT03506009", "intervention_name": "rt-PA", "condition_name": "Argatroban, Rt-PA", "confidence_tier": "bronze", "why_stopped": "it is very difficult to recruit qualified patients", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0188", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Allergovit 6-grasses\nCondition: Healthy Volunteers\nPhase: phase_2\nTermination text: \"The study was terminated due to the interim Analysis results indicating a weaker correlation than anticipated and reported by other study groups.\"", "metadata": {"result_id": 5109, "source_trial_id": "NCT02297490", "intervention_name": "Allergovit 6-grasses", "condition_name": "Healthy Volunteers", "confidence_tier": "bronze", "why_stopped": "The study was terminated due to the interim Analysis results indicating a weaker correlation than anticipated and reported by other study groups.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0189", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: I5NP\nCondition: Acute Kidney Injury\nPhase: phase_1\nTermination text: \"Lack of an available patient population\"", "metadata": {"result_id": 20680, "source_trial_id": "NCT00683553", "intervention_name": "I5NP", "condition_name": "Acute Kidney Injury", "confidence_tier": "bronze", "why_stopped": "Lack of an available patient population", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0190", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Acetylcholine\nCondition: Arterial Stiffness\nPhase: early_phase_1\nTermination text: \"IRB approval has been withdrawn\"", "metadata": {"result_id": 15410, "source_trial_id": "NCT04001647", "intervention_name": "Acetylcholine", "condition_name": "Arterial Stiffness", "confidence_tier": "bronze", "why_stopped": "IRB approval has been withdrawn", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0191", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Hydrocortisone\nCondition: Acute Lymphocytic Leukemia\nPhase: phase_2\nTermination text: \"Original investigator for the trial has left\"", "metadata": {"result_id": 44635, "source_trial_id": "NCT02043587", "intervention_name": "Hydrocortisone", "condition_name": "Acute Lymphocytic Leukemia", "confidence_tier": "bronze", "why_stopped": "Original investigator for the trial has left", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0192", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL\nCondition: Ocular Hypertension\nPhase: phase_2\nTermination text: \"Project cancellation\"", "metadata": {"result_id": 54693, "source_trial_id": "NCT00788541", "intervention_name": "Anecortave Acetate Sterile Suspension, 60 mg/mL", "condition_name": "Ocular Hypertension", "confidence_tier": "bronze", "why_stopped": "Project cancellation", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0193", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Imvotamab\nCondition: Rheumatoid Arthritis\nPhase: phase_1\nTermination text: \"Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis demonstrated that the depth and consistency in B Cell depletion required to measure success was insufficient.\"", "metadata": {"result_id": 55712, "source_trial_id": "NCT06087406", "intervention_name": "Imvotamab", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "bronze", "why_stopped": "Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis demonstrated that the depth and consistency in B Cell depletion required to measure success was insufficient.", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0194", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Seretide\nCondition: Stem Cell Transplant Complications\nPhase: phase_3\nTermination text: \"insufficient enrollment.\"", "metadata": {"result_id": 12098, "source_trial_id": "NCT04655508", "intervention_name": "Seretide", "condition_name": "Stem Cell Transplant Complications", "confidence_tier": "bronze", "why_stopped": "insufficient enrollment.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0195", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: PRM-151 (Zinpentraxin Alfa)\nCondition: Idiopathic Pulmonary Fibrosis\nPhase: phase_3\nTermination text: \"The study was terminated by Sponsor as the futility analysis outcome indicated that the study was unlikely to meet the predefined primary objective of the study. No new safety concerns were identified.\"", "metadata": {"result_id": 46088, "source_trial_id": "NCT04594707", "intervention_name": "PRM-151 (Zinpentraxin Alfa)", "condition_name": "Idiopathic Pulmonary Fibrosis", "confidence_tier": "bronze", "why_stopped": "The study was terminated by Sponsor as the futility analysis outcome indicated that the study was unlikely to meet the predefined primary objective of the study. No new safety concerns were identified.", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL2-0196", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Acetaminophen 500mg\nCondition: Patellofemoral Pain Syndrome\nTermination text: \"Required number of participants were not able to be enrolled.\"", "metadata": {"result_id": 2652, "source_trial_id": "NCT02241148", "intervention_name": "Acetaminophen 500mg", "condition_name": "Patellofemoral Pain Syndrome", "confidence_tier": "bronze", "why_stopped": "Required number of participants were not able to be enrolled.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0197", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: baltaleucel-T\nCondition: EBV\nPhase: phase_2\nTermination text: \"Insufficient enrollment rate\"", "metadata": {"result_id": 21909, "source_trial_id": "NCT01948180", "intervention_name": "baltaleucel-T", "condition_name": "EBV", "confidence_tier": "bronze", "why_stopped": "Insufficient enrollment rate", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0198", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Clostridial collagenase injectable\nCondition: Dupuytren's Disease\nPhase: phase_4\nTermination text: \"difficulty enrolling additional patients\"", "metadata": {"result_id": 15200, "source_trial_id": "NCT01226121", "intervention_name": "Clostridial collagenase injectable", "condition_name": "Dupuytren's Disease", "confidence_tier": "bronze", "why_stopped": "difficulty enrolling additional patients", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0199", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Roflumilast\nCondition: Chronic Obstructive Pulmonary Disease\nPhase: phase_2\nTermination text: \"The recruitment of the study was prematurely stopped in July 2014 for the following reason; no more study medication.\"", "metadata": {"result_id": 62340, "source_trial_id": "NCT01701934", "intervention_name": "Roflumilast", "condition_name": "Chronic Obstructive Pulmonary Disease", "confidence_tier": "bronze", "why_stopped": "The recruitment of the study was prematurely stopped in July 2014 for the following reason; no more study medication.", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL2-0200", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Busulphan\nCondition: Myelodysplastic Syndromes\nPhase: phase_2\nTermination text: \"FB ATG is now a standard for sib allo MDS patients\"", "metadata": {"result_id": 23450, "source_trial_id": "NCT00915811", "intervention_name": "Busulphan", "condition_name": "Myelodysplastic Syndromes", "confidence_tier": "bronze", "why_stopped": "FB ATG is now a standard for sib allo MDS patients", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0201", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Rosiglitazone\nCondition: Non Diabetic Subjects With Normoglycemia\nPhase: phase_4\nTermination text: \"Slow recruitment and increase in deployment overseas limiting follow up\"", "metadata": {"result_id": 32733, "source_trial_id": "NCT00819910", "intervention_name": "Rosiglitazone", "condition_name": "Non Diabetic Subjects With Normoglycemia", "confidence_tier": "bronze", "why_stopped": "Slow recruitment and increase in deployment overseas limiting follow up", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0202", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: CDP323\nCondition: Multiple Sclerosis\nPhase: phase_2\nTermination text: \"The study was discontinued due to unfavorable interim analysis\"", "metadata": {"result_id": 26637, "source_trial_id": "NCT00484536", "intervention_name": "CDP323", "condition_name": "Multiple Sclerosis", "confidence_tier": "bronze", "why_stopped": "The study was discontinued due to unfavorable interim analysis", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0203", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: TBL 12\nCondition: Multiple Myeloma\nPhase: phase_2\nTermination text: \"The research is permanently closed to enrollment.\"", "metadata": {"result_id": 46811, "source_trial_id": "NCT01096810", "intervention_name": "TBL 12", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "why_stopped": "The research is permanently closed to enrollment.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0204", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: CHR-2797 (tosedostat)\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_1_2\nTermination text: \"Very poor recruitment of patients to the study\"", "metadata": {"result_id": 9883, "source_trial_id": "NCT00522938", "intervention_name": "CHR-2797 (tosedostat)", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "why_stopped": "Very poor recruitment of patients to the study", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0205", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Mepolizumab\nCondition: Angioedema\nPhase: phase_2\nTermination text: \"Study was closed after the first five participants completed their participation due to lack of efficacy.\"", "metadata": {"result_id": 21906, "source_trial_id": "NCT04128371", "intervention_name": "Mepolizumab", "condition_name": "Angioedema", "confidence_tier": "bronze", "why_stopped": "Study was closed after the first five participants completed their participation due to lack of efficacy.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0206", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Entospletinib\nCondition: Acute Myeloid Leukemia\nPhase: phase_1\nTermination text: \"No signal of efficacy with Entospletinib\"", "metadata": {"result_id": 27537, "source_trial_id": "NCT03135028", "intervention_name": "Entospletinib", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "bronze", "why_stopped": "No signal of efficacy with Entospletinib", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0207", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Nitric Oxide\nCondition: Pressure Ulcer\nPhase: phase_1_2\nTermination text: \"limited recruitment\"", "metadata": {"result_id": 27231, "source_trial_id": "NCT00771368", "intervention_name": "Nitric Oxide", "condition_name": "Pressure Ulcer", "confidence_tier": "bronze", "why_stopped": "limited recruitment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0208", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: dialysate sodium individualization\nCondition: Hypertension\nPhase: phase_1\nTermination text: \"Protocol was not feasible - only 1 of 18 enrollees completed procedures.\"", "metadata": {"result_id": 2720, "source_trial_id": "NCT00259714", "intervention_name": "dialysate sodium individualization", "condition_name": "Hypertension", "confidence_tier": "bronze", "why_stopped": "Protocol was not feasible - only 1 of 18 enrollees completed procedures.", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0209", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: MarzAA\nCondition: Hemophilia A With Inhibitor\nPhase: phase_3\nTermination text: \"Sponsor decision (not a safety decision)\"", "metadata": {"result_id": 32239, "source_trial_id": "NCT04489537", "intervention_name": "MarzAA", "condition_name": "Hemophilia A With Inhibitor", "confidence_tier": "bronze", "why_stopped": "Sponsor decision (not a safety decision)", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0210", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: GRT6010\nCondition: Neuralgia\nPhase: phase_2\nTermination text: \"The trial was early terminated after it was concluded that there was no added benefit from exposing further participants after an unblinded interim analysis.\"", "metadata": {"result_id": 1916, "source_trial_id": "NCT01485094", "intervention_name": "GRT6010", "condition_name": "Neuralgia", "confidence_tier": "bronze", "why_stopped": "The trial was early terminated after it was concluded that there was no added benefit from exposing further participants after an unblinded interim analysis.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0211", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Solumedrol\nCondition: Secondary Progressive Multiple Sclerosis\nTermination text: \"Low enrollment/PI relocated. New site couldn't reach agreement with manufacturer\"", "metadata": {"result_id": 23756, "source_trial_id": "NCT02296346", "intervention_name": "Solumedrol", "condition_name": "Secondary Progressive Multiple Sclerosis", "confidence_tier": "bronze", "why_stopped": "Low enrollment/PI relocated. New site couldn't reach agreement with manufacturer", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0212", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Abemaciclib\nCondition: Biliary Tract Carcinoma\nPhase: phase_2\nTermination text: \"The manufacturer and funder Eli Lilly requested to terminate the study\"", "metadata": {"result_id": 45419, "source_trial_id": "NCT04003896", "intervention_name": "Abemaciclib", "condition_name": "Biliary Tract Carcinoma", "confidence_tier": "bronze", "why_stopped": "The manufacturer and funder Eli Lilly requested to terminate the study", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0213", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Nanoparticle Paclitaxel\nCondition: Vascular Disease, Peripheral\nPhase: phase_2\nTermination text: \"Study was terminated due to changing sponsor priorities, and was not based on safety or outcomes data.\"", "metadata": {"result_id": 23741, "source_trial_id": "NCT00518284", "intervention_name": "Nanoparticle Paclitaxel", "condition_name": "Vascular Disease, Peripheral", "confidence_tier": "bronze", "why_stopped": "Study was terminated due to changing sponsor priorities, and was not based on safety or outcomes data.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0214", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: R-baclofen\nCondition: Autism\nPhase: phase_1\nTermination text: \"too much variability in the TMS measures\"", "metadata": {"result_id": 8338, "source_trial_id": "NCT01172509", "intervention_name": "R-baclofen", "condition_name": "Autism", "confidence_tier": "bronze", "why_stopped": "too much variability in the TMS measures", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0215", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: MK2206\nCondition: Diffuse Large B Cell Lymphoma\nPhase: phase_2\nTermination text: \"Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions\"", "metadata": {"result_id": 35415, "source_trial_id": "NCT01466868", "intervention_name": "MK2206", "condition_name": "Diffuse Large B Cell Lymphoma", "confidence_tier": "bronze", "why_stopped": "Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0216", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Ropivacaine concentration\nCondition: Surgical Anesthesia\nPhase: phase_2\nTermination text: \"Departure of principal investigator\"", "metadata": {"result_id": 26422, "source_trial_id": "NCT01452126", "intervention_name": "Ropivacaine concentration", "condition_name": "Surgical Anesthesia", "confidence_tier": "bronze", "why_stopped": "Departure of principal investigator", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0217", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Fenretinide/LXS + Ketoconazole\nCondition: Ovarian Cancer\nPhase: phase_1_2\nTermination text: \"drug combination not providing any efficacy. Will use this data in opening new trial\"", "metadata": {"result_id": 18233, "source_trial_id": "NCT01535157", "intervention_name": "Fenretinide/LXS + Ketoconazole", "condition_name": "Ovarian Cancer", "confidence_tier": "bronze", "why_stopped": "drug combination not providing any efficacy. Will use this data in opening new trial", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0218", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: 40 mg PRAX-114\nCondition: Post-Traumatic Stress Disorder\nPhase: phase_2\nTermination text: \"No longer developing for this indication\"", "metadata": {"result_id": 11443, "source_trial_id": "NCT05260541", "intervention_name": "40 mg PRAX-114", "condition_name": "Post-Traumatic Stress Disorder", "confidence_tier": "bronze", "why_stopped": "No longer developing for this indication", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0219", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Experimental: Rivaroxaban\nCondition: Antiphospholipid Syndrome\nPhase: phase_3\nTermination text: \"Unbalance in the composite endpoint between arms.\"", "metadata": {"result_id": 22545, "source_trial_id": "NCT02157272", "intervention_name": "Experimental: Rivaroxaban", "condition_name": "Antiphospholipid Syndrome", "confidence_tier": "bronze", "why_stopped": "Unbalance in the composite endpoint between arms.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0220", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Intravitreal Bevacizumab\nCondition: Active Photocoagulated Diabetic Retinopathy\nPhase: phase_2_3\nTermination text: \"Undefined\"", "metadata": {"result_id": 5914, "source_trial_id": "NCT00600262", "intervention_name": "Intravitreal Bevacizumab", "condition_name": "Active Photocoagulated Diabetic Retinopathy", "confidence_tier": "bronze", "why_stopped": "Undefined", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0221", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: DC Vaccine & Cyclophosphamide\nCondition: Malignant Melanoma Stage IV\nPhase: phase_2\nTermination text: \"Early termination due to lesser accrual, and data analysis not done.\"", "metadata": {"result_id": 33695, "source_trial_id": "NCT00722098", "intervention_name": "DC Vaccine & Cyclophosphamide", "condition_name": "Malignant Melanoma Stage IV", "confidence_tier": "bronze", "why_stopped": "Early termination due to lesser accrual, and data analysis not done.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0222", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: ATG-Fresenius S\nCondition: Renal Transplant Rejection\nPhase: phase_3\nTermination text: \"Recruitment became very slow.\"", "metadata": {"result_id": 33286, "source_trial_id": "NCT01324934", "intervention_name": "ATG-Fresenius S", "condition_name": "Renal Transplant Rejection", "confidence_tier": "bronze", "why_stopped": "Recruitment became very slow.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0223", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Part A: 100 mg/mL GSK2618960\nCondition: Multiple Sclerosis, Relapsing-Remitting\nPhase: phase_1\nTermination text: \"GSK confirmed misrepresentation of preclinical data that supported the rationale for GSK2618960 in MS. This decreased benefit assessment for MS\"", "metadata": {"result_id": 7156, "source_trial_id": "NCT01808482", "intervention_name": "Part A: 100 mg/mL GSK2618960", "condition_name": "Multiple Sclerosis, Relapsing-Remitting", "confidence_tier": "bronze", "why_stopped": "GSK confirmed misrepresentation of preclinical data that supported the rationale for GSK2618960 in MS. This decreased benefit assessment for MS", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0224", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: WST11\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_2\nTermination text: \"Early end of enrolment with regards to difficulty met to enrol patients.\"", "metadata": {"result_id": 23904, "source_trial_id": "NCT00974662", "intervention_name": "WST11", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "why_stopped": "Early end of enrolment with regards to difficulty met to enrol patients.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0225", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Gefitinib\nCondition: Breast Cancer\nPhase: phase_2\nTermination text: \"PI left VICC\"", "metadata": {"result_id": 55946, "source_trial_id": "NCT00082667", "intervention_name": "Gefitinib", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "PI left VICC", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0226", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Tezosentan\nCondition: Hypertension, Pulmonary\nPhase: phase_3\nTermination text: \"6 month vital status report not collected after 28 day follow up analysis indicated no difference between placebo \\& tezosentan\"", "metadata": {"result_id": 3139, "source_trial_id": "NCT00458276", "intervention_name": "Tezosentan", "condition_name": "Hypertension, Pulmonary", "confidence_tier": "bronze", "why_stopped": "6 month vital status report not collected after 28 day follow up analysis indicated no difference between placebo \\& tezosentan", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0227", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: veltuzumab\nCondition: Rheumatoid Arthritis\nPhase: phase_2\nTermination text: \"Trial re-design; no safety issues identified\"", "metadata": {"result_id": 19650, "source_trial_id": "NCT01390545", "intervention_name": "veltuzumab", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "bronze", "why_stopped": "Trial re-design; no safety issues identified", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0228", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Fosaprepitant\nCondition: Chemotherapy-Induced Nausea and Vomiting\nPhase: phase_3\nTermination text: \"Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings\"", "metadata": {"result_id": 48504, "source_trial_id": "NCT02519842", "intervention_name": "Fosaprepitant", "condition_name": "Chemotherapy-Induced Nausea and Vomiting", "confidence_tier": "bronze", "why_stopped": "Further data are no longer required to support an application for use in pediatric patients. The decision to terminate was not based on any new safety findings", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0229", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Sucrase\nCondition: Short Gut Syndrome\nPhase: phase_2\nTermination text: \"Inability to recruit further patients for study\"", "metadata": {"result_id": 28985, "source_trial_id": "NCT04604275", "intervention_name": "Sucrase", "condition_name": "Short Gut Syndrome", "confidence_tier": "bronze", "why_stopped": "Inability to recruit further patients for study", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0230", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Omalizumab\nCondition: Moderate-to-severe Allergic Asthma\nPhase: phase_4\nTermination text: \"Due to low enrollment, this study was terminated early.\"", "metadata": {"result_id": 7854, "source_trial_id": "NCT04195958", "intervention_name": "Omalizumab", "condition_name": "Moderate-to-severe Allergic Asthma", "confidence_tier": "bronze", "why_stopped": "Due to low enrollment, this study was terminated early.", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL2-0231", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)\nCondition: Measles\nPhase: phase_3\nTermination text: \"Study terminated early because of insufficient enrollment before expiration date of the investigational vaccine lot\"", "metadata": {"result_id": 28318, "source_trial_id": "NCT00839917", "intervention_name": "Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)", "condition_name": "Measles", "confidence_tier": "bronze", "why_stopped": "Study terminated early because of insufficient enrollment before expiration date of the investigational vaccine lot", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0232", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Tramadol\nCondition: Cytochrome P450 Phenotype and Genotype Metrics\nTermination text: \"Unexpected non-serious adverse events\"", "metadata": {"result_id": 58790, "source_trial_id": "NCT00981929", "intervention_name": "Tramadol", "condition_name": "Cytochrome P450 Phenotype and Genotype Metrics", "confidence_tier": "bronze", "why_stopped": "Unexpected non-serious adverse events", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0233", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: cilengitide\nCondition: Adult Giant Cell Glioblastoma\nPhase: phase_2\nTermination text: \"due to poor accrual\"", "metadata": {"result_id": 45148, "source_trial_id": "NCT00112866", "intervention_name": "cilengitide", "condition_name": "Adult Giant Cell Glioblastoma", "confidence_tier": "bronze", "why_stopped": "due to poor accrual", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0234", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: N-Acetylcysteine\nCondition: Lymphoblastic Leukemia, Acute, Childhood\nPhase: phase_4\nTermination text: \"The study stopped because the study period already ended\"", "metadata": {"result_id": 50852, "source_trial_id": "NCT05611086", "intervention_name": "N-Acetylcysteine", "condition_name": "Lymphoblastic Leukemia, Acute, Childhood", "confidence_tier": "bronze", "why_stopped": "The study stopped because the study period already ended", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0235", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: REC-4881\nCondition: Solid Tumor\nPhase: phase_2\nTermination text: \"Study was terminated due to sponsor decision. This decision was not related to safety concerns.\"", "metadata": {"result_id": 57294, "source_trial_id": "NCT06005974", "intervention_name": "REC-4881", "condition_name": "Solid Tumor", "confidence_tier": "bronze", "why_stopped": "Study was terminated due to sponsor decision. This decision was not related to safety concerns.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0236", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: ITI-214 Dose A\nCondition: Schizophrenia\nPhase: phase_1\nTermination text: \"Business Decision; No Safety or Efficacy Concerns\"", "metadata": {"result_id": 58853, "source_trial_id": "NCT01900522", "intervention_name": "ITI-214 Dose A", "condition_name": "Schizophrenia", "confidence_tier": "bronze", "why_stopped": "Business Decision; No Safety or Efficacy Concerns", "therapeutic_area": "psychiatry"}, "split": "test"}
+{"question_id": "CTL2-0237", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Lithium\nCondition: Depressive Disorders\nTermination text: \"number of enrolled individuals after 5 years still off the estimated sample size\"", "metadata": {"result_id": 17297, "source_trial_id": "NCT00520026", "intervention_name": "Lithium", "condition_name": "Depressive Disorders", "confidence_tier": "bronze", "why_stopped": "number of enrolled individuals after 5 years still off the estimated sample size", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0238", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: ITV DepoCyt + Temozolomide\nCondition: Glioblastoma Multiforme\nPhase: phase_1_2\nTermination text: \"The study was terminated due to lack of adequate patient enrollment into trial.\"", "metadata": {"result_id": 15046, "source_trial_id": "NCT01044966", "intervention_name": "ITV DepoCyt + Temozolomide", "condition_name": "Glioblastoma Multiforme", "confidence_tier": "bronze", "why_stopped": "The study was terminated due to lack of adequate patient enrollment into trial.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0239", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Lamivudine\nCondition: Hepatitis B\nPhase: phase_3\nTermination text: \"poor patient recrutment\"", "metadata": {"result_id": 21939, "source_trial_id": "NCT00120796", "intervention_name": "Lamivudine", "condition_name": "Hepatitis B", "confidence_tier": "bronze", "why_stopped": "poor patient recrutment", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0240", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Pacritinib\nCondition: Non-Small Cell Lung Cancer\nPhase: phase_1\nTermination text: \"Drug shortage\"", "metadata": {"result_id": 49807, "source_trial_id": "NCT02342353", "intervention_name": "Pacritinib", "condition_name": "Non-Small Cell Lung Cancer", "confidence_tier": "bronze", "why_stopped": "Drug shortage", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0241", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: ALXN1102\nCondition: Paroxysmal Nocturnal Hemoglobinuria (PNH)\nPhase: phase_1\nTermination text: \"Inability to reach enrollment as planned\"", "metadata": {"result_id": 38665, "source_trial_id": "NCT01335165", "intervention_name": "ALXN1102", "condition_name": "Paroxysmal Nocturnal Hemoglobinuria (PNH)", "confidence_tier": "bronze", "why_stopped": "Inability to reach enrollment as planned", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0242", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Avandamet\nCondition: Coronary Artery Disease\nPhase: phase_4\nTermination text: \"FDA concerns regarding Avandamet\"", "metadata": {"result_id": 35952, "source_trial_id": "NCT00343395", "intervention_name": "Avandamet", "condition_name": "Coronary Artery Disease", "confidence_tier": "bronze", "why_stopped": "FDA concerns regarding Avandamet", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0243", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Plavix\nCondition: Breast Neoplasms\nPhase: phase_2\nTermination text: \"Stopped due to low percentage of patients with detectable CTCs at baseline.\"", "metadata": {"result_id": 61131, "source_trial_id": "NCT00263211", "intervention_name": "Plavix", "condition_name": "Breast Neoplasms", "confidence_tier": "bronze", "why_stopped": "Stopped due to low percentage of patients with detectable CTCs at baseline.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0244", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Screening for diabetes with 1-hour GCT and HbA1\nCondition: Gestational Diabetes\nPhase: phase_3\nTermination text: \"Former PI Left the Institution\"", "metadata": {"result_id": 22310, "source_trial_id": "NCT03116009", "intervention_name": "Screening for diabetes with 1-hour GCT and HbA1", "condition_name": "Gestational Diabetes", "confidence_tier": "bronze", "why_stopped": "Former PI Left the Institution", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0245", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: GLP-1 receptor agonist\nCondition: Diabetes Mellitus, Type 2\nPhase: phase_2\nTermination text: \"Not able to recruit participants\"", "metadata": {"result_id": 6932, "source_trial_id": "NCT04964388", "intervention_name": "GLP-1 receptor agonist", "condition_name": "Diabetes Mellitus, Type 2", "confidence_tier": "bronze", "why_stopped": "Not able to recruit participants", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0246", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: infusion of MYOCET\nCondition: Cerebral Lymphoma B Cell Refractory\nPhase: phase_2\nTermination text: \"The laboratory's partner on this study decides to terminate the contract with the CHRU Brest, because of the difficulty of the recruitment.\"", "metadata": {"result_id": 19716, "source_trial_id": "NCT01848652", "intervention_name": "infusion of MYOCET", "condition_name": "Cerebral Lymphoma B Cell Refractory", "confidence_tier": "bronze", "why_stopped": "The laboratory's partner on this study decides to terminate the contract with the CHRU Brest, because of the difficulty of the recruitment.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0247", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Palovarotene\nCondition: Fibrodysplasia Ossificans Progressiva\nPhase: phase_2\nTermination text: \"Subjects were enrolled into a different Phase 2 study (PVO-1A-202, NCT02279095).\"", "metadata": {"result_id": 23051, "source_trial_id": "NCT02521792", "intervention_name": "Palovarotene", "condition_name": "Fibrodysplasia Ossificans Progressiva", "confidence_tier": "bronze", "why_stopped": "Subjects were enrolled into a different Phase 2 study (PVO-1A-202, NCT02279095).", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0248", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: VS-5584\nCondition: Lymphoma\nPhase: phase_1\nTermination text: \"Lack of recruitment and the company's decision to de-prioritize 5584 development\"", "metadata": {"result_id": 33171, "source_trial_id": "NCT01991938", "intervention_name": "VS-5584", "condition_name": "Lymphoma", "confidence_tier": "bronze", "why_stopped": "Lack of recruitment and the company's decision to de-prioritize 5584 development", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0249", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Hexvix\nCondition: Bladder Cancer\nPhase: phase_2\nTermination text: \"slow inclusion rate\"", "metadata": {"result_id": 38430, "source_trial_id": "NCT01551407", "intervention_name": "Hexvix", "condition_name": "Bladder Cancer", "confidence_tier": "bronze", "why_stopped": "slow inclusion rate", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0250", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Nivolumab 10 MG/ML\nCondition: Melanoma (Skin)\nPhase: phase_2_3\nTermination text: \"Closed earlier than expected due to the need for a redesign to reflect the recent change in standard of care guidelines. New design will include these treatments.\"", "metadata": {"result_id": 49532, "source_trial_id": "NCT04901988", "intervention_name": "Nivolumab 10 MG/ML", "condition_name": "Melanoma (Skin)", "confidence_tier": "bronze", "why_stopped": "Closed earlier than expected due to the need for a redesign to reflect the recent change in standard of care guidelines. New design will include these treatments.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0251", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: MBG453\nCondition: Myelodysplastic Syndromes\nPhase: phase_2\nTermination text: \"The trial closed early due to changes in support for the study drug.\"", "metadata": {"result_id": 3617, "source_trial_id": "NCT04823624", "intervention_name": "MBG453", "condition_name": "Myelodysplastic Syndromes", "confidence_tier": "bronze", "why_stopped": "The trial closed early due to changes in support for the study drug.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0252", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Conestat alfa\nCondition: Coronavirus Infections\nPhase: phase_2\nTermination text: \"Aim to enroll 120 patients deemed not sufficient to show a difference in the primary outcome measure. Standard of care treatment recently changed in Switzerland adding further heterogeneity to trial population when including future participants.\"", "metadata": {"result_id": 58211, "source_trial_id": "NCT04414631", "intervention_name": "Conestat alfa", "condition_name": "Coronavirus Infections", "confidence_tier": "bronze", "why_stopped": "Aim to enroll 120 patients deemed not sufficient to show a difference in the primary outcome measure. Standard of care treatment recently changed in Switzerland adding further heterogeneity to trial population when including future participants.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0253", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Anakinra\nCondition: Pain\nTermination text: \"Due to inability to demonstrate benefit in this patient population.\"", "metadata": {"result_id": 23483, "source_trial_id": "NCT01466764", "intervention_name": "Anakinra", "condition_name": "Pain", "confidence_tier": "bronze", "why_stopped": "Due to inability to demonstrate benefit in this patient population.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0254", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Conventional therapy\nCondition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)\nPhase: phase_2_3\nTermination text: \"safety and efficacy reason\"", "metadata": {"result_id": 37020, "source_trial_id": "NCT01223755", "intervention_name": "Conventional therapy", "condition_name": "Autosomal Dominant Polycystic Kidney Disease (ADPKD)", "confidence_tier": "bronze", "why_stopped": "safety and efficacy reason", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0255", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Concept2 inhaler\nCondition: Chronic Obstructive Pulmonary Disease\nPhase: phase_3\nTermination text: \"devices malfunctioned\"", "metadata": {"result_id": 29098, "source_trial_id": "NCT03379233", "intervention_name": "Concept2 inhaler", "condition_name": "Chronic Obstructive Pulmonary Disease", "confidence_tier": "bronze", "why_stopped": "devices malfunctioned", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL2-0256", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ferinject ®\nCondition: Iron Deficiency Anemia\nPhase: phase_4\nTermination text: \"Not being able to recuit sufficient patients due to a lack of complience\"", "metadata": {"result_id": 28308, "source_trial_id": "NCT00706667", "intervention_name": "Ferinject ®", "condition_name": "Iron Deficiency Anemia", "confidence_tier": "bronze", "why_stopped": "Not being able to recuit sufficient patients due to a lack of complience", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0257", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: clenbuterol\nCondition: Heart Failure\nPhase: phase_1\nTermination text: \"No longer could obtain clenbuterol\"", "metadata": {"result_id": 60374, "source_trial_id": "NCT00585546", "intervention_name": "clenbuterol", "condition_name": "Heart Failure", "confidence_tier": "bronze", "why_stopped": "No longer could obtain clenbuterol", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0258", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Fenofibrate\nCondition: Multiple Myeloma\nPhase: phase_2\nTermination text: \"Lack of adequate accrual.\"", "metadata": {"result_id": 53502, "source_trial_id": "NCT01965834", "intervention_name": "Fenofibrate", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "why_stopped": "Lack of adequate accrual.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0259", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: Dexamethasone\nCondition: Infant, Premature\nPhase: phase_3\nTermination text: \"The trial was halted because of unanticipated nonrespiratory adverse events related to dexamethasone therapy.\"", "metadata": {"result_id": 14402, "source_trial_id": "NCT00005777", "intervention_name": "Dexamethasone", "condition_name": "Infant, Premature", "confidence_tier": "bronze", "why_stopped": "The trial was halted because of unanticipated nonrespiratory adverse events related to dexamethasone therapy.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0260", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Budesonide Foam\nCondition: Proctitis\nPhase: phase_3\nTermination text: \"Terminated for non-safety reasons when Sponsor felt that sufficient long-term safety data was obtained.\"", "metadata": {"result_id": 49414, "source_trial_id": "NCT01349673", "intervention_name": "Budesonide Foam", "condition_name": "Proctitis", "confidence_tier": "bronze", "why_stopped": "Terminated for non-safety reasons when Sponsor felt that sufficient long-term safety data was obtained.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0261", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: TF0023\nCondition: COVID-19 Pneumonia\nPhase: phase_2\nTermination text: \"Low patient accrual.\"", "metadata": {"result_id": 8587, "source_trial_id": "NCT05212818", "intervention_name": "TF0023", "condition_name": "COVID-19 Pneumonia", "confidence_tier": "bronze", "why_stopped": "Low patient accrual.", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0262", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: bevacizumab [Avastin]\nCondition: Breast Cancer\nPhase: phase_2\nTermination text: \"To be confirmed\"", "metadata": {"result_id": 52792, "source_trial_id": "NCT00845910", "intervention_name": "bevacizumab [Avastin]", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "To be confirmed", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0263", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Apalutamide\nCondition: Prostate Cancer\nPhase: phase_3\nTermination text: \"PI is terminating the study due to slow/low accrual\"", "metadata": {"result_id": 5999, "source_trial_id": "NCT03777982", "intervention_name": "Apalutamide", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "why_stopped": "PI is terminating the study due to slow/low accrual", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0264", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Radium-223 dichloride (Xofigo, BAY88-8223)\nCondition: Multiple Myeloma\nPhase: phase_1_2\nTermination text: \"Due to the changes of standard of care and the slow recruitment of participants.\"", "metadata": {"result_id": 58687, "source_trial_id": "NCT02928029", "intervention_name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "why_stopped": "Due to the changes of standard of care and the slow recruitment of participants.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0265", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: BION-1301\nCondition: Multiple Myeloma\nPhase: phase_1_2\nTermination text: \"No objective responses observed following completion of Phase 1 dose-escalation\"", "metadata": {"result_id": 33630, "source_trial_id": "NCT03340883", "intervention_name": "BION-1301", "condition_name": "Multiple Myeloma", "confidence_tier": "bronze", "why_stopped": "No objective responses observed following completion of Phase 1 dose-escalation", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0266", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: Nivolumab\nCondition: Castration-Resistant Prostate Carcinoma\nPhase: phase_2\nTermination text: \"The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events.\"", "metadata": {"result_id": 32205, "source_trial_id": "NCT04159896", "intervention_name": "Nivolumab", "condition_name": "Castration-Resistant Prostate Carcinoma", "confidence_tier": "bronze", "why_stopped": "The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA events.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0267", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: alvocidib\nCondition: Acute Myeloid Leukemia\nPhase: phase_2\nTermination text: \"Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the study no longer reasonably feasible to complete.\"", "metadata": {"result_id": 47825, "source_trial_id": "NCT02520011", "intervention_name": "alvocidib", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "bronze", "why_stopped": "Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the study no longer reasonably feasible to complete.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0268", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Nilotinib\nCondition: Chronic Myelogenous Leukemia\nPhase: phase_2\nTermination text: \"Original principal investigator left institution\"", "metadata": {"result_id": 27102, "source_trial_id": "NCT02709083", "intervention_name": "Nilotinib", "condition_name": "Chronic Myelogenous Leukemia", "confidence_tier": "bronze", "why_stopped": "Original principal investigator left institution", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0269", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Quetiapine\nCondition: Postpartum Depressive Disorder\nPhase: phase_2\nTermination text: \"Recruitment behind plan, no increase expected\"", "metadata": {"result_id": 516, "source_trial_id": "NCT00681668", "intervention_name": "Quetiapine", "condition_name": "Postpartum Depressive Disorder", "confidence_tier": "bronze", "why_stopped": "Recruitment behind plan, no increase expected", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0270", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Sprifermin (AS902330) 10 mcg\nCondition: Isolated Cartilage Injury of the Knee\nPhase: phase_2\nTermination text: \"The study was discontinued due to low recruitment.\"", "metadata": {"result_id": 22729, "source_trial_id": "NCT01066871", "intervention_name": "Sprifermin (AS902330) 10 mcg", "condition_name": "Isolated Cartilage Injury of the Knee", "confidence_tier": "bronze", "why_stopped": "The study was discontinued due to low recruitment.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0271", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: VIB7734\nCondition: Acute Lung Injury\nPhase: phase_1\nTermination text: \"Study met predefined futility criteria for efficacy endpoints.\"", "metadata": {"result_id": 2350, "source_trial_id": "NCT04526912", "intervention_name": "VIB7734", "condition_name": "Acute Lung Injury", "confidence_tier": "bronze", "why_stopped": "Study met predefined futility criteria for efficacy endpoints.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0272", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: AMT2003\nCondition: Prostate Cancer\nPhase: phase_2_3\nTermination text: \"Lack of efficacy. Stopped at first interim evaluation point\"", "metadata": {"result_id": 23353, "source_trial_id": "NCT00332280", "intervention_name": "AMT2003", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "why_stopped": "Lack of efficacy. Stopped at first interim evaluation point", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0273", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: NNC 0070-0002-0182\nCondition: Obesity\nPhase: phase_1\nTermination text: \"The trial is terminated due to re-evaluation of the compound\"", "metadata": {"result_id": 3459, "source_trial_id": "NCT00665665", "intervention_name": "NNC 0070-0002-0182", "condition_name": "Obesity", "confidence_tier": "bronze", "why_stopped": "The trial is terminated due to re-evaluation of the compound", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0274", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Sitravatinib\nCondition: Breast Cancer Metastatic\nPhase: phase_2\nTermination text: \"Terminated by sponsor due to lack of interest\"", "metadata": {"result_id": 46688, "source_trial_id": "NCT04123704", "intervention_name": "Sitravatinib", "condition_name": "Breast Cancer Metastatic", "confidence_tier": "bronze", "why_stopped": "Terminated by sponsor due to lack of interest", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0275", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: ALXN1007 10 mg/kg once weekly\nCondition: Acute Graft-versus-Host Disease\nPhase: phase_2\nTermination text: \"Terminated early at the Sponsor's discretion, not due to safety concerns.\"", "metadata": {"result_id": 46644, "source_trial_id": "NCT02245412", "intervention_name": "ALXN1007 10 mg/kg once weekly", "condition_name": "Acute Graft-versus-Host Disease", "confidence_tier": "bronze", "why_stopped": "Terminated early at the Sponsor's discretion, not due to safety concerns.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0276", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Intrathecal hydromorphone\nCondition: Cesarean Section\nPhase: phase_1\nTermination text: \"Lack of reliable supply of of preservative free IV Hydromorphone for intrathecal use.\"", "metadata": {"result_id": 3190, "source_trial_id": "NCT02787928", "intervention_name": "Intrathecal hydromorphone", "condition_name": "Cesarean Section", "confidence_tier": "bronze", "why_stopped": "Lack of reliable supply of of preservative free IV Hydromorphone for intrathecal use.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0277", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Standard of Care\nCondition: COVID-19\nPhase: phase_1_2\nTermination text: \"The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.\"", "metadata": {"result_id": 1850, "source_trial_id": "NCT05381363", "intervention_name": "Standard of Care", "condition_name": "COVID-19", "confidence_tier": "bronze", "why_stopped": "The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0278", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Stavudine\nCondition: Metabolic Complications\nPhase: phase_4\nTermination text: \"DSMB decision to begin closeout process in view of April 2010 SA HAART guideline\"", "metadata": {"result_id": 15003, "source_trial_id": "NCT01601899", "intervention_name": "Stavudine", "condition_name": "Metabolic Complications", "confidence_tier": "bronze", "why_stopped": "DSMB decision to begin closeout process in view of April 2010 SA HAART guideline", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0279", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Antibiotics\nCondition: Endocarditis, Bacterial\nPhase: phase_4\nTermination text: \"Inability to reach the estimated sample size\"", "metadata": {"result_id": 944, "source_trial_id": "NCT04222257", "intervention_name": "Antibiotics", "condition_name": "Endocarditis, Bacterial", "confidence_tier": "bronze", "why_stopped": "Inability to reach the estimated sample size", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0280", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: XIFAXAN® (Rifaximin)\nCondition: Major Liver Resection\nPhase: phase_2\nTermination text: \"Prematurely terminated due to organisational reasons\"", "metadata": {"result_id": 39993, "source_trial_id": "NCT02555293", "intervention_name": "XIFAXAN® (Rifaximin)", "condition_name": "Major Liver Resection", "confidence_tier": "bronze", "why_stopped": "Prematurely terminated due to organisational reasons", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0281", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Niclosamide\nCondition: Covid19\nPhase: phase_2\nTermination text: \"The termination of the study was a decision based on topline data analysis (no efficacy as per Day 43) of the study data.\"", "metadata": {"result_id": 36506, "source_trial_id": "NCT04858425", "intervention_name": "Niclosamide", "condition_name": "Covid19", "confidence_tier": "bronze", "why_stopped": "The termination of the study was a decision based on topline data analysis (no efficacy as per Day 43) of the study data.", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0282", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Intralesional Triamcinolone 10 mg/ml\nCondition: Alopecia Areata\nPhase: phase_4\nTermination text: \"The PI left the Columbia University Medical Center. Study was not Completed.\"", "metadata": {"result_id": 23164, "source_trial_id": "NCT01898806", "intervention_name": "Intralesional Triamcinolone 10 mg/ml", "condition_name": "Alopecia Areata", "confidence_tier": "bronze", "why_stopped": "The PI left the Columbia University Medical Center. Study was not Completed.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0283", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Teplizumab\nCondition: Psoriasis\nPhase: phase_1_2\nTermination text: \"Injection site reaction met protocol-defined stopping criteria.\"", "metadata": {"result_id": 24560, "source_trial_id": "NCT00954915", "intervention_name": "Teplizumab", "condition_name": "Psoriasis", "confidence_tier": "bronze", "why_stopped": "Injection site reaction met protocol-defined stopping criteria.", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0284", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: NKTR-118\nCondition: Opioid-induced Constipation\nPhase: phase_3\nTermination text: \"The study was stopped early due to recruitment challenges\"", "metadata": {"result_id": 16292, "source_trial_id": "NCT01384292", "intervention_name": "NKTR-118", "condition_name": "Opioid-induced Constipation", "confidence_tier": "bronze", "why_stopped": "The study was stopped early due to recruitment challenges", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0285", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Diaper care with Theraworx\nCondition: Diaper Dermatitis\nPhase: phase_4\nTermination text: \"Principal Investigator left the Institution and decision was made by funders to terminate the trial.\"", "metadata": {"result_id": 18396, "source_trial_id": "NCT04101890", "intervention_name": "Diaper care with Theraworx", "condition_name": "Diaper Dermatitis", "confidence_tier": "bronze", "why_stopped": "Principal Investigator left the Institution and decision was made by funders to terminate the trial.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0286", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Carboplatin\nCondition: Peritoneal Cavity Cancer\nPhase: phase_2\nTermination text: \"Study was terminated due to lack of available funding.\"", "metadata": {"result_id": 22133, "source_trial_id": "NCT00331422", "intervention_name": "Carboplatin", "condition_name": "Peritoneal Cavity Cancer", "confidence_tier": "bronze", "why_stopped": "Study was terminated due to lack of available funding.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0287", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: Anakinra\nCondition: Rheumatoid Arthritis\nPhase: phase_2\nTermination text: \"The safety profile of combination therapy became unacceptable.\"", "metadata": {"result_id": 60675, "source_trial_id": "NCT00537667", "intervention_name": "Anakinra", "condition_name": "Rheumatoid Arthritis", "confidence_tier": "bronze", "why_stopped": "The safety profile of combination therapy became unacceptable.", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0288", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Herceptin™ (Her)\nCondition: Breast Cancer\nPhase: phase_3\nTermination text: \"Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely.\"", "metadata": {"result_id": 12239, "source_trial_id": "NCT00004935", "intervention_name": "Herceptin™ (Her)", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0289", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: IV bolus injection of Sildenafil\nCondition: Cirrhosis\nPhase: phase_1\nTermination text: \"The study is closed due to lack of funding to support the study.\"", "metadata": {"result_id": 27202, "source_trial_id": "NCT01954524", "intervention_name": "IV bolus injection of Sildenafil", "condition_name": "Cirrhosis", "confidence_tier": "bronze", "why_stopped": "The study is closed due to lack of funding to support the study.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0290", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Soticlestat\nCondition: Dravet Syndrome (DS)\nPhase: phase_3\nTermination text: \"Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-3003 study is no longer necessary. Therefore, Takeda has made a decision to close this study\"", "metadata": {"result_id": 40089, "source_trial_id": "NCT05163314", "intervention_name": "Soticlestat", "condition_name": "Dravet Syndrome (DS)", "confidence_tier": "bronze", "why_stopped": "Due to negative results from phase 3 SKYLINE and SKYWAY studies and unrelated to patient safety it has been determined that supplementary data from TAK-935-3003 study is no longer necessary. Therefore, Takeda has made a decision to close this study", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0291", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: pazopanib hydrochloride\nCondition: Advanced Soft Tissue Sarcoma\nPhase: phase_1_2\nTermination text: \"Study was terminated at completion of the Phase 1 dose escalation due to loss of financial support.\"", "metadata": {"result_id": 54381, "source_trial_id": "NCT03660930", "intervention_name": "pazopanib hydrochloride", "condition_name": "Advanced Soft Tissue Sarcoma", "confidence_tier": "bronze", "why_stopped": "Study was terminated at completion of the Phase 1 dose escalation due to loss of financial support.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0292", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Lisdexamfetamine Dimesylate\nCondition: Bulimia Nervosa\nPhase: phase_2\nTermination text: \"Loss of resources due to COVID-19 resulted in insufficient funds to complete the trial as planned. However, sufficient data was collected to fulfill the aims of the trial. Discontinuation is not related to the drug, its use, or adverse events.\"", "metadata": {"result_id": 52787, "source_trial_id": "NCT03397446", "intervention_name": "Lisdexamfetamine Dimesylate", "condition_name": "Bulimia Nervosa", "confidence_tier": "bronze", "why_stopped": "Loss of resources due to COVID-19 resulted in insufficient funds to complete the trial as planned. However, sufficient data was collected to fulfill the aims of the trial. Discontinuation is not related to the drug, its use, or adverse events.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0293", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: SNK01\nCondition: Advanced Solid Tumor\nPhase: phase_1_2\nTermination text: \"Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.\"", "metadata": {"result_id": 40194, "source_trial_id": "NCT05099549", "intervention_name": "SNK01", "condition_name": "Advanced Solid Tumor", "confidence_tier": "bronze", "why_stopped": "Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best options to advance this project with an allogeneic off-the-shelf NK cell product while NKGen will focus on CNS with SNK01.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0294", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: AMG 479\nCondition: Lung Cancer\nPhase: phase_1_2\nTermination text: \"Subjects discontinued study\"", "metadata": {"result_id": 13445, "source_trial_id": "NCT00791154", "intervention_name": "AMG 479", "condition_name": "Lung Cancer", "confidence_tier": "bronze", "why_stopped": "Subjects discontinued study", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0295", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ifosfamide\nCondition: Childhood Germ Cell Tumor\nPhase: phase_2\nTermination text: \"lack of patient inclusion\"", "metadata": {"result_id": 36889, "source_trial_id": "NCT00003852", "intervention_name": "Ifosfamide", "condition_name": "Childhood Germ Cell Tumor", "confidence_tier": "bronze", "why_stopped": "lack of patient inclusion", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0296", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Fosbretabulin Tromethamine\nCondition: Platinum Resistant Ovarian Cancer\nPhase: phase_2_3\nTermination text: \"The study was terminated early due to the lack of efficacy and the study sponsor's decision to no longer continue the study\"", "metadata": {"result_id": 49119, "source_trial_id": "NCT02641639", "intervention_name": "Fosbretabulin Tromethamine", "condition_name": "Platinum Resistant Ovarian Cancer", "confidence_tier": "bronze", "why_stopped": "The study was terminated early due to the lack of efficacy and the study sponsor's decision to no longer continue the study", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0297", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Cladribine\nCondition: Recurrent Acute Myeloid Leukemia\nPhase: phase_1\nTermination text: \"Terminated due to unfavorable risk-benefit ratio of investigational regimen.\"", "metadata": {"result_id": 1754, "source_trial_id": "NCT04196010", "intervention_name": "Cladribine", "condition_name": "Recurrent Acute Myeloid Leukemia", "confidence_tier": "bronze", "why_stopped": "Terminated due to unfavorable risk-benefit ratio of investigational regimen.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0298", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: 0.75% bupivacaine\nCondition: SI Joint Pain\nPhase: phase_4\nTermination text: \"Data could not be interpreted. Re-design efforts failed.\"", "metadata": {"result_id": 4634, "source_trial_id": "NCT01874236", "intervention_name": "0.75% bupivacaine", "condition_name": "SI Joint Pain", "confidence_tier": "bronze", "why_stopped": "Data could not be interpreted. Re-design efforts failed.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0299", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Enoxaparin\nCondition: Catheter-related Occlusion\nPhase: phase_2\nTermination text: \"Futility; unable to complete screening due to clinical practice change\"", "metadata": {"result_id": 8071, "source_trial_id": "NCT00633061", "intervention_name": "Enoxaparin", "condition_name": "Catheter-related Occlusion", "confidence_tier": "bronze", "why_stopped": "Futility; unable to complete screening due to clinical practice change", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0300", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: FXR-450\nCondition: Healthy\nPhase: phase_1\nTermination text: \"Please see termination statement in the detailed description.\"", "metadata": {"result_id": 56068, "source_trial_id": "NCT00509756", "intervention_name": "FXR-450", "condition_name": "Healthy", "confidence_tier": "bronze", "why_stopped": "Please see termination statement in the detailed description.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0301", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: M4112\nCondition: Metastatic or Locally Advanced Unresectable Solid Tumors\nPhase: phase_1\nTermination text: \"The study was terminated early due to lackluster pharmacodynamic data that showed no significant reduction of plasma kynurenine at steady state of M4112.\"", "metadata": {"result_id": 331, "source_trial_id": "NCT03306420", "intervention_name": "M4112", "condition_name": "Metastatic or Locally Advanced Unresectable Solid Tumors", "confidence_tier": "bronze", "why_stopped": "The study was terminated early due to lackluster pharmacodynamic data that showed no significant reduction of plasma kynurenine at steady state of M4112.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0302", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: Futibatinib\nCondition: Advanced and Metastatic Urothelial Cancer\nPhase: phase_2\nTermination text: \"Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.\"", "metadata": {"result_id": 57850, "source_trial_id": "NCT04601857", "intervention_name": "Futibatinib", "condition_name": "Advanced and Metastatic Urothelial Cancer", "confidence_tier": "bronze", "why_stopped": "Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0303", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Capecitabine\nCondition: Pancreatic Cancer\nPhase: phase_2\nTermination text: \"Poor accrual and change of SOC (FOLFIRINOX in adjuvant setting)\"", "metadata": {"result_id": 1924, "source_trial_id": "NCT02767752", "intervention_name": "Capecitabine", "condition_name": "Pancreatic Cancer", "confidence_tier": "bronze", "why_stopped": "Poor accrual and change of SOC (FOLFIRINOX in adjuvant setting)", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0304", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Fludarabine\nCondition: Skin Cancer\nPhase: phase_2\nTermination text: \"Study terminated due to low accrual and change in research focus.\"", "metadata": {"result_id": 62672, "source_trial_id": "NCT02111863", "intervention_name": "Fludarabine", "condition_name": "Skin Cancer", "confidence_tier": "bronze", "why_stopped": "Study terminated due to low accrual and change in research focus.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0305", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Androgen Deprivation Therapy (ADT)\nCondition: Prostate Cancer\nPhase: phase_2\nTermination text: \"Abemaciclib efficacy\"", "metadata": {"result_id": 49523, "source_trial_id": "NCT04298983", "intervention_name": "Androgen Deprivation Therapy (ADT)", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "why_stopped": "Abemaciclib efficacy", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0306", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Oxytocin Intranasal Spray 8 International Unit (8IU)\nCondition: Irritable Mood\nPhase: phase_1_2\nTermination text: \"Per DSMB's recommendation\"", "metadata": {"result_id": 40564, "source_trial_id": "NCT03863288", "intervention_name": "Oxytocin Intranasal Spray 8 International Unit (8IU)", "condition_name": "Irritable Mood", "confidence_tier": "bronze", "why_stopped": "Per DSMB's recommendation", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0307", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Drug GC4711\nCondition: SBRT\nPhase: phase_2\nTermination text: \"Futility Analysis\"", "metadata": {"result_id": 476, "source_trial_id": "NCT04698915", "intervention_name": "Drug GC4711", "condition_name": "SBRT", "confidence_tier": "bronze", "why_stopped": "Futility Analysis", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0308", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Liraglutide\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_4\nTermination text: \"Terminated because of insufficient number of subjects included.\"", "metadata": {"result_id": 2915, "source_trial_id": "NCT01638260", "intervention_name": "Liraglutide", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "bronze", "why_stopped": "Terminated because of insufficient number of subjects included.", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0309", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Radiation therapy and temozolomide\nCondition: Glioblastoma\nPhase: phase_1\nTermination text: \"Terminated (failure to enroll)\"", "metadata": {"result_id": 4594, "source_trial_id": "NCT02880410", "intervention_name": "Radiation therapy and temozolomide", "condition_name": "Glioblastoma", "confidence_tier": "bronze", "why_stopped": "Terminated (failure to enroll)", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0310", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Lower dose formulation of HSV vaccine (GSK4108771A)\nCondition: Herpes Simplex\nPhase: phase_1\nTermination text: \"To enable development of an enhanced version of the vaccine\"", "metadata": {"result_id": 4844, "source_trial_id": "NCT04762511", "intervention_name": "Lower dose formulation of HSV vaccine (GSK4108771A)", "condition_name": "Herpes Simplex", "confidence_tier": "bronze", "why_stopped": "To enable development of an enhanced version of the vaccine", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0311", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: BBI503\nCondition: Gastrointestinal Stromal Tumors\nPhase: phase_2\nTermination text: \"Low feasibility\"", "metadata": {"result_id": 8234, "source_trial_id": "NCT02232620", "intervention_name": "BBI503", "condition_name": "Gastrointestinal Stromal Tumors", "confidence_tier": "bronze", "why_stopped": "Low feasibility", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0312", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Osmotic Release Oral System (OROS) hydromorphone\nCondition: Pain\nPhase: phase_4\nTermination text: \"the study was stopped due to non-availability of 4mg\"", "metadata": {"result_id": 57068, "source_trial_id": "NCT01648699", "intervention_name": "Osmotic Release Oral System (OROS) hydromorphone", "condition_name": "Pain", "confidence_tier": "bronze", "why_stopped": "the study was stopped due to non-availability of 4mg", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0313", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Furosemide\nCondition: Renal Failure\nPhase: phase_3\nTermination text: \"Number included has been reached\"", "metadata": {"result_id": 7953, "source_trial_id": "NCT00298454", "intervention_name": "Furosemide", "condition_name": "Renal Failure", "confidence_tier": "bronze", "why_stopped": "Number included has been reached", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0314", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Atropine\nCondition: Spinal Anesthesia\nTermination text: \"The research was terminated because the recruitment of the study subjects was not smooth and the overseas training of the investigator was scheduled.\"", "metadata": {"result_id": 947, "source_trial_id": "NCT03322150", "intervention_name": "Atropine", "condition_name": "Spinal Anesthesia", "confidence_tier": "bronze", "why_stopped": "The research was terminated because the recruitment of the study subjects was not smooth and the overseas training of the investigator was scheduled.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0315", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: CN1, 0.5mg/kg and CN401, 400mg\nCondition: Relapsed Lymphoid Malignancies\nPhase: phase_1_2\nTermination text: \"Sponsor decided that there was no benefit in the drug treatment and due to company change in landscape in the new year.\"", "metadata": {"result_id": 54042, "source_trial_id": "NCT04880564", "intervention_name": "CN1, 0.5mg/kg and CN401, 400mg", "condition_name": "Relapsed Lymphoid Malignancies", "confidence_tier": "bronze", "why_stopped": "Sponsor decided that there was no benefit in the drug treatment and due to company change in landscape in the new year.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0316", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Glasdegib\nCondition: Acute Myeloid Leukemia\nPhase: phase_3\nTermination text: \"Study turned out no longer feasible. End of Recruitment: 25.5.2022\"", "metadata": {"result_id": 32706, "source_trial_id": "NCT04093505", "intervention_name": "Glasdegib", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "bronze", "why_stopped": "Study turned out no longer feasible. End of Recruitment: 25.5.2022", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0317", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: disulfiram\nCondition: Glioblastoma\nPhase: early_phase_1\nTermination text: \"Problems with including patients\"", "metadata": {"result_id": 1160, "source_trial_id": "NCT03151772", "intervention_name": "disulfiram", "condition_name": "Glioblastoma", "confidence_tier": "bronze", "why_stopped": "Problems with including patients", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0318", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: SGLT-2 inhibitor\nCondition: Heart Failure With Reduced Ejection Fraction\nPhase: phase_4\nTermination text: \"Double blind packaged drug is up to expiration date\"", "metadata": {"result_id": 7583, "source_trial_id": "NCT05737186", "intervention_name": "SGLT-2 inhibitor", "condition_name": "Heart Failure With Reduced Ejection Fraction", "confidence_tier": "bronze", "why_stopped": "Double blind packaged drug is up to expiration date", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0319", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Weight Loss and Weight Maintenance\nCondition: Sarcopenic Obesity\nPhase: phase_1_2\nTermination text: \"Grant Transfer Not Approved\"", "metadata": {"result_id": 6935, "source_trial_id": "NCT04282603", "intervention_name": "Weight Loss and Weight Maintenance", "condition_name": "Sarcopenic Obesity", "confidence_tier": "bronze", "why_stopped": "Grant Transfer Not Approved", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0320", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: escitalopram\nCondition: HIV\nPhase: phase_4\nTermination text: \"Failure to recruit.\"", "metadata": {"result_id": 62372, "source_trial_id": "NCT01797380", "intervention_name": "escitalopram", "condition_name": "HIV", "confidence_tier": "bronze", "why_stopped": "Failure to recruit.", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0321", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Bacille Calmette Guerin (BCG)\nCondition: Malaria\nPhase: phase_4\nTermination text: \"A cluster of deaths in the BCG-arm compared with controls\"", "metadata": {"result_id": 38697, "source_trial_id": "NCT00126217", "intervention_name": "Bacille Calmette Guerin (BCG)", "condition_name": "Malaria", "confidence_tier": "bronze", "why_stopped": "A cluster of deaths in the BCG-arm compared with controls", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0322", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Standard treatment\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_4\nTermination text: \"No sufficient numbers of eligible participants\"", "metadata": {"result_id": 6442, "source_trial_id": "NCT02029846", "intervention_name": "Standard treatment", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "bronze", "why_stopped": "No sufficient numbers of eligible participants", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0323", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Sunitinib malate\nCondition: Transitional Cell Carcinoma of the Bladder\nPhase: phase_2\nTermination text: \"Patient Toxicities\"", "metadata": {"result_id": 58865, "source_trial_id": "NCT00859339", "intervention_name": "Sunitinib malate", "condition_name": "Transitional Cell Carcinoma of the Bladder", "confidence_tier": "bronze", "why_stopped": "Patient Toxicities", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0324", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Herceptin\nCondition: Breast Cancer\nPhase: phase_2\nTermination text: \"Due to low accrual\"", "metadata": {"result_id": 24386, "source_trial_id": "NCT00138125", "intervention_name": "Herceptin", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "Due to low accrual", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0325", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Rapamycin\nCondition: Autosomal Dominant Polycystic Kidney Disease\nPhase: phase_2_3\nTermination text: \"This study was stopped after larger studies published in the NEJM failed to show a benefit in treating ADPKD\"", "metadata": {"result_id": 18611, "source_trial_id": "NCT00920309", "intervention_name": "Rapamycin", "condition_name": "Autosomal Dominant Polycystic Kidney Disease", "confidence_tier": "bronze", "why_stopped": "This study was stopped after larger studies published in the NEJM failed to show a benefit in treating ADPKD", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0326", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Ocrelizumab\nCondition: Relapsing-Remitting Multiple Sclerosis\nPhase: phase_2\nTermination text: \"Lack of recruitment due to low acceptance of the control arm.\"", "metadata": {"result_id": 15085, "source_trial_id": "NCT04971005", "intervention_name": "Ocrelizumab", "condition_name": "Relapsing-Remitting Multiple Sclerosis", "confidence_tier": "bronze", "why_stopped": "Lack of recruitment due to low acceptance of the control arm.", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0327", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: BAY1097761 Active Dose 1\nCondition: Acute Respiratory Distress Syndrome\nPhase: phase_2\nTermination text: \"Terminated (based on Part A results, Bayer decided to not continue investigating BAY 1097761 further in Part B; this was not due to any safety data for BAY 1097761)\"", "metadata": {"result_id": 10974, "source_trial_id": "NCT04417036", "intervention_name": "BAY1097761 Active Dose 1", "condition_name": "Acute Respiratory Distress Syndrome", "confidence_tier": "bronze", "why_stopped": "Terminated (based on Part A results, Bayer decided to not continue investigating BAY 1097761 further in Part B; this was not due to any safety data for BAY 1097761)", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0328", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Clazakizumab\nCondition: Antibody-mediated Rejection\nPhase: phase_3\nTermination text: \"Early stop for lack of efficacy/futility (at Interim analysis)\"", "metadata": {"result_id": 51290, "source_trial_id": "NCT03744910", "intervention_name": "Clazakizumab", "condition_name": "Antibody-mediated Rejection", "confidence_tier": "bronze", "why_stopped": "Early stop for lack of efficacy/futility (at Interim analysis)", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0329", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Antiemetic\nCondition: Anesthesia, Pediatrics, Surgery\nPhase: phase_4\nTermination text: \"PI has left Riley Anesthesia. Lack of staff for continued recruitment\"", "metadata": {"result_id": 17759, "source_trial_id": "NCT02724033", "intervention_name": "Antiemetic", "condition_name": "Anesthesia, Pediatrics, Surgery", "confidence_tier": "bronze", "why_stopped": "PI has left Riley Anesthesia. Lack of staff for continued recruitment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0330", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Standard treatment\nCondition: Graft vs Host Disease\nPhase: phase_2\nTermination text: \"impossibility to recruit in the BAT arm\"", "metadata": {"result_id": 6588, "source_trial_id": "NCT02396628", "intervention_name": "Standard treatment", "condition_name": "Graft vs Host Disease", "confidence_tier": "bronze", "why_stopped": "impossibility to recruit in the BAT arm", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0331", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Tafasitamab\nCondition: Diffuse Large B-Cell Lymphoma\nPhase: phase_1_2\nTermination text: \"The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns\"", "metadata": {"result_id": 10414, "source_trial_id": "NCT05626322", "intervention_name": "Tafasitamab", "condition_name": "Diffuse Large B-Cell Lymphoma", "confidence_tier": "bronze", "why_stopped": "The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0332", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Nicoderm C-Q Transdermal Product\nCondition: Tobacco Smoking\nPhase: phase_4\nTermination text: \"Recruitment for the study proved to be a significant challenge, raising important concerns about its overall feasibility.\"", "metadata": {"result_id": 24959, "source_trial_id": "NCT04038255", "intervention_name": "Nicoderm C-Q Transdermal Product", "condition_name": "Tobacco Smoking", "confidence_tier": "bronze", "why_stopped": "Recruitment for the study proved to be a significant challenge, raising important concerns about its overall feasibility.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0333", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Oregano extract cream\nCondition: Atopic Dermatitis\nTermination text: \"Lack of response to recruitment\"", "metadata": {"result_id": 23660, "source_trial_id": "NCT02289989", "intervention_name": "Oregano extract cream", "condition_name": "Atopic Dermatitis", "confidence_tier": "bronze", "why_stopped": "Lack of response to recruitment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0334", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Gefitinib\nCondition: Kidney Cancer\nPhase: phase_2\nTermination text: \"Protocol was closed due to slow accrual.\"", "metadata": {"result_id": 4123, "source_trial_id": "NCT00467077", "intervention_name": "Gefitinib", "condition_name": "Kidney Cancer", "confidence_tier": "bronze", "why_stopped": "Protocol was closed due to slow accrual.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0335", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Cesamet\nCondition: Nausea and Vomiting\nPhase: phase_4\nTermination text: \"Enrollment was too slow\"", "metadata": {"result_id": 4377, "source_trial_id": "NCT00418678", "intervention_name": "Cesamet", "condition_name": "Nausea and Vomiting", "confidence_tier": "bronze", "why_stopped": "Enrollment was too slow", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0336", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Fentanyl and Ketamine\nCondition: Pain, Acute\nPhase: phase_4\nTermination text: \"Residency completed.\"", "metadata": {"result_id": 494, "source_trial_id": "NCT03959852", "intervention_name": "Fentanyl and Ketamine", "condition_name": "Pain, Acute", "confidence_tier": "bronze", "why_stopped": "Residency completed.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0337", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: CGC-11047\nCondition: Prostate Cancer\nPhase: phase_2\nTermination text: \"Further evaluation of phase I dosing\"", "metadata": {"result_id": 6907, "source_trial_id": "NCT00585416", "intervention_name": "CGC-11047", "condition_name": "Prostate Cancer", "confidence_tier": "bronze", "why_stopped": "Further evaluation of phase I dosing", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0338", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: rhGAD65\nCondition: Type 1 Diabetes Mellitus\nPhase: phase_3\nTermination text: \"The primary endpoint at 15 months was not met.\"", "metadata": {"result_id": 27652, "source_trial_id": "NCT00723411", "intervention_name": "rhGAD65", "condition_name": "Type 1 Diabetes Mellitus", "confidence_tier": "bronze", "why_stopped": "The primary endpoint at 15 months was not met.", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0339", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: mometasone furoate nasal spray\nCondition: Perennial Allergic Rhinitis\nPhase: phase_4\nTermination text: \"Very poor enrollment\"", "metadata": {"result_id": 63197, "source_trial_id": "NCT00491374", "intervention_name": "mometasone furoate nasal spray", "condition_name": "Perennial Allergic Rhinitis", "confidence_tier": "bronze", "why_stopped": "Very poor enrollment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0340", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: foradil\nCondition: Chronic Obstructive Pulmonary Disease\nPhase: phase_4\nTermination text: \"Delays in the opening and activation of participating sites, and a low recruitment rate, with only 48 participants enrolled over the course of one year\"", "metadata": {"result_id": 37892, "source_trial_id": "NCT06282861", "intervention_name": "foradil", "condition_name": "Chronic Obstructive Pulmonary Disease", "confidence_tier": "bronze", "why_stopped": "Delays in the opening and activation of participating sites, and a low recruitment rate, with only 48 participants enrolled over the course of one year", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL2-0341", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Nabilone\nCondition: Obesity\nPhase: phase_2\nTermination text: \"Poor tolerability of medication and no preliminary efficacy\"", "metadata": {"result_id": 33385, "source_trial_id": "NCT04801641", "intervention_name": "Nabilone", "condition_name": "Obesity", "confidence_tier": "bronze", "why_stopped": "Poor tolerability of medication and no preliminary efficacy", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0342", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Chloroquine\nCondition: COVID-19\nPhase: phase_2_3\nTermination text: \"Teminated due to changes in treatment guidelines .\"", "metadata": {"result_id": 7100, "source_trial_id": "NCT04333628", "intervention_name": "Chloroquine", "condition_name": "COVID-19", "confidence_tier": "bronze", "why_stopped": "Teminated due to changes in treatment guidelines .", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0343", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: gemcitabine -oxaliplatine combination\nCondition: Thyroid Cancer\nPhase: phase_2\nTermination text: \"inefficiency\"", "metadata": {"result_id": 8026, "source_trial_id": "NCT02472080", "intervention_name": "gemcitabine -oxaliplatine combination", "condition_name": "Thyroid Cancer", "confidence_tier": "bronze", "why_stopped": "inefficiency", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0344", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: metoprolol succinate\nCondition: Hypertension\nTermination text: \"due to slow enrollment\"", "metadata": {"result_id": 12162, "source_trial_id": "NCT01441570", "intervention_name": "metoprolol succinate", "condition_name": "Hypertension", "confidence_tier": "bronze", "why_stopped": "due to slow enrollment", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0345", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Diclofenac\nCondition: Pulmonary Embolism\nPhase: phase_2_3\nTermination text: \"Low recruitment rate\"", "metadata": {"result_id": 15881, "source_trial_id": "NCT01590342", "intervention_name": "Diclofenac", "condition_name": "Pulmonary Embolism", "confidence_tier": "bronze", "why_stopped": "Low recruitment rate", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL2-0346", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: RPT193\nCondition: Asthma\nPhase: phase_2\nTermination text: \"Study on clinical hold by FDA\"", "metadata": {"result_id": 45255, "source_trial_id": "NCT05935332", "intervention_name": "RPT193", "condition_name": "Asthma", "confidence_tier": "bronze", "why_stopped": "Study on clinical hold by FDA", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL2-0347", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Salbutamol + Tiotropium\nCondition: Chronic Obstructive Pulmonary Disease\nPhase: phase_4\nTermination text: \"Problems with data collection\"", "metadata": {"result_id": 44962, "source_trial_id": "NCT00783250", "intervention_name": "Salbutamol + Tiotropium", "condition_name": "Chronic Obstructive Pulmonary Disease", "confidence_tier": "bronze", "why_stopped": "Problems with data collection", "therapeutic_area": "respiratory"}, "split": "test"}
+{"question_id": "CTL2-0348", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Eculizumab\nCondition: Complement Activity\nPhase: phase_2\nTermination text: \"Based on results from Alexion PROTECT DGF study\"", "metadata": {"result_id": 57123, "source_trial_id": "NCT01919346", "intervention_name": "Eculizumab", "condition_name": "Complement Activity", "confidence_tier": "bronze", "why_stopped": "Based on results from Alexion PROTECT DGF study", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0349", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Intramyocardial injection of autologous CD34-positive cells (stem cells)\nCondition: Cardiovascular Disease\nPhase: phase_1\nTermination text: \"Study terminated due to lack of funding.\"", "metadata": {"result_id": 22483, "source_trial_id": "NCT00620048", "intervention_name": "Intramyocardial injection of autologous CD34-positive cells (stem cells)", "condition_name": "Cardiovascular Disease", "confidence_tier": "bronze", "why_stopped": "Study terminated due to lack of funding.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0350", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "hard", "context_text": "Drug: Triazavirin (Riamilovir)\nCondition: Covid19\nPhase: phase_2_3\nTermination text: \"DSMB report\"", "metadata": {"result_id": 33335, "source_trial_id": "NCT04581915", "intervention_name": "Triazavirin (Riamilovir)", "condition_name": "Covid19", "confidence_tier": "bronze", "why_stopped": "DSMB report", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0351", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: [C-11] Meta-hydroxyephedrine radioactive tracer (MHED)\nCondition: Ventricular Tachycardia\nPhase: early_phase_1\nTermination text: \"Investigator departing institution and enrollment not met.\"", "metadata": {"result_id": 53189, "source_trial_id": "NCT02962076", "intervention_name": "[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)", "condition_name": "Ventricular Tachycardia", "confidence_tier": "bronze", "why_stopped": "Investigator departing institution and enrollment not met.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0352", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: IMVAMUNE\nCondition: Non-melanoma Skin Cancer\nPhase: phase_1_2\nTermination text: \"Inability to recruit patients/lack of funding\"", "metadata": {"result_id": 19152, "source_trial_id": "NCT04410874", "intervention_name": "IMVAMUNE", "condition_name": "Non-melanoma Skin Cancer", "confidence_tier": "bronze", "why_stopped": "Inability to recruit patients/lack of funding", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0353", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: nortriptyline\nCondition: Functional Dyspepsia\nPhase: phase_3\nTermination text: \"The inclusion of participants went more difficult than initially thought. Preliminary analysis showed that the difference between the groups was great enough to draw conclusions from it, so the trial is terminated prematurely.\"", "metadata": {"result_id": 629, "source_trial_id": "NCT03652571", "intervention_name": "nortriptyline", "condition_name": "Functional Dyspepsia", "confidence_tier": "bronze", "why_stopped": "The inclusion of participants went more difficult than initially thought. Preliminary analysis showed that the difference between the groups was great enough to draw conclusions from it, so the trial is terminated prematurely.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0354", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Warfarin\nCondition: Venous Thromboembolism\nTermination text: \"Enrolment was halted prematurely because of the observed excess in recurrences\"", "metadata": {"result_id": 57200, "source_trial_id": "NCT00428441", "intervention_name": "Warfarin", "condition_name": "Venous Thromboembolism", "confidence_tier": "bronze", "why_stopped": "Enrolment was halted prematurely because of the observed excess in recurrences", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0355", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: goserelin acetate\nCondition: Stage IIIB Breast Cancer\nPhase: phase_2\nTermination text: \"Due to funding source and lack of accrual\"", "metadata": {"result_id": 25866, "source_trial_id": "NCT01368263", "intervention_name": "goserelin acetate", "condition_name": "Stage IIIB Breast Cancer", "confidence_tier": "bronze", "why_stopped": "Due to funding source and lack of accrual", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0356", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: AUY922\nCondition: Advanced Non Small Cell Lung Cancer (NSCLC)\nPhase: phase_2\nTermination text: \"An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.\"", "metadata": {"result_id": 6562, "source_trial_id": "NCT01646125", "intervention_name": "AUY922", "condition_name": "Advanced Non Small Cell Lung Cancer (NSCLC)", "confidence_tier": "bronze", "why_stopped": "An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0357", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Rucaparib\nCondition: Solid Tumors\nPhase: phase_1_2\nTermination text: \"Study terminated due to safety issues.\"", "metadata": {"result_id": 3468, "source_trial_id": "NCT02711137", "intervention_name": "Rucaparib", "condition_name": "Solid Tumors", "confidence_tier": "bronze", "why_stopped": "Study terminated due to safety issues.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0358", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Temodar (Temozolomide)\nCondition: Melanoma\nPhase: phase_1\nTermination text: \"Phase I/II study halted as Phase I, Low Response Rate\"", "metadata": {"result_id": 23595, "source_trial_id": "NCT01067066", "intervention_name": "Temodar (Temozolomide)", "condition_name": "Melanoma", "confidence_tier": "bronze", "why_stopped": "Phase I/II study halted as Phase I, Low Response Rate", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0359", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: temozolomide\nCondition: Metastases, Neoplasm\nPhase: phase_2\nTermination text: \"Slow Enrollment\"", "metadata": {"result_id": 732, "source_trial_id": "NCT00034697", "intervention_name": "temozolomide", "condition_name": "Metastases, Neoplasm", "confidence_tier": "bronze", "why_stopped": "Slow Enrollment", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0360", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Mesenchymal Stromal Cells\nCondition: Kidney Transplant Rejection\nPhase: phase_1\nTermination text: \"Failure to enroll the number of patients required by the protocol due to the low number of living donor transplants performed at the Clinical Center\"", "metadata": {"result_id": 27172, "source_trial_id": "NCT02012153", "intervention_name": "Mesenchymal Stromal Cells", "condition_name": "Kidney Transplant Rejection", "confidence_tier": "bronze", "why_stopped": "Failure to enroll the number of patients required by the protocol due to the low number of living donor transplants performed at the Clinical Center", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0361", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: Active\nCondition: Respiratory Syncytial Virus Infections\nPhase: phase_1\nTermination text: \"Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study\"", "metadata": {"result_id": 35314, "source_trial_id": "NCT06102174", "intervention_name": "Active", "condition_name": "Respiratory Syncytial Virus Infections", "confidence_tier": "bronze", "why_stopped": "Study discontinued due to business reasons. There were no safety concerns in the decision to stop study and no changes to sponsor's assessment of the risk-benefit profile for participants who received sisunatovir in the study", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0362", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: leucovorin calcium\nCondition: Colorectal Cancer\nPhase: phase_2\nTermination text: \"Toxicity and lack of efficacy\"", "metadata": {"result_id": 50530, "source_trial_id": "NCT00541112", "intervention_name": "leucovorin calcium", "condition_name": "Colorectal Cancer", "confidence_tier": "bronze", "why_stopped": "Toxicity and lack of efficacy", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0363", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: bortezomib\nCondition: Secondary Acute Myeloid Leukemia\nPhase: phase_2\nTermination text: \"Closed early due to slow enrollment\"", "metadata": {"result_id": 49566, "source_trial_id": "NCT01465386", "intervention_name": "bortezomib", "condition_name": "Secondary Acute Myeloid Leukemia", "confidence_tier": "bronze", "why_stopped": "Closed early due to slow enrollment", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0364", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Vitamin B Complex\nCondition: Acute Lymphoblastic Leukemia\nPhase: phase_2\nTermination text: \"PI Request. Slow accrual and lack of clinical interest\"", "metadata": {"result_id": 10271, "source_trial_id": "NCT03564678", "intervention_name": "Vitamin B Complex", "condition_name": "Acute Lymphoblastic Leukemia", "confidence_tier": "bronze", "why_stopped": "PI Request. Slow accrual and lack of clinical interest", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0365", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Sevoflurane\nCondition: COVID19 Infection\nPhase: phase_4\nTermination text: \"Low recruitment ratio\"", "metadata": {"result_id": 49796, "source_trial_id": "NCT04359862", "intervention_name": "Sevoflurane", "condition_name": "COVID19 Infection", "confidence_tier": "bronze", "why_stopped": "Low recruitment ratio", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0366", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Esmolol\nCondition: Vomiting\nPhase: phase_4\nTermination text: \"The early report didn't show any benefit.\"", "metadata": {"result_id": 37755, "source_trial_id": "NCT01114997", "intervention_name": "Esmolol", "condition_name": "Vomiting", "confidence_tier": "bronze", "why_stopped": "The early report didn't show any benefit.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0367", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: LY2525623 Intravenous\nCondition: Psoriasis\nPhase: phase_2\nTermination text: \"The trial was terminated for several reasons, including complexities in development of LY2525623, but not because of safety concerns\"", "metadata": {"result_id": 10754, "source_trial_id": "NCT01018810", "intervention_name": "LY2525623 Intravenous", "condition_name": "Psoriasis", "confidence_tier": "bronze", "why_stopped": "The trial was terminated for several reasons, including complexities in development of LY2525623, but not because of safety concerns", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0368", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: High Dose Aspirin (1300 mg/day)\nCondition: Multiple Sclerosis\nPhase: phase_3\nTermination text: \"Interim analysis indicated treatment unlikely effective;slow recruitment\"", "metadata": {"result_id": 20717, "source_trial_id": "NCT00467584", "intervention_name": "High Dose Aspirin (1300 mg/day)", "condition_name": "Multiple Sclerosis", "confidence_tier": "bronze", "why_stopped": "Interim analysis indicated treatment unlikely effective;slow recruitment", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0369", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "hard", "context_text": "Drug: Dabigatran\nCondition: Thrombosis\nPhase: phase_2\nTermination text: \"safety reasons\"", "metadata": {"result_id": 18343, "source_trial_id": "NCT02872649", "intervention_name": "Dabigatran", "condition_name": "Thrombosis", "confidence_tier": "bronze", "why_stopped": "safety reasons", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0370", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Ifosfamide\nCondition: Osteosarcoma\nPhase: phase_2\nTermination text: \"Not adequate enrollment (sample size not possible to reach)\"", "metadata": {"result_id": 44070, "source_trial_id": "NCT02718482", "intervention_name": "Ifosfamide", "condition_name": "Osteosarcoma", "confidence_tier": "bronze", "why_stopped": "Not adequate enrollment (sample size not possible to reach)", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0371", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Ropivacine 0.2%\nCondition: Peripheral Nerve Block\nTermination text: \"The computer is crushed and all data is lost (IT was not able to recover it. Last data was collected 6.17.14)\"", "metadata": {"result_id": 11805, "source_trial_id": "NCT02161484", "intervention_name": "Ropivacine 0.2%", "condition_name": "Peripheral Nerve Block", "confidence_tier": "bronze", "why_stopped": "The computer is crushed and all data is lost (IT was not able to recover it. Last data was collected 6.17.14)", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0372", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Beraprost\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_4\nTermination text: \"Upon interim analysis, sponsor's decision due to absence of demonstration of efficacy.\"", "metadata": {"result_id": 27971, "source_trial_id": "NCT02786979", "intervention_name": "Beraprost", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "bronze", "why_stopped": "Upon interim analysis, sponsor's decision due to absence of demonstration of efficacy.", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0373", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: CADI-05\nCondition: Stage III or Stage IV Melanoma\nPhase: phase_1_2\nTermination text: \"DSMB reviewed data of 1st 10 subjects; determined no safety concerns. Efficacy as a single agent in this patient population was unlikely. Voluntary Termination\"", "metadata": {"result_id": 23880, "source_trial_id": "NCT00675727", "intervention_name": "CADI-05", "condition_name": "Stage III or Stage IV Melanoma", "confidence_tier": "bronze", "why_stopped": "DSMB reviewed data of 1st 10 subjects; determined no safety concerns. Efficacy as a single agent in this patient population was unlikely. Voluntary Termination", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0374", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Phase 1 Dose Escalation\nCondition: Glioblastoma\nPhase: phase_1\nTermination text: \"Results did not clearly support continuing development in recurrent GBM\"", "metadata": {"result_id": 56364, "source_trial_id": "NCT01499251", "intervention_name": "Phase 1 Dose Escalation", "condition_name": "Glioblastoma", "confidence_tier": "bronze", "why_stopped": "Results did not clearly support continuing development in recurrent GBM", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0375", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: oral vancomycin\nCondition: Clostridium Difficile Infection\nPhase: phase_4\nTermination text: \"Low recruitment due to few eligible participants.\"", "metadata": {"result_id": 32364, "source_trial_id": "NCT03200093", "intervention_name": "oral vancomycin", "condition_name": "Clostridium Difficile Infection", "confidence_tier": "bronze", "why_stopped": "Low recruitment due to few eligible participants.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0376", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: EXPAREL\nCondition: Pain\nPhase: phase_2\nTermination text: \"Ran out of medication\"", "metadata": {"result_id": 18690, "source_trial_id": "NCT03827213", "intervention_name": "EXPAREL", "condition_name": "Pain", "confidence_tier": "bronze", "why_stopped": "Ran out of medication", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0377", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Talazoparib\nCondition: Breast Cancer\nPhase: phase_2\nTermination text: \"This study has been terminated due to Lack of Accrual.\"", "metadata": {"result_id": 52582, "source_trial_id": "NCT04690855", "intervention_name": "Talazoparib", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "This study has been terminated due to Lack of Accrual.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0378", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Paricalcitol\nCondition: Vitamin D Deficiency\nTermination text: \"Terminated after 86 pt included, because of recruitment problems\"", "metadata": {"result_id": 6014, "source_trial_id": "NCT00469599", "intervention_name": "Paricalcitol", "condition_name": "Vitamin D Deficiency", "confidence_tier": "bronze", "why_stopped": "Terminated after 86 pt included, because of recruitment problems", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0379", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Saline solution\nCondition: Takotsubo Cardiomyopathy\nPhase: phase_2\nTermination text: \"inability to recruiti a sufficient number of patients\"", "metadata": {"result_id": 7405, "source_trial_id": "NCT02867878", "intervention_name": "Saline solution", "condition_name": "Takotsubo Cardiomyopathy", "confidence_tier": "bronze", "why_stopped": "inability to recruiti a sufficient number of patients", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0380", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Pemafibrate\nCondition: Diabetic Macular Edema\nPhase: phase_3\nTermination text: \"recruitment for the substudy did not meet the goals\"", "metadata": {"result_id": 40216, "source_trial_id": "NCT03345901", "intervention_name": "Pemafibrate", "condition_name": "Diabetic Macular Edema", "confidence_tier": "bronze", "why_stopped": "recruitment for the substudy did not meet the goals", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0381", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Sotatercept\nCondition: Solid Tumors\nPhase: phase_2\nTermination text: \"Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from manufacturer. No alternatives available for use.\"", "metadata": {"result_id": 61423, "source_trial_id": "NCT01190644", "intervention_name": "Sotatercept", "condition_name": "Solid Tumors", "confidence_tier": "bronze", "why_stopped": "Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from manufacturer. No alternatives available for use.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0382", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Standar medical treatmen\nCondition: Coronavirus\nPhase: phase_2\nTermination text: \"inability to recruit more patients\"", "metadata": {"result_id": 5535, "source_trial_id": "NCT04374539", "intervention_name": "Standar medical treatmen", "condition_name": "Coronavirus", "confidence_tier": "bronze", "why_stopped": "inability to recruit more patients", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0383", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Doxorubin\nCondition: Hepatocellular Carcinoma\nPhase: phase_3\nTermination text: \"This study was closed early due to lack of enrollments and insufficient funding.\"", "metadata": {"result_id": 58309, "source_trial_id": "NCT03960008", "intervention_name": "Doxorubin", "condition_name": "Hepatocellular Carcinoma", "confidence_tier": "bronze", "why_stopped": "This study was closed early due to lack of enrollments and insufficient funding.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0384", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: BIIB063\nCondition: Healthy\nPhase: phase_1\nTermination text: \"Clinical study terminated due to preclinical safety findings in non-human primates.\"", "metadata": {"result_id": 20308, "source_trial_id": "NCT02555085", "intervention_name": "BIIB063", "condition_name": "Healthy", "confidence_tier": "bronze", "why_stopped": "Clinical study terminated due to preclinical safety findings in non-human primates.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0385", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: magnesium sulfate\nCondition: Premature Labor\nTermination text: \"No enrollment in past year, lack of interest\"", "metadata": {"result_id": 28311, "source_trial_id": "NCT00306462", "intervention_name": "magnesium sulfate", "condition_name": "Premature Labor", "confidence_tier": "bronze", "why_stopped": "No enrollment in past year, lack of interest", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0386", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Faropenem medoxomil\nCondition: Chronic Bronchitis\nPhase: phase_3\nTermination text: \"financial reasons\"", "metadata": {"result_id": 37103, "source_trial_id": "NCT00255983", "intervention_name": "Faropenem medoxomil", "condition_name": "Chronic Bronchitis", "confidence_tier": "bronze", "why_stopped": "financial reasons", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0387", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Standard of Care\nCondition: Hemostasis, Surgical\nPhase: phase_4\nTermination text: \"The study was stopped due to slow enrollment\"", "metadata": {"result_id": 15218, "source_trial_id": "NCT00350519", "intervention_name": "Standard of Care", "condition_name": "Hemostasis, Surgical", "confidence_tier": "bronze", "why_stopped": "The study was stopped due to slow enrollment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0388", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Debio 1347\nCondition: Solid Tumor\nPhase: phase_2\nTermination text: \"Due to lower antitumor activity than expected\"", "metadata": {"result_id": 63105, "source_trial_id": "NCT03834220", "intervention_name": "Debio 1347", "condition_name": "Solid Tumor", "confidence_tier": "bronze", "why_stopped": "Due to lower antitumor activity than expected", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0389", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat\nCondition: Metastatic Colorectal Cancer\nPhase: phase_3\nTermination text: \"Only one patient included as per Feb. 4, 2008.\"", "metadata": {"result_id": 55053, "source_trial_id": "NCT00396487", "intervention_name": "Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat", "condition_name": "Metastatic Colorectal Cancer", "confidence_tier": "bronze", "why_stopped": "Only one patient included as per Feb. 4, 2008.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0390", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Vioxx\nCondition: Glioma\nPhase: phase_1\nTermination text: \"Unavailability of study drug.\"", "metadata": {"result_id": 11145, "source_trial_id": "NCT00038389", "intervention_name": "Vioxx", "condition_name": "Glioma", "confidence_tier": "bronze", "why_stopped": "Unavailability of study drug.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0391", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Prednisone\nCondition: High-grade B-cell Lymphoma\nPhase: phase_1\nTermination text: \"The study was terminated early because copanlisib was removed from the market by the Food and Drug Administration (FDA) and the manufacturer.\"", "metadata": {"result_id": 19905, "source_trial_id": "NCT04933617", "intervention_name": "Prednisone", "condition_name": "High-grade B-cell Lymphoma", "confidence_tier": "bronze", "why_stopped": "The study was terminated early because copanlisib was removed from the market by the Food and Drug Administration (FDA) and the manufacturer.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0392", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Belatacept\nCondition: Delayed Graft Function\nPhase: early_phase_1\nTermination text: \"Drug unavailability due to a manufacturing transition.\"", "metadata": {"result_id": 63496, "source_trial_id": "NCT02134288", "intervention_name": "Belatacept", "condition_name": "Delayed Graft Function", "confidence_tier": "bronze", "why_stopped": "Drug unavailability due to a manufacturing transition.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0393", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: MK0518 (Raltegravir)\nCondition: HIV Infection\nPhase: phase_3\nTermination text: \"primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir\"", "metadata": {"result_id": 49008, "source_trial_id": "NCT00443703", "intervention_name": "MK0518 (Raltegravir)", "condition_name": "HIV Infection", "confidence_tier": "bronze", "why_stopped": "primary efficacy analysis at Week 24 did not demonstrate non-inferiority of raltegravir versus lopinavir (+) ritonavir", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0394", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Testosterone\nCondition: Aging\nPhase: early_phase_1\nTermination text: \"Lack of funding.\"", "metadata": {"result_id": 45817, "source_trial_id": "NCT02679274", "intervention_name": "Testosterone", "condition_name": "Aging", "confidence_tier": "bronze", "why_stopped": "Lack of funding.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0395", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: Eteplirsen\nCondition: Duchenne Muscular Dystrophy\nPhase: phase_2\nTermination text: \"Participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment. There are no safety concerns with Eteplirsen.\"", "metadata": {"result_id": 13510, "source_trial_id": "NCT03985878", "intervention_name": "Eteplirsen", "condition_name": "Duchenne Muscular Dystrophy", "confidence_tier": "bronze", "why_stopped": "Participants were either transitioned to a post-trial access program or another Sarepta study, or they declined further treatment. There are no safety concerns with Eteplirsen.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0396", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: Olanzapine Tablets 20 mg\nCondition: Healthy\nPhase: phase_1\nTermination text: \"during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced to 5 mg due to safety concerns.\"", "metadata": {"result_id": 33218, "source_trial_id": "NCT00647972", "intervention_name": "Olanzapine Tablets 20 mg", "condition_name": "Healthy", "confidence_tier": "bronze", "why_stopped": "during Period 1 due to numerous orthostatic AEs that occurred. Subsequently, RLD was reduced to 5 mg due to safety concerns.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0397", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Dornase alfa\nCondition: Cystic Fibrosis\nPhase: phase_4\nTermination text: \"This study was terminated for administrative reasons. There were no safety concerns.\"", "metadata": {"result_id": 36918, "source_trial_id": "NCT00434278", "intervention_name": "Dornase alfa", "condition_name": "Cystic Fibrosis", "confidence_tier": "bronze", "why_stopped": "This study was terminated for administrative reasons. There were no safety concerns.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0398", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Ranibizumab\nCondition: Choroidal Neovascularization\nPhase: phase_2_3\nTermination text: \"Study was terminated based on the results of analyses performed as planned at Month 12.\"", "metadata": {"result_id": 16939, "source_trial_id": "NCT00433017", "intervention_name": "Ranibizumab", "condition_name": "Choroidal Neovascularization", "confidence_tier": "bronze", "why_stopped": "Study was terminated based on the results of analyses performed as planned at Month 12.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0399", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: oxaliplatin\nCondition: Hepatocellular Carcinoma\nPhase: phase_2\nTermination text: \"Did not meet the criteria for continuation to second stage\"", "metadata": {"result_id": 58140, "source_trial_id": "NCT00351195", "intervention_name": "oxaliplatin", "condition_name": "Hepatocellular Carcinoma", "confidence_tier": "bronze", "why_stopped": "Did not meet the criteria for continuation to second stage", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0400", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: eFT508\nCondition: Castrate-resistant Prostate Cancer (CRPC)\nPhase: phase_2\nTermination text: \"Terminated early due to a lack of efficacy.\"", "metadata": {"result_id": 8233, "source_trial_id": "NCT03690141", "intervention_name": "eFT508", "condition_name": "Castrate-resistant Prostate Cancer (CRPC)", "confidence_tier": "bronze", "why_stopped": "Terminated early due to a lack of efficacy.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0401", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: palbociclib isethionate\nCondition: Recurrent Childhood Gliosarcoma\nPhase: phase_1\nTermination text: \"Data for the primary objectives is complete and the MTD identified in Stratum II.\"", "metadata": {"result_id": 44393, "source_trial_id": "NCT02255461", "intervention_name": "palbociclib isethionate", "condition_name": "Recurrent Childhood Gliosarcoma", "confidence_tier": "bronze", "why_stopped": "Data for the primary objectives is complete and the MTD identified in Stratum II.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0402", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: Midazolam\nCondition: Advanced Cancer\nPhase: phase_1\nTermination text: \"Terminated based on safety results from another trial\"", "metadata": {"result_id": 13148, "source_trial_id": "NCT01209832", "intervention_name": "Midazolam", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "why_stopped": "Terminated based on safety results from another trial", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0403", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Terlipressin\nCondition: Liver Failure\nPhase: phase_2\nTermination text: \"Interim analysis revealed that no statistical difference will be identified after inclusion of the patient cohort as foreseen in the sample size calculation\"", "metadata": {"result_id": 55108, "source_trial_id": "NCT01921985", "intervention_name": "Terlipressin", "condition_name": "Liver Failure", "confidence_tier": "bronze", "why_stopped": "Interim analysis revealed that no statistical difference will be identified after inclusion of the patient cohort as foreseen in the sample size calculation", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0404", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Etoricoxib\nCondition: Pain\nPhase: phase_4\nTermination text: \"The gynecological laparoscopic surgery transition to day surgery made following the study protocol not possible.\"", "metadata": {"result_id": 22766, "source_trial_id": "NCT00763685", "intervention_name": "Etoricoxib", "condition_name": "Pain", "confidence_tier": "bronze", "why_stopped": "The gynecological laparoscopic surgery transition to day surgery made following the study protocol not possible.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0405", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Bupivacain/levobupivacaine\nCondition: Postoperative Pain\nPhase: phase_4\nTermination text: \"Groin surgery was changed to a laparoscopic technique; recruitable patients ceased.\"", "metadata": {"result_id": 52602, "source_trial_id": "NCT00970086", "intervention_name": "Bupivacain/levobupivacaine", "condition_name": "Postoperative Pain", "confidence_tier": "bronze", "why_stopped": "Groin surgery was changed to a laparoscopic technique; recruitable patients ceased.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0406", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: Capmatinib\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_3\nTermination text: \"Novartis decided to terminate the study based on a business consideration and not related with any safety concerns. Randomized part was not initiated\"", "metadata": {"result_id": 4227, "source_trial_id": "NCT04816214", "intervention_name": "Capmatinib", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "why_stopped": "Novartis decided to terminate the study based on a business consideration and not related with any safety concerns. Randomized part was not initiated", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0407", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: dimethyl sulfoxide\nCondition: Interstitial Cystitis\nPhase: phase_2\nTermination text: \"Poor recruitment, poor patient compliance, lack of funding\"", "metadata": {"result_id": 22826, "source_trial_id": "NCT00317070", "intervention_name": "dimethyl sulfoxide", "condition_name": "Interstitial Cystitis", "confidence_tier": "bronze", "why_stopped": "Poor recruitment, poor patient compliance, lack of funding", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0408", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Laxative Agent\nCondition: Chronic Constipation\nTermination text: \"A pre-specified interim analysis was conducted as planned, we calculated a P-value greater than 0.57 when comparing response rates between taVNS and sham group, resulting in an early termination of the study.\"", "metadata": {"result_id": 50701, "source_trial_id": "NCT05723731", "intervention_name": "Laxative Agent", "condition_name": "Chronic Constipation", "confidence_tier": "bronze", "why_stopped": "A pre-specified interim analysis was conducted as planned, we calculated a P-value greater than 0.57 when comparing response rates between taVNS and sham group, resulting in an early termination of the study.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0409", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: rhPRG4\nCondition: Ocular Graft-versus-host Disease\nPhase: phase_1_2\nTermination text: \"Efficacy signal substantial enough to more to larger study\"", "metadata": {"result_id": 51340, "source_trial_id": "NCT06495307", "intervention_name": "rhPRG4", "condition_name": "Ocular Graft-versus-host Disease", "confidence_tier": "bronze", "why_stopped": "Efficacy signal substantial enough to more to larger study", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0410", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: MRI with PFP\nCondition: Cystic Fibrosis\nPhase: early_phase_1\nTermination text: \"Enrollment barriers made study completion impossible\"", "metadata": {"result_id": 43967, "source_trial_id": "NCT03497117", "intervention_name": "MRI with PFP", "condition_name": "Cystic Fibrosis", "confidence_tier": "bronze", "why_stopped": "Enrollment barriers made study completion impossible", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0411", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: 0.12% chlorhexidine solution\nCondition: Lung Cancer\nPhase: phase_2_3\nTermination text: \"Slow patient accrual and plans to perform multi-center study\"", "metadata": {"result_id": 48220, "source_trial_id": "NCT01446874", "intervention_name": "0.12% chlorhexidine solution", "condition_name": "Lung Cancer", "confidence_tier": "bronze", "why_stopped": "Slow patient accrual and plans to perform multi-center study", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0412", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Isatuximab\nCondition: Acute Myeloid Leukemia\nPhase: phase_2\nTermination text: \"Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.\"", "metadata": {"result_id": 26193, "source_trial_id": "NCT03860844", "intervention_name": "Isatuximab", "condition_name": "Acute Myeloid Leukemia", "confidence_tier": "bronze", "why_stopped": "Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due to safety concerns.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0413", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: AZD0233\nCondition: Dilated Cardiomyopathy\nPhase: phase_1\nTermination text: \"The study has been terminated due to adverse finding in a non-clinical, chronic toxicology study.\"", "metadata": {"result_id": 64119, "source_trial_id": "NCT06381466", "intervention_name": "AZD0233", "condition_name": "Dilated Cardiomyopathy", "confidence_tier": "bronze", "why_stopped": "The study has been terminated due to adverse finding in a non-clinical, chronic toxicology study.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0414", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: LY3872386\nCondition: Healthy\nPhase: phase_1\nTermination text: \"Based on emerging nonclinical data, the study was terminated.\"", "metadata": {"result_id": 45266, "source_trial_id": "NCT06119529", "intervention_name": "LY3872386", "condition_name": "Healthy", "confidence_tier": "bronze", "why_stopped": "Based on emerging nonclinical data, the study was terminated.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0415", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Neladenoson bialanate (BAY 1067197)\nCondition: Pharmacology, Clinical\nPhase: phase_1\nTermination text: \"The cessation of the development project for neladenoson bialanate.\"", "metadata": {"result_id": 45011, "source_trial_id": "NCT04322253", "intervention_name": "Neladenoson bialanate (BAY 1067197)", "condition_name": "Pharmacology, Clinical", "confidence_tier": "bronze", "why_stopped": "The cessation of the development project for neladenoson bialanate.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0416", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: AVE5530\nCondition: Hypercholesterolemia\nPhase: phase_3\nTermination text: \"AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy\"", "metadata": {"result_id": 13854, "source_trial_id": "NCT00718965", "intervention_name": "AVE5530", "condition_name": "Hypercholesterolemia", "confidence_tier": "bronze", "why_stopped": "AVE5530 in hypercholesterolemia was stopped due to insufficient efficacy", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0417", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Naloxegol\nCondition: Constipation\nPhase: phase_4\nTermination text: \"The study was stopped due to challenges recruiting eligible patients.\"", "metadata": {"result_id": 4984, "source_trial_id": "NCT02839889", "intervention_name": "Naloxegol", "condition_name": "Constipation", "confidence_tier": "bronze", "why_stopped": "The study was stopped due to challenges recruiting eligible patients.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0418", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: BE1116\nCondition: Traumatic Injury\nPhase: phase_3\nTermination text: \"Study was terminated early because mortality was lower than expected and a significant increase in sample size would have been required to meet statistical goals of the study. No safety reasons were involved in the decision to terminate the study.\"", "metadata": {"result_id": 13998, "source_trial_id": "NCT05568888", "intervention_name": "BE1116", "condition_name": "Traumatic Injury", "confidence_tier": "bronze", "why_stopped": "Study was terminated early because mortality was lower than expected and a significant increase in sample size would have been required to meet statistical goals of the study. No safety reasons were involved in the decision to terminate the study.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0419", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: CAP7.1\nCondition: Advanced Endstage Solid Carcinomas in Adults\nPhase: phase_2\nTermination text: \"The study was terminated to be redesigned for a trial according to EMA proposal.\"", "metadata": {"result_id": 54452, "source_trial_id": "NCT02094560", "intervention_name": "CAP7.1", "condition_name": "Advanced Endstage Solid Carcinomas in Adults", "confidence_tier": "bronze", "why_stopped": "The study was terminated to be redesigned for a trial according to EMA proposal.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0420", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: TimoD implant\nCondition: Primary Open-angle Glaucoma\nPhase: phase_1\nTermination text: \"The study was terminated early due to the difficulties to enrol participant\"", "metadata": {"result_id": 27622, "source_trial_id": "NCT06321562", "intervention_name": "TimoD implant", "condition_name": "Primary Open-angle Glaucoma", "confidence_tier": "bronze", "why_stopped": "The study was terminated early due to the difficulties to enrol participant", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0421", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: DM1157\nCondition: Malaria\nPhase: phase_1\nTermination text: \"There was toxicity in higher dose groups and a therapeutic dose level was not found in lower dose groups.\"", "metadata": {"result_id": 12919, "source_trial_id": "NCT03490162", "intervention_name": "DM1157", "condition_name": "Malaria", "confidence_tier": "bronze", "why_stopped": "There was toxicity in higher dose groups and a therapeutic dose level was not found in lower dose groups.", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0422", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Alemtuzumab\nCondition: Diabetes Mellitus\nPhase: phase_4\nTermination text: \"The clinical use of Campath for transplant patients was temporarily suspended.\"", "metadata": {"result_id": 7873, "source_trial_id": "NCT00177138", "intervention_name": "Alemtuzumab", "condition_name": "Diabetes Mellitus", "confidence_tier": "bronze", "why_stopped": "The clinical use of Campath for transplant patients was temporarily suspended.", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0423", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Alisertib\nCondition: Nodal Marginal Zone B-cell Lymphoma\nPhase: phase_2\nTermination text: \"Slow patient enrollment and study discontinued after 14 patients enrolled\"", "metadata": {"result_id": 23506, "source_trial_id": "NCT01812005", "intervention_name": "Alisertib", "condition_name": "Nodal Marginal Zone B-cell Lymphoma", "confidence_tier": "bronze", "why_stopped": "Slow patient enrollment and study discontinued after 14 patients enrolled", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0424", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: ferucarbotran (iron-based MRI contrast agent)\nCondition: Type 1 Diabetes Mellitus\nPhase: phase_1\nTermination text: \"Feasibility issues\"", "metadata": {"result_id": 41428, "source_trial_id": "NCT00453817", "intervention_name": "ferucarbotran (iron-based MRI contrast agent)", "condition_name": "Type 1 Diabetes Mellitus", "confidence_tier": "bronze", "why_stopped": "Feasibility issues", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0425", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Ozurdex implant\nCondition: Macular Edema\nTermination text: \"enrollment not met\"", "metadata": {"result_id": 50939, "source_trial_id": "NCT01946399", "intervention_name": "Ozurdex implant", "condition_name": "Macular Edema", "confidence_tier": "bronze", "why_stopped": "enrollment not met", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0426", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Sorafenib + Paclitaxel + Carboplatin\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_3\nTermination text: \"Terminated early when the results from Study NCT00300885 showed an overall lack of efficacy in NSCLC and increased mortality in subjects with squamous subtype.\"", "metadata": {"result_id": 49148, "source_trial_id": "NCT00558636", "intervention_name": "Sorafenib + Paclitaxel + Carboplatin", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "why_stopped": "Terminated early when the results from Study NCT00300885 showed an overall lack of efficacy in NSCLC and increased mortality in subjects with squamous subtype.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0427", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: ICL670\nCondition: Aplastic Anemia\nPhase: phase_4\nTermination text: \"Failure to meet the schedule of patient recruitment\"", "metadata": {"result_id": 14693, "source_trial_id": "NCT01818726", "intervention_name": "ICL670", "condition_name": "Aplastic Anemia", "confidence_tier": "bronze", "why_stopped": "Failure to meet the schedule of patient recruitment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0428", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Topotecan\nCondition: Small-cell Lung Cancer\nPhase: phase_1\nTermination text: \"With a favorable safety profile the difference between treatment groups for the primary composite endpoint was not sufficient to generate statistically significant results with the targeted sample size\"", "metadata": {"result_id": 47166, "source_trial_id": "NCT04022876", "intervention_name": "Topotecan", "condition_name": "Small-cell Lung Cancer", "confidence_tier": "bronze", "why_stopped": "With a favorable safety profile the difference between treatment groups for the primary composite endpoint was not sufficient to generate statistically significant results with the targeted sample size", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0429", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Pregabalin\nCondition: Visceral Pain\nPhase: phase_4\nTermination text: \"Change of PI. Former PI changed from Research Center and Promoter obliged unexpectedly to change the PI.\"", "metadata": {"result_id": 8045, "source_trial_id": "NCT01768988", "intervention_name": "Pregabalin", "condition_name": "Visceral Pain", "confidence_tier": "bronze", "why_stopped": "Change of PI. Former PI changed from Research Center and Promoter obliged unexpectedly to change the PI.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0430", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)\nCondition: Metastatic Adenocarcinoma of the Pancreas\nPhase: phase_1\nTermination text: \"recruiting or enrolling participants has halted prematurely and will not resume\"", "metadata": {"result_id": 15336, "source_trial_id": "NCT01654861", "intervention_name": "Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)", "condition_name": "Metastatic Adenocarcinoma of the Pancreas", "confidence_tier": "bronze", "why_stopped": "recruiting or enrolling participants has halted prematurely and will not resume", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0431", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Becaplermin\nCondition: Diabetic Neuropathies\nPhase: phase_3\nTermination text: \"Slow recruitment; Study did not address safety concern raised by European Medicines Agency\"", "metadata": {"result_id": 4881, "source_trial_id": "NCT00034788", "intervention_name": "Becaplermin", "condition_name": "Diabetic Neuropathies", "confidence_tier": "bronze", "why_stopped": "Slow recruitment; Study did not address safety concern raised by European Medicines Agency", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0432", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: Encorafenib\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_1_2\nTermination text: \"Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions\"", "metadata": {"result_id": 49297, "source_trial_id": "NCT04585815", "intervention_name": "Encorafenib", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "why_stopped": "Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0433", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: Emapalumab\nCondition: SARS-CoV-2\nPhase: phase_2_3\nTermination text: \"Standard of care evolved during the timeframe of the study and had critical impact on recruitment.~Early termination was not based on safety reasons but due to the reasons mentoined above.~The ongoing patients were completed.\"", "metadata": {"result_id": 55198, "source_trial_id": "NCT04324021", "intervention_name": "Emapalumab", "condition_name": "SARS-CoV-2", "confidence_tier": "bronze", "why_stopped": "Standard of care evolved during the timeframe of the study and had critical impact on recruitment.~Early termination was not based on safety reasons but due to the reasons mentoined above.~The ongoing patients were completed.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0434", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Pasireotide LAR\nCondition: Gonadotroph Adenomas\nPhase: phase_2\nTermination text: \"unable to identify a third subject\"", "metadata": {"result_id": 27458, "source_trial_id": "NCT00929669", "intervention_name": "Pasireotide LAR", "condition_name": "Gonadotroph Adenomas", "confidence_tier": "bronze", "why_stopped": "unable to identify a third subject", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0435", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Theliatinib\nCondition: Cancer\nPhase: phase_1\nTermination text: \"the change of clinical development plan\"", "metadata": {"result_id": 39706, "source_trial_id": "NCT02601274", "intervention_name": "Theliatinib", "condition_name": "Cancer", "confidence_tier": "bronze", "why_stopped": "the change of clinical development plan", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0436", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: ABT-510/Thrombospondin-1 mimetic\nCondition: Carcinoma, Non-Small-Cell Lung\nPhase: phase_2\nTermination text: \"Enrollment suspended based upon interim analysis; subjects allowed to stay on study until disease progression.\"", "metadata": {"result_id": 11689, "source_trial_id": "NCT00061646", "intervention_name": "ABT-510/Thrombospondin-1 mimetic", "condition_name": "Carcinoma, Non-Small-Cell Lung", "confidence_tier": "bronze", "why_stopped": "Enrollment suspended based upon interim analysis; subjects allowed to stay on study until disease progression.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0437", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: elafibranor 120mg\nCondition: Non Alcoholic Steatohepatitis\nPhase: phase_2\nTermination text: \"Due to lack of efficacy (but not due to safety) in a Phase 3 trial of elafibranor in adult participants with NASH and fibrosis, this study in pediatric NASH was prematurely terminated\"", "metadata": {"result_id": 26068, "source_trial_id": "NCT03883607", "intervention_name": "elafibranor 120mg", "condition_name": "Non Alcoholic Steatohepatitis", "confidence_tier": "bronze", "why_stopped": "Due to lack of efficacy (but not due to safety) in a Phase 3 trial of elafibranor in adult participants with NASH and fibrosis, this study in pediatric NASH was prematurely terminated", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0438", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Infliximab\nCondition: Breast Cancer\nPhase: phase_2\nTermination text: \"Recruitment stopped due to slow accrual and lack of evidence of need for further continuation of protocol in inpatient setting.\"", "metadata": {"result_id": 33367, "source_trial_id": "NCT00112749", "intervention_name": "Infliximab", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "Recruitment stopped due to slow accrual and lack of evidence of need for further continuation of protocol in inpatient setting.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0439", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Porfimer Sodium\nCondition: Recurrent Laryngeal Verrucous Carcinoma\nPhase: phase_2\nTermination text: \"Study no longer has an active IDE\"", "metadata": {"result_id": 55506, "source_trial_id": "NCT02068157", "intervention_name": "Porfimer Sodium", "condition_name": "Recurrent Laryngeal Verrucous Carcinoma", "confidence_tier": "bronze", "why_stopped": "Study no longer has an active IDE", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0440", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Ponatinib 15 MG Oral Tablet\nCondition: Acute Lymphoblastic Leukemia, Adult\nPhase: phase_2\nTermination text: \"slower recruitment rate;\"", "metadata": {"result_id": 49270, "source_trial_id": "NCT04554459", "intervention_name": "Ponatinib 15 MG Oral Tablet", "condition_name": "Acute Lymphoblastic Leukemia, Adult", "confidence_tier": "bronze", "why_stopped": "slower recruitment rate;", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0441", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Trabectedin\nCondition: Malignant Mesothelioma\nPhase: phase_2\nTermination text: \"Enrolment halted prematurely and not resumed. 2 patients enrolled. No data was obtained.\"", "metadata": {"result_id": 40895, "source_trial_id": "NCT00027508", "intervention_name": "Trabectedin", "condition_name": "Malignant Mesothelioma", "confidence_tier": "bronze", "why_stopped": "Enrolment halted prematurely and not resumed. 2 patients enrolled. No data was obtained.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0442", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Estradiol\nCondition: Female Breast Cancer\nPhase: phase_2\nTermination text: \"did not meet efficacy goals after interim analysis\"", "metadata": {"result_id": 12243, "source_trial_id": "NCT01083641", "intervention_name": "Estradiol", "condition_name": "Female Breast Cancer", "confidence_tier": "bronze", "why_stopped": "did not meet efficacy goals after interim analysis", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0443", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Tranexamic Acid Injection (TXA)\nCondition: Total Shoulder Athroplasty\nPhase: phase_4\nTermination text: \"Enrollment rate was slower than anticipated\"", "metadata": {"result_id": 5636, "source_trial_id": "NCT04560010", "intervention_name": "Tranexamic Acid Injection (TXA)", "condition_name": "Total Shoulder Athroplasty", "confidence_tier": "bronze", "why_stopped": "Enrollment rate was slower than anticipated", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0444", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Etoricoxib 60 mg\nCondition: Soft Tissue Injuries of the Shoulder\nPhase: phase_3\nTermination text: \"Change in current areas of research interest of the collaborator\"", "metadata": {"result_id": 52463, "source_trial_id": "NCT00876317", "intervention_name": "Etoricoxib 60 mg", "condition_name": "Soft Tissue Injuries of the Shoulder", "confidence_tier": "bronze", "why_stopped": "Change in current areas of research interest of the collaborator", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0445", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: COVID-19 convalescent plasma\nCondition: COVID-19\nPhase: phase_2\nTermination text: \"The EUA for CCP was updated by FDA, stipulating that only high titer units be used. This study required untitered units. The study became infeasible\"", "metadata": {"result_id": 22041, "source_trial_id": "NCT04432272", "intervention_name": "COVID-19 convalescent plasma", "condition_name": "COVID-19", "confidence_tier": "bronze", "why_stopped": "The EUA for CCP was updated by FDA, stipulating that only high titer units be used. This study required untitered units. The study became infeasible", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0446", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Ketamine infusion\nCondition: Adolescent Depression\nPhase: phase_2\nTermination text: \"Terminated early due to concerns from the NIH DSMB regarding the rate of recruitment and the resulting inability to accomplish the initially approved study aims\"", "metadata": {"result_id": 33500, "source_trial_id": "NCT04613453", "intervention_name": "Ketamine infusion", "condition_name": "Adolescent Depression", "confidence_tier": "bronze", "why_stopped": "Terminated early due to concerns from the NIH DSMB regarding the rate of recruitment and the resulting inability to accomplish the initially approved study aims", "therapeutic_area": "psychiatry"}, "split": "test"}
+{"question_id": "CTL2-0447", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "hard", "context_text": "Drug: Opioids\nCondition: Analgesia\nPhase: phase_3\nTermination text: \"Lack of budget\"", "metadata": {"result_id": 9473, "source_trial_id": "NCT03151863", "intervention_name": "Opioids", "condition_name": "Analgesia", "confidence_tier": "bronze", "why_stopped": "Lack of budget", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0448", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "hard", "context_text": "Drug: N-acetyl-L-cysteine (NAC)\nCondition: Thrombocytopenia\nPhase: phase_2_3\nTermination text: \"protocol changed\"", "metadata": {"result_id": 43125, "source_trial_id": "NCT03391856", "intervention_name": "N-acetyl-L-cysteine (NAC)", "condition_name": "Thrombocytopenia", "confidence_tier": "bronze", "why_stopped": "protocol changed", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0449", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: MPC-7869\nCondition: Alzheimer's Disease\nPhase: phase_3\nTermination text: \"Myriad has discontinued the development of Flurizan.\"", "metadata": {"result_id": 32086, "source_trial_id": "NCT00380276", "intervention_name": "MPC-7869", "condition_name": "Alzheimer's Disease", "confidence_tier": "bronze", "why_stopped": "Myriad has discontinued the development of Flurizan.", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0450", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Taxotere\nCondition: Head and Neck Cancer\nPhase: phase_2\nTermination text: \"Early termination due to lack of efficacy (overall response)\"", "metadata": {"result_id": 33728, "source_trial_id": "NCT01794845", "intervention_name": "Taxotere", "condition_name": "Head and Neck Cancer", "confidence_tier": "bronze", "why_stopped": "Early termination due to lack of efficacy (overall response)", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0451", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Gabapentin immediate release\nCondition: Restless Leg Syndrome\nPhase: phase_4\nTermination text: \"Recruitment unsuccessful due to overly restrictive inclusion/exclusion criteria.\"", "metadata": {"result_id": 48420, "source_trial_id": "NCT02117076", "intervention_name": "Gabapentin immediate release", "condition_name": "Restless Leg Syndrome", "confidence_tier": "bronze", "why_stopped": "Recruitment unsuccessful due to overly restrictive inclusion/exclusion criteria.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0452", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Ustekinumab\nCondition: Takayasu Arteritis\nPhase: phase_3\nTermination text: \"Due to difficulties in enrollment and ongoing feasibility issues\"", "metadata": {"result_id": 34306, "source_trial_id": "NCT04882072", "intervention_name": "Ustekinumab", "condition_name": "Takayasu Arteritis", "confidence_tier": "bronze", "why_stopped": "Due to difficulties in enrollment and ongoing feasibility issues", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0453", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Tamsulosin Hydrochloride 0.4 milligrams\nCondition: Urolithiasis\nPhase: phase_4\nTermination text: \"Problems with the number of participants\"", "metadata": {"result_id": 12391, "source_trial_id": "NCT03614052", "intervention_name": "Tamsulosin Hydrochloride 0.4 milligrams", "condition_name": "Urolithiasis", "confidence_tier": "bronze", "why_stopped": "Problems with the number of participants", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0454", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: ritonavir\nCondition: Infection, Human Immunodeficiency Virus\nPhase: phase_1\nTermination text: \"Study prematurely terminated due to safety concerns leading to clinical hold\"", "metadata": {"result_id": 32331, "source_trial_id": "NCT02289482", "intervention_name": "ritonavir", "condition_name": "Infection, Human Immunodeficiency Virus", "confidence_tier": "bronze", "why_stopped": "Study prematurely terminated due to safety concerns leading to clinical hold", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0455", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: GvHD prophylaxis\nCondition: Graft vs Host Disease\nPhase: phase_1\nTermination text: \"low rate of enrolment\"", "metadata": {"result_id": 43877, "source_trial_id": "NCT03963024", "intervention_name": "GvHD prophylaxis", "condition_name": "Graft vs Host Disease", "confidence_tier": "bronze", "why_stopped": "low rate of enrolment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0456", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: pradefovir mesylate\nCondition: Hepatitis B, Chronic\nPhase: phase_2\nTermination text: \"Adverse findings from nonclinical carcinogenicity studies.\"", "metadata": {"result_id": 21516, "source_trial_id": "NCT00230490", "intervention_name": "pradefovir mesylate", "condition_name": "Hepatitis B, Chronic", "confidence_tier": "bronze", "why_stopped": "Adverse findings from nonclinical carcinogenicity studies.", "therapeutic_area": "infectious"}, "split": "test"}
+{"question_id": "CTL2-0457", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Elamipretide\nCondition: Primary Mitochondrial Myopathy\nPhase: phase_3\nTermination text: \"Part1,double blind portion of the trial did not meet the primary end points\"", "metadata": {"result_id": 17734, "source_trial_id": "NCT03323749", "intervention_name": "Elamipretide", "condition_name": "Primary Mitochondrial Myopathy", "confidence_tier": "bronze", "why_stopped": "Part1,double blind portion of the trial did not meet the primary end points", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0458", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Pancrelipase\nCondition: Exocrine Pancreatic Insufficiency\nTermination text: \"No longer required study by FDA for NDA approval.\"", "metadata": {"result_id": 18621, "source_trial_id": "NCT00749099", "intervention_name": "Pancrelipase", "condition_name": "Exocrine Pancreatic Insufficiency", "confidence_tier": "bronze", "why_stopped": "No longer required study by FDA for NDA approval.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0459", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: Lithium carbonate\nCondition: Amyotrophic Lateral Sclerosis\nPhase: phase_2_3\nTermination text: \"NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.\"", "metadata": {"result_id": 7578, "source_trial_id": "NCT00818389", "intervention_name": "Lithium carbonate", "condition_name": "Amyotrophic Lateral Sclerosis", "confidence_tier": "bronze", "why_stopped": "NINDS DSMB recommended trial be terminated for futility after reviewing an interim analysis of 84 subjects.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0460", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: temozolomide\nCondition: Adult Anaplastic Astrocytoma\nPhase: phase_2\nTermination text: \"Slow accrual to some cohorts\"", "metadata": {"result_id": 47225, "source_trial_id": "NCT01478321", "intervention_name": "temozolomide", "condition_name": "Adult Anaplastic Astrocytoma", "confidence_tier": "bronze", "why_stopped": "Slow accrual to some cohorts", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0461", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: AllerT SC\nCondition: Allergic Rhinitis\nPhase: phase_1_2\nTermination text: \"Recruitment was stopped before start of the pollen season\"", "metadata": {"result_id": 11640, "source_trial_id": "NCT01728519", "intervention_name": "AllerT SC", "condition_name": "Allergic Rhinitis", "confidence_tier": "bronze", "why_stopped": "Recruitment was stopped before start of the pollen season", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0462", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: paricalcitol injection 4 mcg/mL\nCondition: Hypertrophy, Left Ventricular\nPhase: phase_3\nTermination text: \"This study was prematurely terminated due to low enrollment\"", "metadata": {"result_id": 6331, "source_trial_id": "NCT00616902", "intervention_name": "paricalcitol injection 4 mcg/mL", "condition_name": "Hypertrophy, Left Ventricular", "confidence_tier": "bronze", "why_stopped": "This study was prematurely terminated due to low enrollment", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0463", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Ontorpacept (TTI-621)\nCondition: Leiomyosarcoma\nPhase: phase_2\nTermination text: \"Pfizer decided to terminate the study for administrative reasons. The termination was neither due to safety concerns nor a request from the regulatory authorities.\"", "metadata": {"result_id": 1250, "source_trial_id": "NCT04996004", "intervention_name": "Ontorpacept (TTI-621)", "condition_name": "Leiomyosarcoma", "confidence_tier": "bronze", "why_stopped": "Pfizer decided to terminate the study for administrative reasons. The termination was neither due to safety concerns nor a request from the regulatory authorities.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0464", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Sorafenib (Nexavar)\nCondition: neurofibromatosis1 (NF1)\nPhase: phase_2\nTermination text: \"Sorafenib ineffective for tx of recurrent or progressive PLGA\"", "metadata": {"result_id": 15597, "source_trial_id": "NCT01338857", "intervention_name": "Sorafenib (Nexavar)", "condition_name": "neurofibromatosis1 (NF1)", "confidence_tier": "bronze", "why_stopped": "Sorafenib ineffective for tx of recurrent or progressive PLGA", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0465", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: mRNA-1273.214\nCondition: SARS-CoV-2\nPhase: phase_2\nTermination text: \"The trial was terminated because data from the dose finding part of the trial did not support further evaluation of effectiveness of mRNA-1273. There were no safety concerns.\"", "metadata": {"result_id": 32088, "source_trial_id": "NCT05584202", "intervention_name": "mRNA-1273.214", "condition_name": "SARS-CoV-2", "confidence_tier": "bronze", "why_stopped": "The trial was terminated because data from the dose finding part of the trial did not support further evaluation of effectiveness of mRNA-1273. There were no safety concerns.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0466", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Metformin\nCondition: Peripheral Arterial Disease\nPhase: phase_4\nTermination text: \"The trial has been terminated due to difficulties with recruitment.\"", "metadata": {"result_id": 16449, "source_trial_id": "NCT01799057", "intervention_name": "Metformin", "condition_name": "Peripheral Arterial Disease", "confidence_tier": "bronze", "why_stopped": "The trial has been terminated due to difficulties with recruitment.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0467", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: KSP/QRH dimer\nCondition: Cholangiocarcinoma\nPhase: phase_1\nTermination text: \"Terminated due to lack of dimer.\"", "metadata": {"result_id": 8200, "source_trial_id": "NCT04304781", "intervention_name": "KSP/QRH dimer", "condition_name": "Cholangiocarcinoma", "confidence_tier": "bronze", "why_stopped": "Terminated due to lack of dimer.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0468", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "easy", "context_text": "Drug: milatuzumab\nCondition: Myelodysplastic Syndrome\nPhase: phase_1\nTermination text: \"PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled\"", "metadata": {"result_id": 50348, "source_trial_id": "NCT01663766", "intervention_name": "milatuzumab", "condition_name": "Myelodysplastic Syndrome", "confidence_tier": "bronze", "why_stopped": "PIs agreed no safety signals were shown, drug did not appear to lessen the risk of preventing GVHD no further patients would be enrolled", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0469", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: PRI-724\nCondition: Advanced Solid Tumors\nPhase: phase_1\nTermination text: \"closing due to low enrollment, no safety issues\"", "metadata": {"result_id": 24604, "source_trial_id": "NCT01302405", "intervention_name": "PRI-724", "condition_name": "Advanced Solid Tumors", "confidence_tier": "bronze", "why_stopped": "closing due to low enrollment, no safety issues", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0470", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: BAY1143269 tablet\nCondition: Medical Oncology\nPhase: phase_1\nTermination text: \"Study stopped due to project prioritization\"", "metadata": {"result_id": 53203, "source_trial_id": "NCT02439346", "intervention_name": "BAY1143269 tablet", "condition_name": "Medical Oncology", "confidence_tier": "bronze", "why_stopped": "Study stopped due to project prioritization", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0471", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: REM0046127 High Dose\nCondition: Alzheimer Disease\nPhase: phase_2\nTermination text: \"Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.\"", "metadata": {"result_id": 110, "source_trial_id": "NCT05478031", "intervention_name": "REM0046127 High Dose", "condition_name": "Alzheimer Disease", "confidence_tier": "bronze", "why_stopped": "Due to the event of repeated elevated transaminase levels in one subject - elevated ALT/AST up to 6x ULN in the absence of any other potential underlying cause - we have decided to terminate the study.", "therapeutic_area": "neurology"}, "split": "test"}
+{"question_id": "CTL2-0472", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Dexamethasone 4 mg/ml\nCondition: Trigger Finger\nPhase: phase_4\nTermination text: \"Preliminary analysis revealed no difference\"", "metadata": {"result_id": 10163, "source_trial_id": "NCT04002037", "intervention_name": "Dexamethasone 4 mg/ml", "condition_name": "Trigger Finger", "confidence_tier": "bronze", "why_stopped": "Preliminary analysis revealed no difference", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0473", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: Metformin\nCondition: Non-small Cell Lung Cancer Stage IIIB/IV\nPhase: phase_2\nTermination text: \"PI left the institution\"", "metadata": {"result_id": 17467, "source_trial_id": "NCT02019979", "intervention_name": "Metformin", "condition_name": "Non-small Cell Lung Cancer Stage IIIB/IV", "confidence_tier": "bronze", "why_stopped": "PI left the institution", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0474", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Liposomal bupivacaine right injection\nCondition: Pain, Postoperative\nPhase: phase_4\nTermination text: \"Early termination due to manufacturer discontinued supplying the product for the study.\"", "metadata": {"result_id": 44705, "source_trial_id": "NCT03383198", "intervention_name": "Liposomal bupivacaine right injection", "condition_name": "Pain, Postoperative", "confidence_tier": "bronze", "why_stopped": "Early termination due to manufacturer discontinued supplying the product for the study.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0475", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Saline\nCondition: Acute Pain\nPhase: phase_4\nTermination text: \"staffing\"", "metadata": {"result_id": 50262, "source_trial_id": "NCT04917055", "intervention_name": "Saline", "condition_name": "Acute Pain", "confidence_tier": "bronze", "why_stopped": "staffing", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0476", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "easy", "context_text": "Drug: [111In]-FPI-1547 Injection\nCondition: Breast Cancer\nPhase: phase_1\nTermination text: \"A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.\"", "metadata": {"result_id": 63326, "source_trial_id": "NCT03746431", "intervention_name": "[111In]-FPI-1547 Injection", "condition_name": "Breast Cancer", "confidence_tier": "bronze", "why_stopped": "A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0477", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: AZD6765\nCondition: Healthy\nPhase: phase_1\nTermination text: \"The benefit of halting the study to analyze the available data outweighs the benefit of delaying the analysis to include data from remaining treatment periods\"", "metadata": {"result_id": 51899, "source_trial_id": "NCT01130909", "intervention_name": "AZD6765", "condition_name": "Healthy", "confidence_tier": "bronze", "why_stopped": "The benefit of halting the study to analyze the available data outweighs the benefit of delaying the analysis to include data from remaining treatment periods", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0478", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: Etrolizumab\nCondition: Ulcerative Colitis\nPhase: phase_3\nTermination text: \"The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.\"", "metadata": {"result_id": 4862, "source_trial_id": "NCT02118584", "intervention_name": "Etrolizumab", "condition_name": "Ulcerative Colitis", "confidence_tier": "bronze", "why_stopped": "The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.", "therapeutic_area": "autoimmune"}, "split": "test"}
+{"question_id": "CTL2-0479", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Oxytocin nasal spray\nCondition: Alcohol Use Disorder\nPhase: phase_2\nTermination text: \"Halted due to recruitment problems.\"", "metadata": {"result_id": 17703, "source_trial_id": "NCT06199076", "intervention_name": "Oxytocin nasal spray", "condition_name": "Alcohol Use Disorder", "confidence_tier": "bronze", "why_stopped": "Halted due to recruitment problems.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0480", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Blood sample\nCondition: End-stage Chronic Kidney Failure\nTermination text: \"Lack of inclusions\"", "metadata": {"result_id": 37958, "source_trial_id": "NCT02857556", "intervention_name": "Blood sample", "condition_name": "End-stage Chronic Kidney Failure", "confidence_tier": "bronze", "why_stopped": "Lack of inclusions", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0481", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Doxycycline\nCondition: Cardiac AL Amyloidosis\nPhase: phase_2_3\nTermination text: \"difficulty in recruitment\"", "metadata": {"result_id": 48748, "source_trial_id": "NCT03474458", "intervention_name": "Doxycycline", "condition_name": "Cardiac AL Amyloidosis", "confidence_tier": "bronze", "why_stopped": "difficulty in recruitment", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0482", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "hard", "context_text": "Drug: Chlorogenic acid\nCondition: Advanced Cancer\nPhase: phase_1\nTermination text: \"Study site change\"", "metadata": {"result_id": 60866, "source_trial_id": "NCT02136342", "intervention_name": "Chlorogenic acid", "condition_name": "Advanced Cancer", "confidence_tier": "bronze", "why_stopped": "Study site change", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0483", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Tacrolimus Extended Release Oral Tablet [Envarsus]\nCondition: Kidney Transplant Rejection\nPhase: early_phase_1\nTermination text: \"Slower than expected recruitment rate\"", "metadata": {"result_id": 14586, "source_trial_id": "NCT03380936", "intervention_name": "Tacrolimus Extended Release Oral Tablet [Envarsus]", "condition_name": "Kidney Transplant Rejection", "confidence_tier": "bronze", "why_stopped": "Slower than expected recruitment rate", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0484", "task": "CT-L2", "gold_answer": "other", "gold_extraction": {"failure_category": "other", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "other", "difficulty": "medium", "context_text": "Drug: jevtana\nCondition: Gastric Cancer\nPhase: phase_2\nTermination text: \"As of 12/12/12 study closed to enrollment because study was determined to be ineffective.\"", "metadata": {"result_id": 26078, "source_trial_id": "NCT01365130", "intervention_name": "jevtana", "condition_name": "Gastric Cancer", "confidence_tier": "bronze", "why_stopped": "As of 12/12/12 study closed to enrollment because study was determined to be ineffective.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0485", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "hard", "context_text": "Drug: Beta Blocker\nCondition: Myocardial Infarction With Non-Obstructive Coronary Arteries\nPhase: phase_4\nTermination text: \"Low inclusion rate.\"", "metadata": {"result_id": 33928, "source_trial_id": "NCT03686696", "intervention_name": "Beta Blocker", "condition_name": "Myocardial Infarction With Non-Obstructive Coronary Arteries", "confidence_tier": "bronze", "why_stopped": "Low inclusion rate.", "therapeutic_area": "cardiology"}, "split": "test"}
+{"question_id": "CTL2-0486", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: Paclitaxel\nCondition: Lung Cancer\nPhase: phase_2\nTermination text: \"Principal Investigator felt risk to patients was too high.\"", "metadata": {"result_id": 39172, "source_trial_id": "NCT00334763", "intervention_name": "Paclitaxel", "condition_name": "Lung Cancer", "confidence_tier": "bronze", "why_stopped": "Principal Investigator felt risk to patients was too high.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0487", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: IMM01\nCondition: Hematologic Malignancy\nPhase: phase_1\nTermination text: \"No expected efficacy was observed in subsequent extended phase.The company decided to initiatively terminate the development of IMM01 as monotherapy and fully promote clinical development of combination therapy.\"", "metadata": {"result_id": 8875, "source_trial_id": "NCT05860075", "intervention_name": "IMM01", "condition_name": "Hematologic Malignancy", "confidence_tier": "bronze", "why_stopped": "No expected efficacy was observed in subsequent extended phase.The company decided to initiatively terminate the development of IMM01 as monotherapy and fully promote clinical development of combination therapy.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0488", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: Pembrolizumab\nCondition: Advanced Solid Tumors\nPhase: phase_1\nTermination text: \"Study was terminated for lack of efficacy.\"", "metadata": {"result_id": 24750, "source_trial_id": "NCT03799003", "intervention_name": "Pembrolizumab", "condition_name": "Advanced Solid Tumors", "confidence_tier": "bronze", "why_stopped": "Study was terminated for lack of efficacy.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0489", "task": "CT-L2", "gold_answer": "design", "gold_extraction": {"failure_category": "design", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "design", "difficulty": "medium", "context_text": "Drug: VI-0521\nCondition: Diabetes\nPhase: phase_2\nTermination text: \"Limited regulatory value to uncontrolled trials. No safety/efficacy concerns.\"", "metadata": {"result_id": 62912, "source_trial_id": "NCT00737633", "intervention_name": "VI-0521", "condition_name": "Diabetes", "confidence_tier": "bronze", "why_stopped": "Limited regulatory value to uncontrolled trials. No safety/efficacy concerns.", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0490", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Consolidation chemotherapy\nCondition: Acute Myeloid Leukemia (AML)\nPhase: phase_3\nTermination text: \"Study terminated 7/23/2019 due to limited participation and testing challenges.\"", "metadata": {"result_id": 945, "source_trial_id": "NCT02927938", "intervention_name": "Consolidation chemotherapy", "condition_name": "Acute Myeloid Leukemia (AML)", "confidence_tier": "bronze", "why_stopped": "Study terminated 7/23/2019 due to limited participation and testing challenges.", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0491", "task": "CT-L2", "gold_answer": "regulatory", "gold_extraction": {"failure_category": "regulatory", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "regulatory", "difficulty": "medium", "context_text": "Drug: Hepatic artery infusion pump floxuridine and dexamethasone\nCondition: Colorectal Neoplasms\nTermination text: \"an alternate device became FDA approved\"", "metadata": {"result_id": 23685, "source_trial_id": "NCT04276090", "intervention_name": "Hepatic artery infusion pump floxuridine and dexamethasone", "condition_name": "Colorectal Neoplasms", "confidence_tier": "bronze", "why_stopped": "an alternate device became FDA approved", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0492", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: IFN-gamma\nCondition: IFN-Gamma Therapy\nPhase: phase_4\nTermination text: \"Early termination due to only 2 subjects completing trial.\"", "metadata": {"result_id": 3782, "source_trial_id": "NCT01147042", "intervention_name": "IFN-gamma", "condition_name": "IFN-Gamma Therapy", "confidence_tier": "bronze", "why_stopped": "Early termination due to only 2 subjects completing trial.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0493", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "easy", "context_text": "Drug: oral beclomethasone 17,21-dipropionate\nCondition: Acute Gastrointestinal Graft vs Host Disease\nPhase: phase_3\nTermination text: \"An independent Data Safety Monitoring Board recommended the study be stopped due to futility\"", "metadata": {"result_id": 354, "source_trial_id": "NCT00926575", "intervention_name": "oral beclomethasone 17,21-dipropionate", "condition_name": "Acute Gastrointestinal Graft vs Host Disease", "confidence_tier": "bronze", "why_stopped": "An independent Data Safety Monitoring Board recommended the study be stopped due to futility", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0494", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Insulin, Asp(B28)-\nCondition: Type 1 Diabetes\nPhase: phase_4\nTermination text: \"No eligible participants left to approach/ recruit\"", "metadata": {"result_id": 5121, "source_trial_id": "NCT02680054", "intervention_name": "Insulin, Asp(B28)-", "condition_name": "Type 1 Diabetes", "confidence_tier": "bronze", "why_stopped": "No eligible participants left to approach/ recruit", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0495", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "medium", "context_text": "Drug: Dexamethasone, desmopressin\nCondition: Leptospirosis\nPhase: phase_2_3\nTermination text: \"Numbe of eligible patients has been decreased over time.\"", "metadata": {"result_id": 47457, "source_trial_id": "NCT00592566", "intervention_name": "Dexamethasone, desmopressin", "condition_name": "Leptospirosis", "confidence_tier": "bronze", "why_stopped": "Numbe of eligible patients has been decreased over time.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0496", "task": "CT-L2", "gold_answer": "efficacy", "gold_extraction": {"failure_category": "efficacy", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "efficacy", "difficulty": "medium", "context_text": "Drug: vildagliptin\nCondition: Type 2 Diabetes Mellitus\nPhase: phase_4\nTermination text: \"The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.\"", "metadata": {"result_id": 34903, "source_trial_id": "NCT01910441", "intervention_name": "vildagliptin", "condition_name": "Type 2 Diabetes Mellitus", "confidence_tier": "bronze", "why_stopped": "The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.", "therapeutic_area": "metabolic"}, "split": "test"}
+{"question_id": "CTL2-0497", "task": "CT-L2", "gold_answer": "strategic", "gold_extraction": {"failure_category": "strategic", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "strategic", "difficulty": "medium", "context_text": "Drug: APR003\nCondition: Advanced Colorectal Carcinoma\nPhase: phase_1\nTermination text: \"Study terminated prematurely due to internal corporate decision\"", "metadata": {"result_id": 19131, "source_trial_id": "NCT04645797", "intervention_name": "APR003", "condition_name": "Advanced Colorectal Carcinoma", "confidence_tier": "bronze", "why_stopped": "Study terminated prematurely due to internal corporate decision", "therapeutic_area": "oncology"}, "split": "test"}
+{"question_id": "CTL2-0498", "task": "CT-L2", "gold_answer": "safety", "gold_extraction": {"failure_category": "safety", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "safety", "difficulty": "medium", "context_text": "Drug: NPT189\nCondition: Amyloidosis\nPhase: phase_1\nTermination text: \"Mild infusion reactions were observed in two healthy volunteers.\"", "metadata": {"result_id": 23727, "source_trial_id": "NCT03879278", "intervention_name": "NPT189", "condition_name": "Amyloidosis", "confidence_tier": "bronze", "why_stopped": "Mild infusion reactions were observed in two healthy volunteers.", "therapeutic_area": "other"}, "split": "test"}
+{"question_id": "CTL2-0499", "task": "CT-L2", "gold_answer": "enrollment", "gold_extraction": {"failure_category": "enrollment", "failure_subcategory": null, "affected_system": null, "severity_indicator": null, "quantitative_evidence": null, "decision_maker": null, "patient_impact": null}, "gold_category": "enrollment", "difficulty": "easy", "context_text": "Drug: Marcaine\nCondition: Pain, Postoperative\nTermination text: \"Patients were not willing to be randomized and therefore recruitment could not continue.\"", "metadata": {"result_id": 12993, "source_trial_id": "NCT01294098", "intervention_name": "Marcaine", "condition_name": "Pain, Postoperative", "confidence_tier": "bronze", "why_stopped": "Patients were not willing to be randomized and therefore recruitment could not continue.", "therapeutic_area": "other"}, "split": "test"}